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I. INTRODUCTION 
Dogs represent a promising large animal translational model for a number of human 
diseases. A wide range of spontaneous diseases in dogs have been shown to be 
advantageous for genetic, diagnostic, pathophysiological and therapeutic 
investigations of their human homologue diseases (DUAN, 2015; GRAHAM & 
SCHUURMAN, 2015; HICKS et al., 2017; ITO et al., 2014; PATTERSON, 2014; 
POTSCHKA et al., 2013; RECCHIA & LIONETTI, 2007; ROWELL et al., 2011; 
TRUVÉ et al., 2016; ZEISS, 2013). The usefulness of dog models for epilepsies, 
diabetes, cancers, as well as ocular and cardiac disorders in translational research 
has been shown (DUAN, 2015; GRAHAM & SCHUURMAN, 2015; HICKS et al., 
2017; ITO et al., 2014; PATTERSON, 2014; POTSCHKA et al., 2013; RECCHIA 
& LIONETTI, 2007; ROWELL et al., 2011; TRUVÉ et al., 2016; ZEISS, 2013). 
It has been postulated that dogs provide an exciting opportunity for the 
identification of epilepsy genes. Epilepsy is one of the most common chronic 
neurological diseases in humans and dogs (EKENSTEDT & OBERBAUER, 2013; 
VOLK, 2015). A strong genetic predisposition is suspected in many dog breeds 
with a high prevalence of idiopathic epilepsy (HÜLSMEYER et al., 2015). The 
genomic divergence between humans and dogs is less than that between humans 
and mice, and humans and dogs have roughly the same number of genes 
(POTSCHKA et al., 2013). Narrow gene pools and a high inbreeding coefficient in 
purebred dogs have reduced genetic heterogeneity compared with humans, and dog 
populations tend to express inherited monogenic diseases (KOSKINEN et al., 2015; 
LINDBLAD-TOH et al., 2005; POTSCHKA et al., 2013). Autosomal recessive 
disorders have been shown to have a substantially high prevalence because breeding 
programs frequently use only champion dogs, which are few in number and often 
carriers of mutations (MELVILLE et al., 2005). Although this is a concern with 
regard to the health of the breed population, it also facilitates gene discovery in this 
species (MELVILLE et al., 2005). 
Dogs are also a valuable model for treatment studies. Rodent models, which are 
regularly used for the investigation of new drugs, are often criticized because they 
do not reflect clinical conditions accurately (POTSCHKA et al., 2013). Concerns 
include the restricted diversity of the genome and limited interindividual 
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pathophysiological differences (POTSCHKA et al., 2013). Dogs appear to be a 
promising model for the investigation of new treatment strategies, particularly in 
the field of epilepsy research. Rodent models are necessary for high-throughput 
screening of potential antiepileptic drugs (AED) (POTSCHKA et al., 2013). 
However, research in rodents mainly uses models of induced epilepsy that often do 
not reflect the clinical condition of spontaneously occurring epilepsies 
(PATTERSON, 2014). Moreover, a multifactorial mechanism is considered to 
underlie drug resistant epilepsy, which is likely better reflected by canine models 
with naturally occurring epilepsy (POTSCHKA et al., 2013). 
The aim of this work was to provide a comprehensive clinical description of a novel 
genetic epilepsy in Rhodesian Ridgeback (RR) dogs. Wireless video-
electroencephalography (EEG) in unsedated dogs was established as a clinical 
research tool to confirm the diagnosis of epilepsy, to recognize myoclonic and 
absence seizures, and to characterize the EEG features of this peculiar 
electroclinical syndrome. Photic stimulation was performed to investigate the reflex 
epileptic trait of the epilepsy syndrome. Segregation/pedigree analyses indicated a 
monogenic autosomal recessive disorder. Subsequent genetic analyses of cases and 
controls collected as part of this study were performed in collaboration with the 
University of Helsinki to identify the underlying genetic cause. 
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II.  REVIEW OF THE LITERATURE 
1. Canine genetic epilepsies 
Epilepsy is the most common chronic neurological disease in dogs (VOLK, 2015). 
Idiopathic and structural epilepsy as well as epilepsy of unknown cause can be 
differentiated based on aetiology (BERENDT et al., 2015). Structural epilepsy can 
be caused by various lesions of the forebrain including vascular events, 
inflammation, trauma, congenital malformation, neoplasia or degenerative diseases 
(BERENDT et al., 2015). Idiopathic epilepsy can be further subdivided into (a) 
genetic epilepsy, when the causative gene has been identified, (b) suspected genetic 
epilepsy, when there is a family history or a high prevalence of epilepsy within a 
breed (>2%), and (c) epilepsy of unknown cause, when there is no apparent 
evidence of a structural process, but no disease mechanism can be identified (Figure 
1) (BERENDT et al., 2015). 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Current aetiological classification of epileptic seizures and epilepsy 
as proposed by the International Veterinary Epilepsy Task Force (BERENDT 
et al., 2015) 
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1.1. Structural epilepsies 
1.1.1. Lafora disease 
Lafora disease belongs to the group of progressive myoclonic epilepsies (PME). 
The condition has been described in the Miniature Wirehaired Dachshund, Beagle, 
Basset Hound, Miniature Poodle, Standard Poodle, Pointer and Corgi breeds (LOHI 
et al., 2005a; SCHOEMAN et al., 2002; SWAIN et al., 2017). 
The discovery of the first epilepsy gene in Miniature Wirehaired Dachshunds with 
Lafora disease represented a milestone in veterinary epilepsy research (LOHI et al., 
2005a). Together with identification of the genetic variant in the EPM2B gene the 
authors also provided a detailed description of the clinicopathological findings 
(LOHI et al., 2005a). 
Affected dogs are presented with progressive myoclonic jerks that are bilaterally 
symmetrical and synchronous and involve mainly the face, neck, and thoracic 
limbs, causing retropulsion of the dog (GREDAL et al., 2003; HAJEK et al., 2016; 
LOHI et al., 2005a). Consciousness appears to be preserved during these episodes 
(GREDAL et al., 2003; HAJEK et al., 2016; SCHOEMAN et al., 2002). Myoclonus 
may occur spontaneously or in response to audiogenic and visual stimuli or sudden 
movements in the visual field (GREDAL et al., 2003; HAJEK et al., 2016; LOHI 
et al., 2005a; SCHOEMAN et al., 2002; SWAIN et al., 2017; WEBB et al., 2009). 
The frequency of myoclonus increases when the dogs are nervous or excited and 
diminishes when they are concentrating on a task (LOHI et al., 2005a). Age of onset 
varies from five months to twelve years, but dogs are usually presented at six to 
nine years of age (GREDAL et al., 2003; LOHI et al., 2005a; SWAIN et al., 2017; 
WEBB et al., 2009). In many dogs, the disease progresses to include generalized 
tonic-clonic seizures (GTCS), focal seizures, atonic attacks, ataxia, blindness, 
deafness, tremor, aggression, loss of house training and cognitive decline (HAJEK 
et al., 2016; LOHI et al., 2005a; SCHOEMAN et al., 2002; SWAIN et al., 2017; 
WEBB et al., 2009). 
Neurological and physical examinations are otherwise unremarkable in affected 
dogs (WEBB et al., 2009). The results of haematological and cerebrospinal fluid 
(CSF) analyses are within normal limits (HAJEK et al., 2016; SCHOEMAN et al., 
2002; WEBB et al., 2009). The results of magnetic resonance imaging (MRI) may 
be normal or reveal generalized ventricular dilation and cortical atrophy (LOHI et 
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al., 2005a; SWAIN et al., 2017; WEBB et al., 2009). Electromyography (EMG) 
shows abnormal spontaneous activity (fibrillation potentials, positive sharp waves) 
in the head and limb musculature (SCHOEMAN et al., 2002). 
Electroencephalography demonstrates bilateral synchronous polyspike-wave 
complexes (PSWC) and erratic myoclonus without an EEG correlate (GREDAL et 
al., 2003; LOHI et al., 2005a; SWAIN et al., 2017). 
In humans, Lafora disease is caused by mutations in the EPM1A gene or the 
NHLRC1 (formerly EPM2B) gene, which encode for the proteins laforin and malin, 
respectively (HAJEK et al., 2016; LOHI et al., 2005b). To date, only a variant in 
the NHLRC1 gene has been associated with Lafora disease in veterinary medicine 
(HAJEK et al., 2016; LOHI et al., 2005a). In contrast to other species, the canine 
NHLRC1 gene sequence harbours a two- or three-copy repeat of a twelve-
nucleotide sequence (HAJEK et al., 2016; LOHI et al., 2005a). In affected dogs, 
this 12-bp repeat is massively expanded (HAJEK et al., 2016; LOHI et al., 2005a). 
The variant has been identified in a number of Miniature Wirehaired Dachshunds 
(19 to 26 copies), two Beagles (same expansion as is in Miniature Wirehaired 
Dachshunds) and one Basset Hound (14 copies) (HAJEK et al., 2016; LOHI et al., 
2005a). Laforin is a glycogen phosphatase, whereas malin is an E3 ubiquitin ligase, 
that regulates laforin (HAJEK et al., 2016; WEBB et al., 2009). Loss of function of 
either leads to the accumulation of starch-like polyglucosans that are poorly 
branched and thus insoluble glycogen-like polysaccharides called Lafora bodies; 
they are pathognomonic for this eponymous disease (HAJEK et al., 2016; LOHI et 
al., 2005b; WEBB et al., 2009). 
If genetic testing is not available, the gold standard for the diagnosis of Lafora 
disease is the combination of typical clinical findings and identification of the 
characteristic intraneural polyglucosan bodies (Lafora bodies) in central nervous 
system tissue (SCHOEMAN et al., 2002). Lafora bodies may also be found in 
peripheral tissues, such as sweat glands of the skin, striated musculature and liver 
(HAJEK et al., 2016; SCHOEMAN et al., 2002). However, the rate of false-
negative results is high because of the variable content of Lafora bodies in these 
locations (HAJEK et al., 2016; SCHOEMAN et al., 2002). On light microscopy, 
Lafora bodies are round to oval and stain basophilic with haematoxylin and eosin 
(HE) stain. A characteristic feature of Lafora bodies is that they are periodic acid 
Schiff (PAS) positive and diastase resistant (LOHI et al., 2005a; SCHOEMAN et 
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al., 2002). 
Treatment is limited to the management of myoclonus and seizures (HAJEK et al., 
2016). Seizures may partially respond to AEDs, and various drugs including 
phenobarbital (PB), potassium bromide (KBr), levetiracetam (LEV), and 
gabapentin have been tried (GREDAL et al., 2003; HAJEK et al., 2016; WEBB et 
al., 2009). Although early studies suggested that dogs may benefit from an 
antioxidant-rich diet aimed at slowing disease progression, long-term observations 
failed to confirm this (HAJEK et al., 2016; SWAIN et al., 2017; WEBB et al., 
2009). 
Because the disease is fatal and the prognosis unfavourable, euthanasia is elected 
in most dogs when clinical signs have an unacceptable impact on the quality of life 
(WEBB et al., 2009). 
1.1.2. Neuronal ceroid lipofuscinosis 
The neuronal ceroid lipofuscinoses (NCL) belong to the group of PMEs although 
epileptic seizures are not a mandatory feature of this disease (DE SIQUEIRA, 2010; 
NITA et al., 2016; SHAHWAN et al., 2005). The NCLs are a heterogenous group 
of genetically determined, neurodegenerative, lysosomal storage disorders 
(FALLER et al., 2016; MOLE & COTMAN, 2015; NITA et al., 2016). A hallmark 
of the disease is the accumulation of autofluorescent storage material in neurons 
and other cell types (ASHWINI et al., 2016). Clinically, it is characterized by 
progressive cognitive and motor decline, vision loss, seizures, behavioural changes, 
and premature death (ASHWINI et al., 2016; KATZ et al., 2011). In addition to 
humans, NCL has been described in other species, including cats, cattle, ducks, 
sheep, ferrets, goats, horses, monkeys, parrots, pigs, mice, and many breeds of dogs 
(GILLIAM et al., 2015; KATZ et al., 2011; WEBER & PEARCE, 2013). 
In human medicine the NCLs were first categorized according to the age of onset 
as infantile, late-infantile, juvenile, and adult (MOLE & COTMAN, 2015; NITA et 
al., 2016). Another classification system used the corresponding eponyms: Haltia-
Santavuori disease, Jansky-Bielschowsky disease, Batten-Spielmeyer-Vogt 
disease, and Kufs disease (NITA et al., 2016). In the literature, “Batten disease” has 
been used for both juvenile NCL and the entire group of NCLs (NITA et al., 2016). 
Furthermore, human NCLs have been subdivided based on ultrastructural findings 
(HIRZ et al., 2017; NITA et al., 2016). A novel nomenclature was recently 
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recommended that took into account the involved gene and specific mutation, 
biochemical and clinical phenotype, ultrastructural findings, degree of functional 
disturbance, and other features (NITA et al., 2016). 
The majority of human NCLs have an autosomal recessive mode of inheritance with 
two exceptions: adult onset NCL is caused by a mutation in CLN4/DNAJC5 that 
has an autosomal dominant pattern of inheritance, and in one case report, a deletion 
in the CLN8 gene was maternally transmitted (MOLE & COTMAN, 2015). To date, 
all canine cases described in veterinary medicine have an autosomal recessive mode 
of inheritance (KARLI et al., 2014). At least 14 different genes are associated with 
human NCL (NITA et al., 2016). Currently, 13 of these genes have been identified 
(CLN1-CLN14, with the exception of CLN9 that refers to a predicted locus with an 
unidentified gene) (MOLE & COTMAN, 2015; NITA et al., 2016). Eight of these 
genes have been associated with canine NCLs in various breeds (Table 1) (HIRZ et 
al., 2017). Epileptic seizures have been reported to occur in association with five of 
these genes (CLN5, CLN7, CLN8, TPP1, ATP13A2) (ASHWINI et al., 2016; 
AWANO et al., 2006a; KOLICHESKI et al., 2017; MELVILLE et al., 2005; 
NAKAMOTO et al., 2011; TAYLOR & FARROW, 1992; WEBER & PEARCE, 
2013; WÖHLKE et al., 2011; FALLER et al., 2016; FARIAS et al., 2011; 
GILLIAM et al., 2015; GUO et al., 2015, 2014; HIRZ et al., 2017; KARLI et al., 
2014; KOLICHESKI et al., 2016). In addition, NCL has been described in 
numerous other dog breeds, namely the Cocker Spaniel, Dalmatian, Labrador 
Retriever, Miniature Schnauzer, Polish Owczarek Nizinny (Polish Lowland 
Sheepdog), Saluki, Japanese Retriever, Welsh Corgi, and Yugoslavian Shepherd 
(APPLEBY et al., 1982; BICHSEL & VANDEVELDE, 1982; GOEBEL et al., 
1988; JOLLY et al., 1997; KARLI et al., 2014; MINATEL et al., 2000; 
NARFSTRÖM et al., 2007; ROSSMEISL et al., 2003; UMEMURA et al., 1985). 
Yet, the genetic background remains obscure in these breeds of dogs. A breed-
specific variant in the Arylsulfatase G (ARSG) gene was shown to cause a late-onset 
form of NCL in American Staffordshire Terriers (ABITBOL et al., 2010). However, 
recent studies suggest that the disease caused by ARSG deficiency in American 
Staffordshire Terriers is instead a mucopolysaccharidosis (FALLER et al., 2016; 
GUO et al., 2015). 
Although autofluorescent lysosomal storage bodies can be found not only in the 
CNS and retina but also in various other tissues, neurological signs are the 
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predominant clinical feature (Table 1) (FALLER et al., 2016; GILLIAM et al., 
2015; HIRZ et al., 2017; SANDERS et al., 2011). Therefore, canine NCL is 
characterized by progressive motor impairment including ataxia, tetraparesis and 
hypermetria, cognitive decline with dementia, disorientation, and loss of 
housetraining and previously learned commands, and behavioural changes such as 
anxiety, nervousness and aggression (AWANO et al., 2006b, 2006a; FARIAS et 
al., 2011; GILLIAM et al., 2015; GUO et al., 2014; HIRZ et al., 2017; 
KOLICHESKI et al., 2016; ROSSMEISL et al., 2003; SANDERS et al., 2010). 
Myoclonic, focal, or generalized tonic-clonic seizures have been described in 
Dachshunds with CLN2, Australian Cattle dogs, Border Collies, and Golden 
Retrievers with CLN5, Chihuahuas and Chinese Crested dogs with CLN7, 
Australian Shepherds, Alpenländische Dachsbracke dogs and English Setters with 
CLN8, and Tibetan Terriers with CLN12 (ASHWINI et al., 2016; AWANO et al., 
2006a; KOLICHESKI et al., 2017; MELVILLE et al., 2005; NAKAMOTO et al., 
2011; TAYLOR & FARROW, 1992; WEBER & PEARCE, 2013; WÖHLKE et al., 
2011; FALLER et al., 2016; FARIAS et al., 2011; GILLIAM et al., 2015; GUO et 
al., 2015, 2014; HIRZ et al., 2017; KARLI et al., 2014; KOLICHESKI et al., 2016). 
Other neurological signs include circling, pacing, vestibular syndrome, tremor, 
hallucinations, dysphagia, incontinence, insomnia, lethargy, and fatigue 
(ASHWINI et al., 2016; FARIAS et al., 2011; GUO et al., 2014; KOIE et al., 2004; 
KOLICHESKI et al., 2016, 2017; NARFSTRÖM et al., 2007; ROSSMEISL et al., 
2003; SANDERS et al., 2010). A hallmark of NCL is progressive vision loss, which 
can be caused by lesions of the visual cortex (central blindness) or by an ongoing 
retinopathy (peripheral blindness) (ROSSMEISL et al., 2003). 
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Clinical Signs 
Other 
bilateral 
ventral 
strabism 
not 
reported 
circling, 
tremor, 
vestibular 
syndrome, 
lethargy 
circling 
circling, 
pacing 
head tilt, 
halluci-
nations 
lethargy, 
vestibular 
syndrome 
Seizures 
generalized 
tonic-clonic 
not reported 
generalized 
tonic-clonic, 
focal, 
myoclonic, 
fly biting, 
trance-like 
episodes 
not reported 
focal, fly 
biting, 
trance-like 
episodes 
fly biting, 
unclassified 
seizures 
not reported 
Cognition 
disorientation 
not reported 
not reported 
not reported 
loss of 
housetraining 
and learned 
commands 
dementia 
not reported 
Behaviour 
anxiety, 
aggression 
not reported 
anxiety, 
aggression 
anxiety 
anxiety, 
aggression 
hyperactivity, 
aggression 
not reported 
Gait 
not reported 
ataxia, 
hypermetria 
ataxia, 
tetraparesis 
ataxia 
ataxia 
ataxia 
ataxia, 
hypermetria 
Vision 
loss of 
vision 
not 
reported 
loss of 
vision 
loss of 
vision 
loss of 
vision 
loss of 
vision 
loss of 
vision 
Onset 
in 
months 
18-24 
11-36 
6-19 
18 
8 
15 
8 
Mutation 
CLN8:g.30,8
52,988_30,9
02,901del 
CTSD:c.597
G>A 
CLN5:c.619
C>T 
CLN6:c.829
T>C 
CLN8:c.585
G>A 
CLN5:c.619
C>T 
PPT1:c.124 
+ 1G>A 
Gene 
CLN8 
CTSD 
(CLN10) 
CLN5 
CLN6 
CLN8 
CLN5 
PPT1 
(CLN1) 
Breed 
Alpenländische 
Dachsbracke 
dog 
American 
Bulldog 
Australian 
Cattle dog 
Australian 
Shepherd 
Australian 
Shepherd 
Border Collie 
Cane Corso 
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Clinical Signs 
Other 
head tilt, 
difficulties in 
food 
prehension, 
circling 
not reported 
weakness 
vomiting, 
circling, 
weakness, 
head tremor 
not reported 
pacing, 
circling, 
tremor 
not reported 
Seizures 
seizures 
behavioural arrest 
not reported 
myoclonic 
unclassified 
seizures 
generalized, 
focal, fly biting, 
trance-like 
episodes 
generalized tonic-
clonic 
Cognition 
disorientation, 
cognitive 
impairment, loss of 
housetraining and 
learned commands 
disorientation 
disorientation 
mental dullness, 
loss of 
housetraining and 
learned commands, 
disorientation 
cognitive 
impairment 
loss of learned 
commands 
loss of learned 
commands, 
disorientation 
Behaviour 
anxiety, 
hyperacusis, 
aggression 
anxiety, 
nervousness 
behavioural 
changes 
hyper-
activity, 
aggression 
not reported 
anxiety, 
aggression 
anxiety, 
aggression, 
nervousness 
Gait 
ataxia 
ataxia 
ataxia 
ataxia, 
hyper-
metria 
ataxia 
ataxia 
ataxia 
Vision 
loss of 
vision 
loss of 
vision 
loss of 
vision 
loss of 
vision 
loss of 
vision 
loss of 
vision 
loss of 
vision 
Onset 
in 
months 
12-18 
12 
8-9 
7-9 
12-24 
13-17 
60-96 
Mutation 
MFSD8c
.843delT 
MFSD8c
.843delT 
PPT1:c.
736_737
insC 
TPP1:c.
325delC 
CLN8:c.
491T>C 
CLN5:c.
934_935
delAG 
ATP13A
2:c.1623
delG 
Gene 
MFSD8 
(CLN7) 
MFSD8 
(CLN7) 
PPT1 
(CLN1) 
TPP1 
(CLN2) 
CLN8 
CLN5 
ATP13A2 
(CLN12) 
Breed 
Chihuahua 
Chinese 
Crested 
dog 
Dachs-
hund 
Dachs-
hund 
English 
Setter 
Golden 
Retriever 
Tibetan 
Terrier 
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Age of onset depends on the breed and underlying gene mutation (HIRZ et al., 
2017). In veterinary medicine, two forms are differentiated: the early or juvenile 
form, which has an approximate age at onset of 18 months and the late or adult 
form, which manifests at about 1.5 to nine years of age (KARLI et al., 2014). Age 
of onset is often underestimated by owners, who do not expect their dogs to develop 
neurological abnormalities (KOLICHESKI et al., 2017). For example, in 
Dachshunds with CLN2, owners reported an age of onset of seven to nine months 
(KOLICHESKI et al., 2017). In an experimental setting, however, animal 
technicians were able to identify affected dogs as early as five months of age 
(KOLICHESKI et al., 2017). Moreover, Sanders et al. demonstrated that in 
Dachshunds with CLN2, electroretinogram responses and cognitive function 
assessed using a reversal learning task were altered at the age of six months and 
clinical signs of motor and visual impairment became apparent only in a later stage 
of the disease (SANDERS et al., 2011). 
A complete blood count (CBC), serum biochemical profile, pre- and postprandial 
serum bile acids, urinalysis, urine metabolic screen for inborn errors of metabolism, 
and CSF examination are within reference intervals (AWANO et al., 2006a; HIRZ 
et al., 2017; KOLICHESKI et al., 2016). Results of neurological examination 
reflect the involved areas of brain. Despite apparent visual deficits, absent menace 
response, and histologically confirmed retinal involvement, the pupillary light 
reflex may be normal, incomplete, or absent (ASHWINI et al., 2016; GUO et al., 
2015; NARFSTRÖM et al., 2007). Ophthalmoscopic examination may be normal 
or reveal fundoscopic changes (GUO et al., 2015; NAKAMOTO et al., 2011; 
NARFSTRÖM et al., 2007). Likewise, electroretinography may show 
physiological or abnormal results (GUO et al., 2014, 2015; NARFSTRÖM et al., 
2007). The results of MRI are consistent with generalized brain atrophy and reveal 
dilation of the ventricular system, thinning of the interthalamic adhesion, and 
widening of the cerebral and cerebellar sulci (GUO et al., 2014; HIRZ et al., 2017; 
KOIE et al., 2004; KOLICHESKI et al., 2016). An unexpected MRI finding in 
Chihuahuas with NCL is diffuse thickening of the meninges with marked contrast 
enhancement that represents collagenous tissue with mild infiltration of 
macrophages, lymphocytes, and plasma cells (NAKAMOTO et al., 2011). In one 
dog, EEG carried out during an episode of facial twitching that progressed to a 
GTCS revealed background slowing (7-9 Hz) and diffuse epileptiform discharges 
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(spike wave activity) (ROSSMEISL et al., 2003). 
Histological examination reveals a decrease in neuronal density in the cerebral 
cortex and granular layer of the cerebellum as well as a reduced number of Purkinje 
cells (FALLER et al., 2016; HIRZ et al., 2017; KOLICHESKI et al., 2017). The 
density of granule cells and neurons in the deep cerebellar nuclei may be decreased 
too (HIRZ et al., 2017; KOLICHESKI et al., 2017). The retina is markedly thinned 
and lacks readily identifiable retinal layers (ASHWINI et al., 2016). 
Autofluorescent storage material can be found throughout the CNS, but is most 
prevalent in the perinuclear area of neurons in the cerebral cortex, the granular layer 
of the cerebellum, the Purkinje cells, and the ganglion cells of the retina (HIRZ et 
al., 2017; KATZ et al., 2011; KOLICHESKI et al., 2017). Abundant deposits of 
intracellular lipid material may also be seen in the basal nuclei, hippocampus, 
thalamus, molecular layer of the cerebellum, brainstem, and spinal cord (ASHWINI 
et al., 2016; FALLER et al., 2016; WÖHLKE et al., 2011). These intracellular 
aggregates stain PAS positive, Sudan blue positive, Sudan black B positive, slightly 
positive with acid-fast staining, and dark blue with Luxol fast blue staining, and 
there is strong staining for lysosomal-associated membrane protein 1 (LAMP-1) 
(FALLER et al., 2016; HIRZ et al., 2017; NAKAMOTO et al., 2011). Lysosomal 
storage bodies can also be found in other organs and tissues such as the heart, 
duodenum, liver, enteric nervous system, and in macrophages in the spleen, lymph 
nodes, and lung (FALLER et al., 2016; HIRZ et al., 2017; KOLICHESKI et al., 
2016). 
Electron microscopic examination may reveal a distinct ultrastructural appearance 
of the accumulated material that includes granular osmiophilic deposits (GRODs), 
curvilinear profiles, rectilinear complexes, fingerprint profiles, and condensed or 
mixed forms (AWANO et al., 2006b; HIRZ et al., 2017; NITA et al., 2016). 
Traditionally, these ultrastructural changes have been used to subclassify human 
NCLs (HIRZ et al., 2017; NITA et al., 2016). However, the ultrastructural findings 
can be quite variable and more than one pattern may be found in many NCLs (NITA 
et al., 2016; O’BRIEN & KATZ, 2008). Moreover, the ultrastructural findings 
depend on the tissue examined (NITA et al., 2016). 
In most types of NCL, the major component of the accumulated autofluorescent 
lipopigment is subunit c of mitochondrial adenosine triphosphate (ATP) synthase 
(SCMAS) (HIRZ et al., 2017; MELVILLE et al., 2005; MINATEL et al., 2000; 
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NARFSTRÖM et al., 2007). In contrast, sphingolipid activator proteins (SAPs or 
saposins) A and D are the principal constituents of the storage bodies in children 
with infantile NCL as well as in Miniature Schnauzers and Polish Lowland 
Sheepdogs (HIRZ et al., 2017; MELVILLE et al., 2005; MINATEL et al., 2000; 
NARFSTRÖM et al., 2007; PALMER et al., 1997). 
Neuronal ceroid lipofuscinoses have an invariably fatal course, although the rate of 
disease progression can vary among breeds (ROSSMEISL et al., 2003). For 
example, the clinical course of CLN10 disease in American Bulldogs is less severe 
than in other breeds, possibly because of a residual cathepsin D enzymatic activity 
of 36% (AWANO et al., 2006b; KOLICHESKI et al., 2017). 
To date, there is no efficient treatment to delay the progression of NCL (SANDERS 
et al., 2011, 2010; WEBER & PEARCE, 2013). However, several therapeutic 
strategies are currently under investigation (ASHWINI et al., 2016; KATZ et al., 
2017, 2015; KOLICHESKI et al., 2017; SANDERS et al., 2011; TRACY et al., 
2016; WHITING et al., 2016). Dachshunds that suffer from CLN2 disease caused 
by tripeptidyl peptidase 1 (TPP1) deficiency have been used as a model to 
investigate a variety of promising treatment approaches and this has paved the way 
for ongoing human trials (ASHWINI et al., 2016; KATZ et al., 2017, 2015; 
KOLICHESKI et al., 2017; SANDERS et al., 2011; TRACY et al., 2016; 
WHITING et al., 2016). A significant delay in the onset and progression of 
neurological signs and the extension of lifespan are achieved by periodic infusion 
of recombinant TPP1 into the CSF (KATZ et al., 2015; WHITING et al., 2016). 
The same effect is observed with TPP1 gene transfer to the ependyma by a single 
administration of a gene vector to the CSF (KATZ et al., 2015; WHITING et al., 
2016). However, these approaches address only the neurological system, although 
retinal ganglion cells may be selectively preserved (KATZ et al., 2017; WHITING 
et al., 2016). Indeed, patients that receive treatments that target the CNS may 
develop clinical signs that are related to extraneuronal lesions, for example cardiac 
dysfunction (ASHWINI et al., 2016; KATZ et al., 2017). Intravitreal stem cell 
therapy was shown to decelerate retinal pathology (TRACY et al., 2016). Systemic 
gene therapy or administration of TPP1 has been suggested as a treatment for 
extraneuronal disease (KATZ et al., 2017). 
In breeds with a high carrier frequency, especially in those that have a later onset 
of NCL, genetic testing constitutes a valuable tool to decrease the number of 
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affected individuals. In a recent study, Kluth et al. showed that selective breeding 
based on genetic testing is a favourable method for the gradual, albeit slow 
reduction of carriers of the ATP13A2 mutation in Tibetan Terriers (KLUTH et al., 
2014). 
1.2. Idiopathic epilepsies 
1.2.1. Benign familial juvenile epilepsy in Lagotto Romagnolo dogs 
Benign familial juvenile epilepsy (BFJE) in Lagotto Romagnolo dogs is a genetic 
focal epilepsy syndrome (JOKINEN et al., 2007; SEPPÄLÄ et al., 2011). Affected 
dogs are presented with focal seizures that are characterized by generalized tremor, 
stiffness, and ataxia with lateralization (JOKINEN et al., 2007). During these 
episodes, consciousness may be preserved or absent (JOKINEN et al., 2007). 
Seizures may occur at any time of the day and during activity as well as at rest 
(JOKINEN et al., 2007). Seizure frequency varies from multiple episodes per day 
to one event per week (JOKINEN et al., 2007). In the interictal period, some dogs 
may demonstrate ataxia and falling (JOKINEN et al., 2007). The mean age of onset 
is 6.3 weeks (five to nine weeks) (JOKINEN et al., 2007). In most cases, the disease 
resolves spontaneously at the age of ten weeks (7.5 to 13 weeks) (JOKINEN et al., 
2007). 
The results of physical examination are normal (JOKINEN et al., 2007). 
Neurological examination may reveal ataxia, hypermetria, tremor, postural reaction 
deficits, and a reduced menace response in some dogs (JOKINEN et al., 2007). 
Neurological deficits resolve with cessation of seizures (JOKINEN et al., 2007). 
The results of a serum biochemical profile, CBC, urinalysis, and CSF examination 
are within reference intervals (JOKINEN et al., 2007). Similarly, EMG, brainstem 
auditory evoked response, and MRI are unremarkable (JOKINEN et al., 2007). 
Histological examination reveals eosinophilic, intracytoplasmic inclusions, likely 
pseudo-Negri bodies, and mild Purkinje cell loss (JOKINEN et al., 2007). Interictal 
EEG under medetomidine sedation demonstrated focal epileptiform discharges 
(sharp waves and spikes) in the centrotemporal and occipital lobes in about 88% of 
affected puppies (JOKINEN et al., 2007; SEPPÄLÄ et al., 2011). 2-[18F] fluoro-
2-deoxy-D-glucose (18FDG)-positron emission tomography (PET)-MRI indicated 
hypometabolism in the parietal, temporal, and occipital cortices with EEG 
abnormalities in the same locations, suggesting that this may be the epileptogenic 
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focus in these dogs (JOKINEN et al., 2014). 
Although Lagotto Romagnolo dogs with BFJE have a good long-term prognosis 
regarding seizure outcome, affected dogs may develop neurobehavioural 
comorbidities in adulthood (JOKINEN et al., 2015). Jokinen et al. demonstrated 
that dogs older than four years of age diagnosed with BFJE in remission had 
significantly higher inattention and excitability/impulsivity scores than appropriate 
controls (JOKINEN et al., 2015). The behavioural abnormalities seen in the Lagotto 
Romagnolo dogs were comparable to attention deficit hyperactivity disorder 
(ADHD) in humans, which is also a frequently observed comorbidity in human 
epilepsy syndromes (JOKINEN et al., 2015). 
While the majority of dogs in the study of Jokinen et al. did not receive an 
antiepileptic medication, the authors recommended treating at least severely 
affected puppies to prevent seizure recurrence in adulthood (JOKINEN et al., 
2007). 
Benign familial juvenile epilepsy has been linked to a truncating mutation in the 
LGI2 gene (c.1552A>T) (SEPPÄLÄ et al., 2011). The disease has an autosomal 
recessive mode of inheritance, although a 1.8% rate of non-penetrance and a 7% 
rate of disease through heterozygosity is observed (SEPPÄLÄ et al., 2011). Carrier 
frequency is as high as 32% (SEPPÄLÄ et al., 2011). LGI2 belongs to the leucine-
rich glioma-inactivated (LGI) protein family, which consists of four members 
(LGI1-4) (SEPPÄLÄ et al., 2011). It is neuronally secreted and has a function 
similar to that of LGI1 (PAKOZDY et al., 2015). Both proteins interact with three 
different members of the a-disintegrin-and-metalloproteinase (ADAM) family 
(ADAM11, ADAM22, ADAM23) (PAKOZDY et al., 2015; SEPPÄLÄ et al., 
2011). One of its functions is the co-assembly of postsynaptic ADAM22 and 
presynaptic ADAM23, pulling the pre- and postsynaptic membranes together, 
hence stabilizing the synapses and enhancing neurotransmission (PAKOZDY et al., 
2015; SEPPÄLÄ et al., 2011). Truncation of either LGI1 or LGI2 prevents its 
secretion and interaction with ADAM proteins (SEPPÄLÄ et al., 2011). In human 
medicine, mutations in the LGI1 gene are known to cause autosomal dominant 
lateral temporal lobe epilepsy starting at about ten years of age (SEPPÄLÄ et al., 
2011). Moreover, limbic encephalitis in humans and cats is caused by auto-
antibodies against LGI1 (PAKOZDY et al., 2015). LGI1 is mainly expressed at the 
end of the pruning phase and thereafter (PAKOZDY et al., 2015; SEPPÄLÄ et al., 
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2011). In contrast, LGI2 expression levels are highest at birth and diminish towards 
the middle of neural pruning (PAKOZDY et al., 2015; SEPPÄLÄ et al., 2011). 
Therefore, it is possible that LGI1 takes over the function of LGI2 during pruning, 
which would explain the remitting course of BFJE (SEPPÄLÄ et al., 2011). 
1.2.2. Genetic epilepsy in Boerboel dogs 
The genetic background of a focal epilepsy syndrome has been identified in 
Boerboel dogs (STASSEN et al., 2013). This syndrome is characterized by epileptic 
seizures that involve spasms of the facial and limb musculature with impaired 
consciousness, vocalization, and anxiety (STASSEN et al., 2013). Age of onset is 
three months, and there are no abnormalities on diagnostic work-up (physical 
examination, CBC, serum biochemical profile, urinalysis, neurometabolic 
screening, MRI, and CSF) (STASSEN et al., 2013). Histological examination 
reveals that the neurons are partially filled with large vacuoles throughout the entire 
brain (STASSEN et al., 2013). Pedigree analysis points to an autosomal recessive 
mode of inheritance (STASSEN et al., 2013). A mutation in a neuronal gene, 
leading to a splicing deficiency was identified (STASSEN et al., 2013). This 
neuronal gene has not been associated with epilepsy to date (STASSEN et al., 
2013). It encodes a mitochondrial membrane protein, the function of which has not 
yet been elucidated (STASSEN et al., 2013). 
1.2.3. ADAM23 – a risk factor for idiopathic epilepsy 
The average prevalence of epilepsy of unknown origin in dogs is 0.62% but may be 
as high as 18% in certain breeds of dogs (KEARSLEY-FLEET et al., 2013; 
KOSKINEN et al., 2015; POTSCHKA et al., 2013). Together with familial based 
data and pedigree studies, this observation raises the suspicion of a genetic 
background (HÜLSMEYER et al., 2015; KOSKINEN et al., 2015). A breakthrough 
in understanding the genetics of idiopathic epilepsy was recently attained when a 
risk factor for idiopathic epilepsy in Belgian Shepherd dogs was identified in the 
ADAM23 gene (SEPPÄLÄ et al., 2012). Belgian Shepherd dogs have a mild 
epilepsy phenotype and experience mainly focal seizures with secondary 
generalization but may also have primary generalized seizures and focal seizures 
without generalization (SEPPÄLÄ et al., 2012). The mean age of onset is 
approximately three years (SEPPÄLÄ et al., 2012). The results of neurological, 
haematological, and CSF examinations as well as MRI are unremarkable 
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(SEPPÄLÄ et al., 2012). Electroencephalography reveals epileptiform discharges 
(sharp waves, spikes, spike-wave complexes (SWC)) with variable foci (SEPPÄLÄ 
et al., 2012). Although the homozygous risk allele is common within the breed 
(22%) and suggests a rather low penetrance, there is a seven-fold increase in the 
risk of idiopathic epilepsy (SEPPÄLÄ et al., 2012). 
Further studies that determined the impact of ADAM23 in several dog breeds with 
idiopathic epilepsy confirmed a six-variant risk haplotype spanning a 28-kb region 
located between exon five and eleven in ADAM23 (KOSKINEN et al., 2015, 2017). 
However, the precise causal variant still needs to be identified (KOSKINEN et al., 
2015, 2017). Associations were identified in Whippet, Australian Shepherd, 
Kromfohrländer, Labrador Retriever, Finnish Spitz, Beagle, Belgian Shepherd, and 
Schipperke dogs (KOSKINEN et al., 2015, 2017). Although not statistically 
significant, this association had a similar trend in the Pyrenean Shepherd, Irish 
Setter and Miniature Pinscher breeds (KOSKINEN et al., 2017). The only breed in 
which there was no association with the haplotype was the Finnish Lapphund 
(KOSKINEN et al., 2017). 
ADAM23 is a membrane-anchored protein, which is highly expressed in the CNS, 
especially by pyramidal cells of the cerebral cortex and hippocampus and the 
Purkinje cells of the cerebellum (KOSKINEN et al., 2015, 2017). It is involved in 
cellular adhesion and interacts with ADAM22 as well as with the two epilepsy-
associated proteins LGI1 and LGI2 and it enhances neurite outgrowth and dendritic 
branching via its interaction with LGI1 (KOSKINEN et al., 2015, 2017; 
PAKOZDY et al., 2015; SEPPÄLÄ et al., 2011, 2012) Moreover, together with 
other proteins, ADAM23 builds a complex that draws the pre- and postsynaptic 
membranes together to increase neurotransmission (PAKOZDY et al., 2015; 
SEPPÄLÄ et al., 2012). Mouse models emphasize the epileptogenic potential of 
ADAM23, and a complete knockout of this gene leads to tonic-clonic seizures, other 
neurological deficits and premature death, and a reduced seizure threshold is 
observed in heterozygous animals (KOSKINEN et al., 2015; PAKOZDY et al., 
2015). 
II. Review of the literature     18 
2. Human juvenile myoclonic epilepsy 
2.1. Clinical aspects 
Juvenile myoclonic epilepsy (JME) is one of the most common forms of human 
idiopathic generalized epilepsies (IGE), accounting for 26.7% of IGE and 4.1% of 
all epilepsies (SERAFINI et al., 2013; YACUBIAN, 2017). The hallmarks of this 
epilepsy syndrome are myoclonic seizures that occur upon awakening and an early 
onset at around puberty (BAYKAN & WOLF, 2017; GENTON et al., 2013; WOLF 
et al., 2015). The mean age at onset is around 14 years and patients have normal 
intelligence (WELTY, 2006; YACUBIAN, 2017). There are no abnormalities on 
neurological examination, and routine brain imaging is unremarkable 
(ALFRADIQUE & VASCONCELOS, 2007; ANDERSON & HAMANDI, 2011; 
KOEPP et al., 2014; WANDSCHNEIDER et al., 2012; WELTY, 2006). It was 
thought that JME affected both genders equally, but recent studies have shown a 
female preponderance (ALFRADIQUE & VASCONCELOS, 2007; GENTON et 
al., 2013; YACUBIAN, 2017). 
2.1.1. The triad of seizure types in JME 
Three seizure types are observed in human JME, namely myoclonic seizures, 
GTCS, and absence seizures. 
Myoclonic jerks are sudden, brief (1-2 s), and spontaneous without loss of 
consciousness (GENTON et al., 2013; WELTY, 2006; YACUBIAN, 2017). They 
predominate in the upper limbs, are bilateral, arrhythmic and irregular, and may be 
single or repetitive in arrhythmic clusters (GENTON et al., 2013; YACUBIAN, 
2017). Myoclonic seizures are grossly symmetrical, but may be perceived as 
affecting the dominant side more, as the jerk will interfere with the activity executed 
by this hand (GENTON et al., 2013; WOLF et al., 2015). Nonetheless, praxis-
induced reflex seizures may indeed predominate in the executive hand (GENTON 
et al., 2013; WOLF et al., 2015; YACUBIAN, 2017). Myoclonic jerks often make 
patients throw or drop objects (this is often misinterpreted as clumsiness by the 
patient), and less commonly make some patients fall (GENTON et al., 2013). 
Complaints associated with myoclonic seizures consist of slurred speech, sighs, 
walking difficulties, and nervousness of the limbs (WELTY, 2006). 
Most patients (80-95%) continue to develop rare GTCS 1.3 to 3.3 years after onset 
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of myoclonic seizures (GENTON et al., 2013; WOLF et al., 2015). Generalized 
tonic-clonic seizures often follow a crescendo of myoclonic seizures and are 
actually clonic-tonic-clonic seizures (GENTON et al., 2013). Many JME patients 
may only seek medical advice after their first GTCS because myoclonic jerks are 
often overlooked or underestimated by patients and their families (GENTON et al., 
2013; WOLF et al., 2015; YACUBIAN, 2017). In these cases, it is up to the 
physician to specifically ask about the occurrence of myoclonic jerks (GENTON et 
al., 2013). 
The third seizure type encountered in about 30% of JME patients is absence seizures 
(NICOLSON & MARSON, 2010; WOLF et al., 2015; YACUBIAN, 2017). They 
are sporadic and brief and often neglected by patients due to incomplete interference 
with consciousness (GENTON et al., 2013; WOLF et al., 2015; YACUBIAN, 
2017). Hence, this seizure type may only be discovered on long-term EEG 
recordings (GENTON et al., 2013). Interestingly, up to 15% of patients with 
childhood absence epilepsy (CAE) or juvenile absence epilepsy go on to develop 
JME (CAMFIELD et al., 2013; GENTON et al., 2013; WOLF et al., 2015). 
2.1.2. Chronodependency and provocative factors 
One of the most striking characteristics of JME is its chronodependency: the strict 
correlation between seizure occurrence and specific time of the day (ANDERSON 
& HAMANDI, 2011; KASTELEIJN-NOLST TRENITÉ et al., 2013a). Myoclonic 
jerks and GTCS occur almost exclusively within the first two hours after 
awakening, mostly in the morning, but to a lesser extent also after a nap or during 
an arousal at night (GENTON et al., 2013; NICOLSON & MARSON, 2010; 
YACUBIAN, 2017). This circumstance is more pronounced after provoked than 
after spontaneous awakening (GENTON et al., 2013; SERAFINI et al., 2013). 
Seizures may also occur in the evening relaxation period (GENTON et al., 2013; 
HASHEMIAGHDAM et al., 2015; WOLF et al., 2015; YACUBIAN, 2017). 
Chronodependency may be the explanation for the peculiar circadian pattern of 
activity in JME patients: they tend to have an evening type of circadian rhythm, 
being most active in the afternoon and evening, not feeling well before ten a.m. and 
going to bed late (GENTON et al., 2013; KASTELEIJN-NOLST TRENITÉ et al., 
2013a). 
A wide variety of provocative factors that are capable of triggering seizures in JME 
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patients have been described. The most frequent precipitating factors are sleep 
deprivation, stress, and alcohol (ALFRADIQUE & VASCONCELOS, 2007; 
ANDERSON & HAMANDI, 2011; GENTON et al., 2013; KASTELEIJN-NOLST 
TRENITÉ et al., 2013a; WELTY, 2006). Visual stimuli such as flashlights, 
television, and videogames can trigger seizures in 15% of patients (ALFRADIQUE 
& VASCONCELOS, 2007; GENTON et al., 2013; KASTELEIJN-NOLST 
TRENITÉ et al., 2013a). However, there is some discrepancy between the high 
proportion of patients exhibiting a photoparoxysmal response (PPR) on EEG with 
photic stimulation and the small number of patients that have clinical 
photosensitivity in daily life (GENTON et al., 2013). Other precipitants are fatigue, 
excitement/frustration, and fever (ALFRADIQUE & VASCONCELOS, 2007; 
KASTELEIJN-NOLST TRENITÉ et al., 2013a). In women menstrual cycle plays 
an important role (ALFRADIQUE & VASCONCELOS, 2007; GENTON et al., 
2013; KASTELEIJN-NOLST TRENITÉ et al., 2013a). Other provocative factors 
are mental concentration, hand activities and complex finger movements, mental 
and written calculation, playing musical instruments, drawing, and specific types 
of music (ALFRADIQUE & VASCONCELOS, 2007; GENTON et al., 2013; 
KASTELEIJN-NOLST TRENITÉ et al., 2013a). Some of these aforementioned 
factors may be attributable to the phenomenon of praxis induction (BAYKAN & 
WOLF, 2017; KASTELEIJN-NOLST TRENITÉ et al., 2013a). Likewise, 
linguistic tasks such as reading are reported to generate perioral reflex myocloni 
(GENTON et al., 2013; KASTELEIJN-NOLST TRENITÉ et al., 2013a). Finally, 
hyperventilation can trigger absence seizures (KASTELEIJN-NOLST TRENITÉ et 
al., 2013a). 
2.1.3. Diagnostic criteria and subsyndromes 
Juvenile myoclonic epilepsy is a clinically and genetically heterogenous disorder 
(ANDERSON & HAMANDI, 2011; KOEPP et al., 2014). As a consequence, 
different diagnostic criteria have been used by scientists and clinicians from 
different countries, complicating comparison of studies and adequate 
recommendations for diagnosis and treatment regimens (KASTELEIJN-NOLST 
TRENITÉ et al., 2013b). Therefore, a group of international experts on JME 
collaborated to reach a consensus on the diagnosis and management of this epileptic 
syndrome (KASTELEIJN-NOLST TRENITÉ et al., 2013b). They proposed two 
groups of diagnostic criteria: one with fairly narrow requirements and the other with 
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more flexible requirements (KASTELEIJN-NOLST TRENITÉ et al., 2013b; 
WOLF et al., 2015). Class I criteria include myoclonic seizures without loss of 
consciousness occurring exclusively within two hours after awakening, with an ictal 
pattern of generalized high amplitude polyspikes or PSWC, an unremarkable EEG 
background, normal intelligence, and an age of onset between ten and 25 years 
(KASTELEIJN-NOLST TRENITÉ et al., 2013b; WOLF et al., 2015; YACUBIAN, 
2017). Class II criteria comprise myoclonic seizures predominantly after 
awakening, a normal EEG background, generalized epileptiform discharges on 
EEG with or without concomitant myoclonic jerks and with some asymmetry 
permitted, no mental retardation or deterioration, and an age of onset between six 
and 25 years (KASTELEIJN-NOLST TRENITÉ et al., 2013b; WOLF et al., 2015; 
YACUBIAN, 2017). Furthermore, class II criteria encompass provocative factors 
such as sleep deprivation, stress, visual stimuli, praxis induction, and GTCS 
preceded by myoclonic seizures (KASTELEIJN-NOLST TRENITÉ et al., 2013b; 
WOLF et al., 2015; YACUBIAN, 2017). 
Four subsyndromes can be distinguished in JME (BAYKAN et al., 2013; 
MARTÍNEZ-JUÁREZ et al., 2006; YACUBIAN, 2017). The largest number of 
patients make up the classic JME group (72%) (MARTÍNEZ-JUÁREZ et al., 2006). 
By definition, the first seizure type these patients experience is a myoclonic seizure 
or a GTCS (MARTÍNEZ-JUÁREZ et al., 2006; YACUBIAN, 2017). Absence 
seizures may emerge in the course of the disease, but they are not a mandatory 
feature (MARTÍNEZ-JUÁREZ et al., 2006). The second group is CAE evolving to 
JME (18%) (BAYKAN et al., 2013; YACUBIAN, 2017). Obviously in these 
patients the first seizure type observed are pyknoleptic seizures that start between 
the age of three to eleven years (MARTÍNEZ-JUÁREZ et al., 2006). This group is 
differentiated from JME with an adolescent onset (twelve years and older) of 
pyknoleptic seizures that accounts for 7% of JME patients (BAYKAN et al., 2013; 
MARTÍNEZ-JUÁREZ et al., 2006). The last group comprises patients with JME 
with astatic seizures, which is observed in 3% of cases (BAYKAN et al., 2013; 
MARTÍNEZ-JUÁREZ et al., 2006). 
2.2. Reflex epileptic traits 
Reflex epileptic seizures are defined as seizures that are triggered reproducibly and 
instantaneously by certain sensory or cognitive stimuli (BENICZKY et al., 2012). 
Four reflex epileptic traits can be distinguished in JME, including photosensitivity, 
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eye closure sensitivity, praxis induction, and orofacial reflex myocloni (BAYKAN 
& WOLF, 2017; BENICZKY et al., 2012; WOLF et al., 2015; YACUBIAN, 2017). 
2.2.1. Photosensitivity 
2.2.1.1. General aspects of photosensitivity 
Photosensitivity is an abnormal visual sensitivity of the brain in reaction to external 
natural or artificial photic stimuli (LU et al., 2008). In the EEG it is expressed as a 
PPR (KASTELEIJN-NOLST TRENITÉ et al., 2013a; WALTZ et al., 1992). Video-
EEG with photic stimulation or intermittent light stimulation (ILS) is used to 
investigate the occurrence of photosensitivity (VERROTTI et al., 2012). This 
photic stimulation can elicit no response, a physiologic response such as photic 
driving, or a PPR (SENEVIRATNE et al., 2012). Flickering light with a frequency 
of 15 to 20 Hz has the highest potential to provoke a PPR (MARTINS DA SILVA 
& LEAL, 2017). A variety of classification systems for PPR have been proposed, 
but in the current literature the classification system established by Waltz et al. 
prevails (PARRA et al., 2005; WALTZ et al., 1992). This system divides PPR into 
four grades (Table 2): grade one is characterized by spikes that are limited to the 
occipital lobe; grade two encompasses parieto-occipital spikes that are followed by 
a slow wave; grade three is characterized by discharges that also spread to the 
frontal regions; and grade four has generalized SWC or PSWC (POLEON & 
SZAFLARSKI, 2017; WALTZ et al., 1992). 
Table 2: Classification of photoparoxysmal response 
The four types of photoparoxysmal response 
1) occipital spikes only 
2) parieto-occipital spikes followed by a biphasic slow wave 
3) parieto-occipital spikes followed by a biphasic wave with anterior 
extension 
4) generalized spike-wave- or polyspike-wave-complexes 
 
Classification of photoparoxysmal response according to Waltz et al. (WALTZ et 
al., 1992). 
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A grade four PPR is observed significantly more frequently in patients with IGE 
and their relatives and has therefore been suggested as a biomarker for IGE 
(WALTZ et al., 1992). Photosensitivity is more common in children with a peak 
age of onset at about twelve years with a five-fold increased prevalence in seven- 
to 19-year-old individuals and it is 1.5 to two times more prevalent in females 
(POLEON & SZAFLARSKI, 2017; VERROTTI et al., 2012). The prevalence of 
PPR in healthy individuals ranges from 0.9 to 9% and varies among the different 
epilepsy syndromes (KOELEMAN et al., 2013; POLEON & SZAFLARSKI, 
2017). Frequency estimations for JME range from 5 to 90% in contrast to a 
prevalence of 18% for CAE, 17% for Lennox-Gastaut syndrome, and 90% for 
Unverricht Lundborg disease and other PMEs (KASTELEIJN-NOLST TRENITÉ 
et al., 2013a; KOELEMAN et al., 2013; POLEON & SZAFLARSKI, 2017). It may 
be possible to explain this large discrepancy by variations in age, gender, treatment, 
and ILS protocols used (KASTELEIJN-NOLST TRENITÉ et al., 2013a; 
KOELEMAN et al., 2013; YACUBIAN, 2017). A standardized ILS protocol has 
been proposed for uniform evaluation of photosensitivity (KASTELEIJN-NOLST 
TRENITÉ et al., 2012). Treatment strategies include AEDs, e.g. valproate, 
lamotrigine and LEV, tinted or polarized glasses, darkened lenses, and avoidance 
of triggers (CRESPEL et al., 2013; KASTELEIJN-NOLST TRENITÉ et al., 2013a; 
POLEON & SZAFLARSKI, 2017). A multitude of studies provide strong evidence 
for a genetic component of PPR and many putative loci have been identified 
(VERROTTI et al., 2012). Nevertheless, the genetics of photosensitivity and its 
correlation to epilepsy are not entirely understood (VERROTTI et al., 2012). 
2.2.1.2. Photosensitivity in JME 
Juvenile myoclonic epilepsy has one of the strongest associations with 
photosensitivity among all epilepsies (GUERRINI & GENTON, 2004). Most 
studies report a prevalence of 30 to 50%, but in one study by Appleton et al., it was 
as high as 90% with more intense and prolonged stimulation (ALFRADIQUE & 
VASCONCELOS, 2007; ANDERSON & HAMANDI, 2011; APPLETON et al., 
2000; BAYKAN & WOLF, 2017; NICOLSON & MARSON, 2010; SERAFINI et 
al., 2013; WELTY, 2006; WOLF et al., 2015). Although electroencephalographic 
paroxysmal responses upon photic stimulation are common, the prevalence of 
clinical response to visual stimuli in daily life is lower (BAYKAN & WOLF, 2017; 
GENTON et al., 2013). Similar to other epilepsy syndromes, photosensitivity is 
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more prevalent in adolescent JME patients (KASTELEIJN-NOLST TRENITÉ et 
al., 2013a). Females are more often affected (48%) than males (26%) (SERAFINI 
et al., 2013). Other factors influencing photosensitivity in JME are current AED 
treatment, sleep deprivation, time of stimulation (more pronounced in the morning), 
and stimulation methodology, e.g. luminance, flicker frequency, amount of 
stimulated retina, and duration of stimulation (ANDERSON & HAMANDI, 2011; 
BAYKAN & WOLF, 2017; KASTELEIJN-NOLST TRENITÉ et al., 2013a; 
SERAFINI et al., 2013). The high prevalence of 90% described by Appleton et al. 
raises the question of whether photosensitivity is really an endophenotype of JME 
or whether there is a common mechanism for photosensitivity and ictogenesis in 
JME (APPLETON et al., 2000; BAYKAN & WOLF, 2017). 
2.2.2. Eye closure sensitivity 
Eye closure sensitivity is defined as the occurrence of occipitally accentuated 3 Hz 
spike and wave discharges within 2 s after eye closure (BAYKAN & WOLF, 2017; 
WOLF et al., 2015; YACUBIAN, 2017). The clinical pendant is eyelid myoclonia 
with or without absence seizures (BAYKAN & WOLF, 2017; WOLF et al., 2015). 
There is some overlap with photosensitivity, however it should be pointed out that 
the two entities are not identical (BAYKAN & WOLF, 2017; WOLF et al., 2015). 
Eye closure sensitivity is a core feature of Jeavons syndrome (eyelid myoclonia 
with absences), but can also be observed in 15-20% of JME patients (BAYKAN & 
WOLF, 2017; WOLF et al., 2015; YACUBIAN, 2017). Interestingly, only slow 
(spontaneous or voluntary) eye closure elicits eyelid myoclonia (BAYKAN & 
WOLF, 2017; DA CONCEIÇÃO et al., 2015; WOLF et al., 2015). In contrast, eye 
closure sensitivity is not observed with spontaneous or reflex blinking, suggesting 
an interaction between the supplementary motor area (SMA) and the visual system 
as the origin of this reflex epileptic trait (BAYKAN & WOLF, 2017; DA 
CONCEIÇÃO et al., 2015; WOLF et al., 2015). A functional MRI (fMRI) study by 
Vaudano et al. found an activation of the occipital cortex at eye closure followed 
by an activation of the SMA area 3 s later during eyelid myoclonia, supporting the 
hypothesis of the involvement of these two areas in ictogenesis (BAYKAN & 
WOLF, 2017; VAUDANO et al., 2014; WOLF et al., 2015). 
2.2.3. Praxis induction 
Praxis induction is defined as epileptic seizures that are precipitated by complex, 
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visuomotor tasks involving decision-making (BAYKAN & WOLF, 2017; WOLF 
et al., 2015; YACUBIAN, 2017). Myoclonic seizures elicited by praxis induction 
typically predominate in the active limb (BAYKAN & WOLF, 2017). This 
phenomenon is almost exclusively found in JME patients with a prevalence ranging 
from 30 to 50% (BAYKAN & WOLF, 2017). An fMRI study by Vollmar et al. 
revealed insights into the pathomechanism of this reflex epileptic trait (VOLLMAR 
et al., 2011). Study participants were confronted with a frontal lobe task using 
visuomotor coordination (VOLLMAR et al., 2011; WOLF et al., 2015). 
Performance did not differ between patients and controls (VOLLMAR et al., 2011; 
WOLF et al., 2015). However, JME patients showed an increased coactivation of 
the primary motor cortex and SMA as well as an increased functional connectivity 
between these areas and the frontoparietal cognitive networks and an impaired 
deactivation of the default mode network (VOLLMAR et al., 2011; WOLF et al., 
2015). The authors concluded that these findings may explain how cognitive 
activity can provoke myoclonic jerks in JME patients (VOLLMAR et al., 2011; 
WOLF et al., 2015). Although praxis induction is only observed in a subgroup of 
JME patients, the aforementioned study suggests that the underlying 
pathomechanism is a feature of JME patients in general, and individuals with praxis 
induction exhibit only a higher degree of this mechanism (BAYKAN & WOLF, 
2017; VOLLMAR et al., 2011). Moreover, it was proposed that patients with praxis 
induction may also represent a more severe subtype of JME because this reflex 
epileptic trait is a strong negative prognostic factor regarding response to AED 
treatment (BAYKAN & WOLF, 2017; GUARANHA et al., 2011; UCHIDA et al., 
2015). 
2.2.4. Orofacial reflex myocloni 
Orofacial reflex myocloni are small, lightning-like myocloni in the perioral 
muscles, jaw, tongue, and throat, triggered by language-related activities such as 
reading and talking (BAYKAN & WOLF, 2017; SALEK-HADDADI et al., 2009; 
WOLF et al., 2015; YACUBIAN, 2017; YACUBIAN & WOLF, 2015). It is the 
hallmark of primary reading epilepsy, but also represents a reflex epileptic trait in 
25 to 30% of JME patients (BAYKAN & WOLF, 2017; SALEK-HADDADI et al., 
2009; WOLF et al., 2015; YACUBIAN & WOLF, 2015). It is attributable to 
hyperactivation of the network that is required for linguistic communication 
(BAYKAN & WOLF, 2017; YACUBIAN, 2017; YACUBIAN & WOLF, 2015). 
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The observation that emotional or difficult tasks increase provocation and 
myoclonic jerks occur with some delay suggests that a certain number of neurons 
must be activated within cortico-reticular and cortico-cortical circuitries to elicit a 
myoclonic response (SALEK-HADDADI et al., 2009; WOLF et al., 2015). 
2.3. Electroencephalographic findings 
Typical EEG changes can be detected in 75 to 85% of JME patients on routine EEG 
examination, although a prevalence of only 54% has been reported in one study 
(GENTON et al., 1995; SERAFINI et al., 2013). Prolonged recordings or activation 
procedures such as photic stimulation or sleep deprivation may assist in the 
identification of paroxysmal EEG discharges (ALFRADIQUE & 
VASCONCELOS, 2007; SERAFINI et al., 2013; WELTY, 2006). Since 
epileptiform activity follows a circadian distribution similar to myoclonic seizures, 
EEGs performed in the morning hours are more likely to be diagnostic compared 
to those performed in the afternoon (SERAFINI et al., 2013). 
Electroencephalographic recording during sleep may also be beneficial because 
epileptic discharges increase at sleep onset, during sleep arousals, especially when 
provoked, and during the transition phase (one hour prior and half an hour after 
awakening) (BAYKAN & WOLF, 2017; SERAFINI et al., 2013). 
The EEG of patients with JME reveals a normal background rhythm 
(ALFRADIQUE & VASCONCELOS, 2007; BAYKAN & WOLF, 2017; 
SERAFINI et al., 2013). Characteristic interictal findings consist of 3-6 Hz 
generalized bilateral synchronous, but not necessarily symmetrical, PSWC with a 
frontocentral accentuation (ALFRADIQUE & VASCONCELOS, 2007; 
ANDERSON & HAMANDI, 2011; BAYKAN & WOLF, 2017; KOEPP et al., 
2014; NICOLSON & MARSON, 2010; SERAFINI et al., 2013; WELTY, 2006). 
Other interictal findings include single spikes, generalized spike-wave discharges, 
and irregular SWC, or diffuse or intermittent slowing (ALFRADIQUE & 
VASCONCELOS, 2007; SERAFINI et al., 2013). Asymmetric EEG changes and 
focal discharges, such as focal spikes, sharp waves, slow waves, or focal onset of 
generalized seizures are observed in 6 to 48% and may erroneously lead to a 
diagnosis of a focal epilepsy syndrome (ANDERSON & HAMANDI, 2011; 
BAYKAN & WOLF, 2017; KOEPP et al., 2014; SERAFINI et al., 2013; WELTY, 
2006). Asymmetric and focal epileptiform discharges may remain stable for years, 
but more commonly switch hemisphere, even during the same recording 
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(BAYKAN & WOLF, 2017; SERAFINI et al., 2013). Myoclonic jerks are 
associated with PSWC that consist of runs of 10-27 Hz spikes followed by 3-4 Hz 
slow waves with a frontocentral maximum (ALFRADIQUE & VASCONCELOS, 
2007; KOEPP et al., 2014; SERAFINI et al., 2013; WANDSCHNEIDER et al., 
2012; WOLF et al., 2015; YACUBIAN, 2017). The number of spikes in the PSWC 
ranges from five to 20 and is correlated with severity rather than duration of 
myoclonic seizures (ALFRADIQUE & VASCONCELOS, 2007; SERAFINI et al., 
2013). Other ictal patterns include 3-5 Hz generalized, irregular SWC, slow sharp 
waves, and groups of slow waves, sharp waves, or spikes (ALFRADIQUE & 
VASCONCELOS, 2007; SOUSA et al., 2005). Absence seizures are characterized 
by 3-4 Hz SWC (PANAYIOTOPOULOS et al., 1989). This pattern may be similar 
to the one observed in CAE or may be preceded or superimposed by 
single/double/triple or multiple spikes (PANAYIOTOPOULOS et al., 1989; 
SERAFINI et al., 2013). 
2.4. Treatment, neuropsychological aspects, and outcome 
Juvenile myoclonic epilepsy has been considered a highly treatable disorder with 
seizure freedom being achieved in 80 to 96% of patients (ALFRADIQUE & 
VASCONCELOS, 2007; BAYKAN & WOLF, 2017; KOEPP et al., 2014). 
However, due to a high relapse rate of about 90%, JME has been considered a 
lifelong disorder requiring AED treatment throughout life (BAYKAN & WOLF, 
2017; KOEPP et al., 2014; WELTY, 2006). Recent studies have cast doubt on both 
of these paradigms since long-term surveys demonstrated remission in only two 
thirds of patients and up to 30% were seizure free and off AEDs (BAYKAN & 
WOLF, 2017; BAYKAN et al., 2013; KOEPP et al., 2014; NICOLSON & 
MARSON, 2010; YACUBIAN, 2017). Treatment is based on appropriate AEDs, 
avoidance of precipitating factors, such as fatigue, sleep deprivation, provoked 
awakening, alcohol, and photic stimuli, and management of co-pathologies 
(ALFRADIQUE & VASCONCELOS, 2007; CRESPEL et al., 2013; WELTY, 
2006; YACUBIAN, 2017). The first choice AED is valproic acid, which has an 
efficacy of up to 90% (ALFRADIQUE & VASCONCELOS, 2007; BAYKAN & 
WOLF, 2017; BAYKAN et al., 2013; WELTY, 2006; YACUBIAN, 2017). 
However, due to its high teratogenic potential, the use of valproic acid is 
discouraged in women of childbearing age (BAYKAN & WOLF, 2017; WELTY, 
2006; YACUBIAN, 2017). Valuable alternatives include LEV, lamotrigine, 
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topiramate, and zonisamide (ALFRADIQUE & VASCONCELOS, 2007; 
CRESPEL et al., 2013; HASHEMIAGHDAM et al., 2015; NOACHTAR et al., 
2008; WELTY, 2006). In contrast, some AEDs may aggravate myoclonic seizures, 
especially sodium channel blockers, such as phenytoin, oxcarbazepine, 
carbamazepine, and lamotrigine, but also gabapentin, pregabalin, tiagabine, and 
vigabatrin (ALFRADIQUE & VASCONCELOS, 2007; CRESPEL et al., 2013; 
KOEPP et al., 2014; YACUBIAN, 2017). 
Early descriptions of JME depicted specific personality traits, such as emotional 
instability, forgetfulness, unreliability, poor planning, rapid and frequent mood 
changes, impulsivity, and indifference (ANDERSON & HAMANDI, 2011; 
BAYKAN & WOLF, 2017). Psychiatric disorders are encountered in 26.5 to 47% 
of JME patients, particularly anxiety, mood, and cluster B personality disorders 
(ALFRADIQUE & VASCONCELOS, 2007; BAYKAN & WOLF, 2017; DE 
ARAUJO FILHO & YACUBIAN, 2013; KOEPP et al., 2014). The risk for 
psychiatric comorbidities appears to be increased in patients with praxis induction 
or eye closure sensitivity/photosensitivity (BAYKAN & WOLF, 2017). 
Neuropsychological problems do not seem to reflect a genetic variation but rather 
a higher grade of frontal lobe impairment (BAYKAN & WOLF, 2017). 
Despite good response to AED treatment, 74% of patients have at least one major 
unfavourable social outcome, including depression, failure to complete high school, 
unemployment, alcohol or substance abuse, divorce, unplanned pregnancy, 
abortion, social isolation, and even criminal records (BAYKAN et al., 2013; 
KOEPP et al., 2014; WOLF et al., 2015; YACUBIAN, 2017). In addition to other 
factors, circadian dysrhythmia may contribute markedly to poor social outcome 
(SCHMITZ et al., 2013; WOLF et al., 2015). Negative prognostic factors 
influencing outcome of JME comprise a combination of all three seizure types, 
more than one AED, non-classical JME such as CAE evolving to JME, psychiatric 
comorbidities, delay in diagnosis, focal EEG abnormalities, long disease duration, 
and expression of reflex epileptic traits (BAYKAN et al., 2013; KOEPP et al., 2014; 
YACUBIAN, 2017). 
2.5. Genetics 
Twin and family studies suggest that JME is a heritable IGE syndrome (PELJTO et 
al., 2014; VADLAMUDI et al., 2014; ZIFKIN et al., 2005). The risk of epilepsy is 
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increased in first-degree relatives of JME patients and a positive family history is 
encountered in 40% of affected individuals (KOEPP et al., 2014; WELTY, 2006). 
Despite this strong genetic background and heritability estimates of up to 70%, the 
underlying genetic variants are still unknown in over 90% of cases, emphasizing 
the hypothesis of JME as a spectrum disorder with extensive genetic heterogeneity 
(BAYKAN & WOLF, 2017; DELGADO-ESCUETA et al., 2013; VADLAMUDI 
et al., 2014; WOLF et al., 2015). In only a small subgroup (1-2%) of patients is the 
disease attributable to a single gene defect, whereas in the majority of cases, a 
complex oligo- or polygenic mode of inheritance is suspected (KOEPP et al., 2014; 
WOLF et al., 2015). To date, five Mendelian genes, specifically calcium channel 
beta4 subunit (CACNB4), calcium channel sensor receptor (CASR), gamma-
aminobutyric acid (GABA) receptor alpha one subunit (GABRA1), GABA receptor 
delta subunit (GABRD), and EF-hand domain containing one (EFHC1), and three 
single nucleotide polymorphisms in three genes, namely bromodomain-containing 
2 (BRD2), connexin 36 (Cx-36), and malic enzyme 2 (ME2) have been identified 
(BAYKAN & WOLF, 2017; DELGADO-ESCUETA et al., 2013; WOLF et al., 
2015). Moreover, copy number variants at 15q13.3, 15q11.2, and 16p13.11 have 
been associated with JME (HELBIG et al., 2013; KOEPP et al., 2014). The 
microdeletion at 15q13.3 contains cholinergic receptor nicotinic alpha7 subunit 
(CHRNA7), coding for the α7 subunit of the nicotinergic acetylcholine (ACh) 
receptor (nAChR), as prime candidate gene (HELBIG et al., 2009). This 
microdeletion implicates a 50-fold increased risk for IGE (WOLF et al., 2015). 
Interestingly, the same copy number variants are also associated with a broad 
spectrum of neuropsychiatric diseases, suggesting a major role of 
neurodevelopmental mechanisms in the pathogenesis of JME (BAYKAN & 
WOLF, 2017; HELBIG et al., 2013; WOLF et al., 2015). 
2.6. Pathophysiology – insights from advanced neuroimaging 
Although no structural abnormalities are found using standard MRI or computed 
tomography, advanced neuroimaging techniques have identified subtle functional 
and structural changes in JME patients (ALFRADIQUE & VASCONCELOS, 
2007; ANDERSON & HAMANDI, 2011; BAYKAN & WOLF, 2017; KOEPP et 
al., 2013, 2014; WANDSCHNEIDER et al., 2012). 
Quantitative and voxel-based MRI studies reveal increased grey matter volumes 
affecting primarily orbitofrontal and superior mesial areas close to the SMA, 
II. Review of the literature     30 
increased frontal CSF, and reduced occipital grey matter concentrations in patients 
with photosensitivity (ANDERSON & HAMANDI, 2011; KOEPP et al., 2013, 
2014; WANDSCHNEIDER et al., 2012; WOLF et al., 2015). Moreover, there is a 
decrease of grey matter volume of the thalamus that is correlated with age, disease 
duration, as well as personality traits (ANDERSON & HAMANDI, 2011; WOLF 
et al., 2015). Interestingly, these changes are evident within twelve months of 
disease onset (KOEPP et al., 2013, 2014; WANDSCHNEIDER et al., 2012). 
Therefore, it is assumed that seizures and neurocognitive abnormalities are a 
consequence of an altered thalamo-frontocortical circuitry (KOEPP et al., 2013, 
2014; WANDSCHNEIDER et al., 2012). 
The use of 18FDG- and H₂15O-PET has identified increased metabolic activity 
during generalized SWC in the thalamus (ANDERSON & HAMANDI, 2011; 
KOEPP et al., 2014). In a study utilizing a visual working memory task, JME 
patients performed worse than controls, and 18FDG-PET showed glucose 
hypometabolism in the ventral premotor cortex, the caudate nucleus, and 
dorsolateral prefrontal cortex at resting state, suggesting frontal lobe dysfunction 
(ANDERSON & HAMANDI, 2011; KOEPP et al., 2013, 2014; 
WANDSCHNEIDER et al., 2012; WOLF et al., 2015). Increased 18FDG uptake in 
the lateral orbital and medial temporal area presumably represents a compensatory 
process for frontal lobe impairment (KOEPP et al., 2013; WANDSCHNEIDER et 
al., 2012). Results of PET studies support the hypothesis of a dysfunctional 
thalamo-frontocortical network leading to seizures and decreased cognitive 
performance (WANDSCHNEIDER et al., 2012). 
Combined EEG and fMRI studies have shown thalamic and mesial frontal 
activation several seconds before generalized spike wave activity, followed by 
deactivation of the association cortex including frontal, parietal, and cingulate 
areas, the so-called default mode network (ANDERSON & HAMANDI, 2011; 
KOEPP et al., 2014; WOLF et al., 2015). Another fMRI study that used a working 
memory task revealed a coactivation of the primary motor cortex and the SMA, 
reduced deactivation of the default mode network, and increased functional 
connectivity between the primary motor cortex, SMA, and frontoparietal cognitive 
networks (KOEPP et al., 2013, 2014; VOLLMAR et al., 2011; 
WANDSCHNEIDER et al., 2012; WOLF et al., 2015; YACUBIAN, 2017). These 
observations provide an explanation for the cognitive triggering of myoclonic 
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seizures (KOEPP et al., 2013; VOLLMAR et al., 2011; WANDSCHNEIDER et al., 
2012). 
Increased structural connectivity between the motor cortex, SMA, and prefrontal 
cortex can also be seen with diffusion tensor tractography (KOEPP et al., 2013; 
WANDSCHNEIDER et al., 2012). These findings are similar to those obtained by 
fMRI and strengthen the theory of an altered network enabling ictogenesis by 
cognitive effort (WANDSCHNEIDER et al., 2012). 
Proton magnetic resonance spectroscopy (1H-MRS) reveals reduced N-acetyl 
aspartate (NAA) concentrations in the prefrontal cortex and thalamus and in the 
occipital lobe in patients with photosensitivity (BAYKAN & WOLF, 2017; KOEPP 
et al., 2013, 2014; WANDSCHNEIDER et al., 2012; WOLF et al., 2015). N-acetyl 
aspartate is a neuron-specific metabolite and reduced levels are considered a marker 
of neuronal loss or dysfunction (ANDERSON & HAMANDI, 2011; KOEPP et al., 
2014; WANDSCHNEIDER et al., 2012). Similar to progressive thalamic volume 
loss observed with voxel-based morphometry, 1H-MRS thalamic changes are 
progressive as well (ANDERSON & HAMANDI, 2011; KOEPP et al., 2014). 
Decreased NAA concentrations in the thalamus and frontal lobe are negatively 
correlated with age and disease duration (ANDERSON & HAMANDI, 2011; 
KOEPP et al., 2013). Moreover, the degree of neuronal dysfunction is associated 
with epilepsy severity and more substantial personality disorders (ANDERSON & 
HAMANDI, 2011). 
In summary, advanced neuroimaging studies show structural and functional 
thalamic and frontal lobe abnormalities as well as altered connectivity between the 
motor cortex, SMA, and prefrontal cortex (ANDERSON & HAMANDI, 2011; 
BAYKAN & WOLF, 2017; KOEPP et al., 2013, 2014; WANDSCHNEIDER et al., 
2012). These changes are consistent with the frontal accentuation of EEG 
paroxysms and neuropsychological profiles and provide an explanation for the 
seizure-provoking mechanisms in JME (ANDERSON & HAMANDI, 2011; 
KOEPP et al., 2013). This thalamo-frontocortical network dysfunction challenges 
the dogma of JME as a generalized epilepsy syndrome, and reclassification to a 
frontal lobe variant of a multi-regional, thalamocortical network epilepsy has been 
proposed (ANDERSON & HAMANDI, 2011; KOEPP et al., 2013). 
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Significance 
Comprehensive clinical, neurological, and genetic examinations characterized a 
generalized myoclonic epilepsy syndrome with photosensitivity in young 
Rhodesian Ridgeback dogs. The average age of onset of seizures was 6 mo. Genetic 
analyses revealed a defective DIRAS family GTPase1 (DIRAS1) gene and protein. 
DIRAS1 is widely expressed in the brain and has been suggested to regulate 
acetylcholine release and play a role in neurodevelopment. This study reveals a 
candidate gene for human myoclonic epilepsies, and a translational model to further 
elucidate the role of DIRAS1 in neurotransmission and neurodevelopment, and its 
modulation as a therapeutic option in common epilepsy. 
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Abstract 
The clinical and electroencephalographic features of a canine generalized 
myoclonic epilepsy with photosensitivity and onset in young Rhodesian Ridgeback 
dogs (6 wk to 18 mo) are described. A fully penetrant recessive 4-bp deletion was 
identified in the DIRAS family GTPase 1 (DIRAS1) gene with an altered expression 
pattern of DIRAS1 protein in the affected brain. This neuronal DIRAS1 gene with 
a proposed role in cholinergic transmission provides not only a candidate for human 
myoclonic epilepsy but also insights into the disease etiology, while establishing a 
spontaneous model for future intervention studies and functional characterization. 
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Introduction 
Dogs provide physiologically relevant models of human disease. Aggressive 
breeding has resulted in a unique genetic architecture that facilitates gene discovery 
(1). Many breeds originate from a limited number of founder animals and the use 
of popular sires is a common practice. As a consequence, each breed represents an 
isolated population with high levels of phenotypic homogeneity, reduced genetic 
diversity, and enrichment of breed-specific disorders (2). Hundreds of naturally 
occurring canine conditions are analogous to human diseases, such as diabetes, 
cancers, epilepsies, eye diseases, autoimmune diseases, and monogenic diseases. 
Epilepsy is the most common chronic neurological disease in dogs (3). A strong 
genetic background is suspected in many dog breeds with a high prevalence (4) and 
several genes have been discovered in both symptomatic and idiopathic epilepsy. 
Most of these genes represent orthologs to the corresponding human epilepsy genes, 
such the canine models for progressive myoclonic epilepsy, including NHLRC1 in 
Lafora disease (5, 6) and CLN1, CLN2, ATP13A2, CLN5, CLN6, CLN8, and 
MFSD8 in different types of neuronal ceroid lipofuscinosis (1, 7). Only two genes 
have been associated with idiopathic epilepsy in dogs, ADAM23 and LGI2 (8, 9). 
In this study, we describe a unique model of genetic generalized epilepsy in 
Rhodesian Ridgeback (RR) dogs characterized by a young age of onset. The RR is 
an African dog breed, originating from Rhodesia, now Zimbabwe. The breed-
defining characteristic is a dorsal ridge, caused by a lateral instead of caudal 
orientation of the hair in this region (10). The RR reflects a mixture of several 
European dog breeds and the local ridged Hottentot Khoi dog and was initially bred 
for lion hunting (10, 11). The presence of multiple affected dogs with a distinct 
phenotype in many litters proposed an inherited condition, which warranted us to 
embark a comprehensive study to describe the clinical features and find the genetic 
cause. 
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Results 
Generalized Myoclonic Epilepsy with Photosensitivity in Young RR Dogs.  
Altogether, we studied 95 RR dogs, of which 24 (15 males, 9 females) shared a 
unique epilepsy phenotype of frequent myoclonic jerks/twitches, with an onset in 
young dogs (mean 6 mo; median 3.5 mo; range 6 wk–18 mo) as the outstanding 
feature. Eleven dogs were 5- to 18-mo-old (juvenile, adolescence) at age of onset, 
in 12 dogs onset was between 2 and 4 mo of age (corresponding to 2–10 y in 
humans, childhood), and in one dog it was at 6 wk (infantile). Photosensitivity was 
reported in eight dogs. The disease progressed to generalized tonic-clonic seizures 
(GTCS) in 38% of dogs within 6 mo (median; 1.5–29 mo) after onset of myoclonic 
seizures. Owners of three dogs (>8 y of age) reported that dogs retained normal 
cognition throughout life. 
Myoclonic jerks were described by the owners as severe startling or even 
resembling an electric shock. Preceding alterations in behavior were not observed. 
Myoclonic twitches mainly occurred when the animals were in a recumbent 
position and relaxed, drowsy, or in the first stages of sleep, and with the eyes either 
closed or open. Occasionally twitches occurred also when the dogs were sitting, 
standing, or walking (Movie S1). No autonomic signs occurred during the 
myoclonic seizures. Based on video review, myoclonic jerks were predominantly 
confined to the trunk, proximal limb musculature (especially the thoracic limbs), 
cervical musculature producing nodding movements of the head (Movie S2), and 
the face (masticatory muscles resulting in chewing movements, eyelid and ear 
twitches). Myoclonic jerks would often be limited to or start at one side of the body; 
however, a consistent side predilection could not be detected. Intensity varied 
between events and individual dogs. Some muscle contractions were rather subtle, 
with just a small range of motion, whereas others were very vigorous and at times 
made the dogs jump into the air or dash against the floor, wall, or furniture. 
Although a single event lasted less than 1 s, twitches often occurred in series as 
repetitive myoclonic muscle contractions. GTCS were also frequently preceded by 
a series of myoclonic twitches. Some dogs appeared confused or scared following 
the episodes and seemed to be very agitated after the events, rising up and 
wandering around restlessly. Hence, sleep appeared impaired in these dogs. Dogs 
were normal between events. Owners reported daily (87%) or almost daily (13%; 
every second to third day) occurrence of myoclonic twitches with a frequency of 
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up to 150 twitches per day. Up to 50 jerks per hour were recorded with EEG in 
some dogs. Two dogs showed increased myoclonic jerks during heat (cases 2 and 
11). In three siblings (cases 8, 9, and 10) and another dog (case 6) onset of 
myoclonus was observed 2 d after vaccination. Onset of GTCS appeared to be 
temporally related to vaccination in another two dogs (cases 6 and 7). 
Diagnostic investigations (Table S1) failed to identify any consistent structural 
abnormalities. A few dogs had potential brain abnormalities on neuroimaging 
evaluations that may be incidental findings, such as ventricular asymmetry (12) 
(Table S2). Twenty-one RRs with myoclonic epilepsy were treated with a variety 
of antiepileptic drugs (AEDs: phenobarbital, potassium bromide, primidone, 
levetiracetam, clonazepam, imepitoin; monotherapy or combination) in adequate 
dosages and with serum concentrations (phenobarbital: mean 28.6 mg/L; potassium 
bromide: mean 1,353 mg/L) within therapeutic range (13). Levetiracetam, which is 
also an effective drug for juvenile myoclonic epilepsy (JME) in humans (14), and 
potassium bromide seemed to be the most effective based on response of dog 
owners. 
By the time of submission, three dogs were euthanized at 9 mo, 2 y, and 5 y of age 
because of poor seizure control; three dogs died from causes unrelated to the 
epilepsy and one died for unknown reasons (Table S2). One dog was available for 
postmortem examination (case 2) that ruled out extracranial pathologies. In this 
single brain, histology showed postictal changes only including mild clustered 
neuronal hypereosinophilia in lateral geniculate nucleus and pyramidal cell layers 
of the neocortex. Histoarchitectural changes, dysmorphic neurons, and reactive 
gliosis were not evident. The remaining dogs were alive without any evidence of 
mental or cognitive decline. 
Ambulatory Wireless Video EEG Defines the Electroclinical Syndrome. 
Simultaneous video and EEG recordings documented the epileptic origin of the 
events in 82% of examined cases (Table S2). EEG was recorded for prolonged times 
(>1 h, 13 recording leads) in 17 affected RRs displaying myoclonic twitches, and 
11 breed-matched controls (10 healthy RRs, 1 RR with idiopathic epilepsy with 
GTCS). Background activity was appropriate to state in all dogs (15). Myoclonic 
twitches of variable intensity occurred in all but two cases during EEG recording. 
The characteristic ictal pattern was generalized 4–5 Hz spike-and-wave complexes 
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(SWC) (Fig. 1 A and B) or polyspike-wave complexes (PSWC) during the initial 
phase, with a predominantly fronto-central maximum that often switched between 
different leads over both hemispheres, and occasionally generalized with a time lag. 
Another ictal pattern comprised biphasic spikes and paroxysmal bursts consisting 
of 7- to 8-Hz spikes that at times again were followed by SWC and an occasional 
occurrence of focal activity (Fig. S1). In some dogs, myoclonic activity was 
consistent with onset of ictal discharges, whereas in others myoclonic twitches were 
preceded by a crescendo of EEG paroxysms. Not all motor activity was 
accompanied by EEG paroxysms, but myoclonic jerks appeared identical and 
muscle artifact may have obscured the EEG correlate on some occasions. Affected 
RRs displayed also epileptiform discharges comprising ictal spikes or interictal 4-
to 5-Hz SWC (Fig. S1). Furthermore, some dogs intermittently displayed 
rhythmical 4- to 5-Hz slowing that at times morphed into SWC accompanied by 
myoclonic jerks. During EEG recording, myoclonic twitches emerged 
predominantly during quiet rest, drowsiness, or slow-wave sleep. In some dogs, 
single episodes were recorded while awake and even less often while standing. 
Similarly, EEG paroxysms emerged with higher frequency when the dogs were less 
alert. The effect of sleep deprivation was not assessed. For the EEG, instead of sleep 
deprivation, we encouraged the dogs to nap. Unremarkable EEG recordings were 
obtained from control dogs. 
Photosensitivity Is a Feature of Generalized Myoclonic Epilepsy in RR Dogs. 
Visually induced seizures were reported in 8 of 23 (35%; confidence interval 95%: 
18.7–55.2%) RRs with generalized myoclonic epilepsy (Table S2). These were 
described as myoclonic seizures triggered by visual stimuli, such as light flashes, 
sudden incidence of light when opening the shutters in the morning, or sunlight 
interrupted by trees while walking through the forest. A videotape was provided 
where each photic stimulus (produced by photoflashes) was followed by myoclonic 
jerks (Movie S3). Upon video-EEG recording with photic stimulation in six 
affected RRs, four dogs (66%) displayed photoconvulsive responses time-locked 
with the onset of the photic stimulus (Table S2 and Movie S4). Video-EEG with 
photic stimulation did not reveal any abnormalities in clinically healthy RR 
controls, including three heterozygous carriers of the gene deletion. Besides light, 
noise was also a triggering factor in three siblings (cases 8–10). 
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Genetic Analyses Reveal a 4-bp Deletion Mutation in DIRAS1. 
The pedigree established around the affected dogs suggested an autosomal 
recessive inheritance (Fig. S2). To identify the genetic cause of the generalized 
myoclonic epilepsy in RRs, we combined a genome wide association study 
(GWAS) and next-generation sequencing analyses using whole-exome (WES) and 
whole-genome (WGS) resequencing. Assuming a recessive mode of inheritance, 
the WES analysis of two unrelated cases against 169 exomes from nonepileptic 
dogs (Table S3) resulted in a group of 10 variants, of which 6 were in the predicted 
coding regions (Table S4). Only one nonsynonymous variant was found, a 4-bp 
deletion in the exon 2 of the DIRAS1 gene (c.564_567delAGAC; gene structure 
according to the Broad Institute CanFam3 Improved Annotation Data v1) (Fig. 2D), 
resulting in a frameshift and a stop loss (Fig. S3). A GWAS and haplotype analysis 
in 10 RR cases and 18 RR controls supported the WES study by identifying the 
best-associated region (P = 0.977 × 10−5) (Table S5) in a 1.6-Mb region 
(55,597,243–57,195,857) at chromosome 20 (Fig. 2A), including the DIRAS1 gene 
(Fig. 2C). The critical region was further split into a 300-kb and an 890-kb region 
(Fig. 2B) by a 400-kb recombination in one of the cases. WGS of one epileptic dog 
also identified the c.564_567delAGAC deletion in DIRAS1, but it was absent from 
99 control whole genomes (Table S3). Structural variation analysis in the WGS data 
were performed within the original 1.6-Mb associated region of the epileptic RR 
dog. Only one 35-kb duplication (56,210,949–56,246,523) was found in the region; 
however, it resided outside of the 890-kb disease-associated haploblock, which 
starts at 56.3Mb (Fig. 2B). In addition, the duplication was present in several 
nonepileptic control dogs within our 99 dogs WGS data (Table S3), excluding it as 
an epilepsy candidate in RRs. 
The genotyping of the DIRAS1 deletion in 14 clinically verified RR cases and 26 
controls revealed a homozygous mutant genotype in all cases, a heterozygous 
genotype in the obligate carriers, and the homozygous wild-type genotype in 
controls (Fig. 2D), indicating a complete segregation of the deletion allele with the 
disease. Genotyping additional 498 RRs from 13 countries indicated a carrier 
frequency of ∼15% (Table S6). To investigate the breed and epilepsy specificity of 
the deletion, we genotyped an additional 965 epileptic dogs in 12 breeds, but did 
not find any carriers, indicating that the mutation is specific to generalized 
myoclonic epilepsy in RRs. Collectively, these results strongly suggest that the 
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deletion in the coding region of DIRAS1 causes the generalized myoclonic epilepsy 
in the breed. 
Altered Intracellular Expression Pattern of Mutant DIRAS1. 
The expression pattern of the DIRAS1 transcript is poorly characterized and 
suggested to be limited to the brain and heart (16). We amplified the transcript in 
28 canine tissues, including 12 brain regions, the spinal cord, and 15 peripheral 
tissues, and found abundant expression in all brain regions, whereas the pattern was 
more limited and variable in extra neural tissues (Fig. S4). The possible 
developmental expression pattern of DIRAS1 was also investigated in the frontal 
cortices at six different time points: 2, 5, and 23 mo and 4, 5, and 9 y. The results 
indicate increased expression until adulthood (Fig. 3A). 
The 4-bp deletion resides at the end of the DIRAS1 coding region, resulting in a 
frameshift at the C-terminal end of the predicted protein (Fig. S3). The last 10 amino 
acids of DIRAS1 change causing a stop loss, which is followed by 104 extra amino 
acids. The only functional domain, RAS, remains intact, but the protein has 
additional low complexity regions toward its C terminus (Fig. S3), likely rendering 
the mutated protein functionally altered. The effect of the deletion mutation on the 
stability of the DIRAS1 transcript was investigated by quantitative PCR in the 
frontal cortices between the age-matched 2-y-old case and control dogs. The result 
suggested only a modest decrease in the case (Fig. 3B), which also agrees with an 
unremarkable change in the semiquantitative PCR (Fig. S4). 
Immunolabeling revealed abundant expression of DIRAS1 antigen throughout the 
brain (brainstem, cerebellum, and prosencephalon), including the cholinergic basal 
forebrain nuclei, depicted in Fig. 4. The intracellular expression pattern of wild- 
type and mutant DIRAS1 somewhat differed between the single affected dog and 
control dogs. Distinctive nuclear and membranous pattern observed in the control 
dogs (RRs and non- RRs) (Fig. 4 A and C) had changed to advanced diffuse staining 
of nerve cell somata in the affected RR (Fig. 4 B and D). These results suggest that 
there is a persistent expression of the mutated DIRAS1 protein with an altered 
intracellular localization. 
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Discussion 
This study characterizes a breed-specific generalized myoclonic epilepsy with an 
early onset. Results from genetic and functional studies suggest that the epilepsy is 
caused by a 4-bp deletion in the coding region of the DIRAS1 gene, resulting in a 
frameshift and a stop loss. We found abundant expression of DIRAS1 throughout 
the canine brain with a difference in subcellular expression patterns between wild-
type and mutant proteins. Although mammalian functions are unknown, previous 
studies suggest that DIRAS1 is needed for acetylcholine transmission at 
neuromuscular junctions in Caenorhabditis elegans (17) and neuronal development 
in zebrafish (18). Therefore, this canine DIRAS1 defect provides not only a 
candidate gene for generalized myoclonic epilepsies but also insights to the disease 
etiology, while establishing a spontaneous model for preclinical studies and 
functional characterization. 
Common human idiopathic generalized epilepsies recognized by the International 
League Against Epilepsy include childhood absence epilepsy, epilepsy with 
myoclonic absences, epilepsy with myoclonic atonic seizures, epilepsy with GTCS 
alone, juvenile absence epilepsy, myoclonic epilepsy in infancy, and JME (19). 
Generalized myoclonic epilepsy in RR dogs reveals important parallels to JME, 
which is one of the most common forms of epilepsy in humans (14, 20–23). As in 
humans, jerks are bilateral, arrhythmic, at times asymmetric, and predominate upon 
the upper limbs and trunk (20, 21), whereby additional nodding movements of the 
head were present in some RRs. EEG recordings revealed a pattern found in human 
JME patients: SW or PSW discharges with a fronto-central accentuation and a 
normal background activity with an occasional occurrence of focal activity, EEG 
asymmetries switching sides, and diffuse or intermittent slowing (22, 24, 25). An 
important characteristic shared by human JME and generalized myoclonic epilepsy 
in RRs is the manifestation with photosensitivity, particularly as JME has one of 
the strongest associations with photosensitivity among all epilepsies (26, 27). 
Phenotypic heterogeneity was apparent because not all dogs were photosensitive, 
which may reflect influences of age, sex, or individual genetic background of the 
dogs. In humans, photosensitivity is an age-dependent phenomenon and is more 
prevalent in children with a peak age of onset about 12 y (27). There is also strong 
evidence for a genetic component of photoparoxysmal response (PPR) in humans 
and many loci have been identified (27–30). Thus, affected RRs provide another 
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spontaneous large animal model to investigate the neural mechanisms of 
photosensitivity (31, 32). 
However, there are also a number of differentiating characteristics and phenotypic 
heterogeneity: the low prevalence of GTCS (JME 80–95%; RRs 38%), the absence 
of absence seizures (although this seizure type might be difficult to recognize in 
dogs), and a variable age of onset, with several dogs showing a relatively early onset 
(6–10 wk) in the socialization period (6–12 wk) and others during the juvenile 
period (starting at 12 wk) and adolescence up to 18 mo, when behavioral maturation 
tends to reach adult values in the dogs (33–35). Differences between dog breeds 
exist and differences in the order of development of social and motor skills between 
dogs and humans have been encountered (34). Thus, early age of onset may still be 
in line with human genetic generalized epilepsy syndromes, such as JME, in which 
25% may have absence - and not myoclonic - seizures in childhood. People with 
JME also have 2- to 3-Hz and 4- to 6-Hz interictal epileptic discharges, and most 
have polyspikes (22). EEG failed to demonstrate clear ictal discharges in 
association with myoclonus on some occasions. Although it was considered that 
EEG was obscured by muscle artifact of the myoclonus, myoclonic behavior needs 
to be monitored with telemetry for further investigations. There is also a possibility 
that the generator for myoclonic seizures is not superficial, rather subcortical. EEG 
will not be able to detect deep neuronal function if the generator is at the brainstem 
level. Although photosensitivity was observed in 35% of dogs, the prevalence of 
photosensitivity based upon the EEG studies appears to be higher (66%) than in 
humans and, in humans, the photoparoxysmal and photoconvulsive responses are 
maximal fronto-centrally and not occipitally. There is a high prevalence of MRI 
findings, which is not typical for human JME. We acknowledge that the presence 
of MRI findings points toward a symptomatic etiology; however, there were no 
consistent findings. Ventricle asymmetry is also frequently present in dogs without 
epileptic seizures, and thus may be clinically not relevant (12). Similarly, a small 
amount of meningeal enhancement is consistently demonstrated in normal dogs 
(36). However, we cannot exclude that some of the structural abnormalities 
interacted with the phenotype: for example, lowered seizure threshold on both 
hemispheres. The EEG phenotype is consistent with generalized myoclonic 
epilepsy, and certainly not focal epilepsy. Finally, human JME is characterized by 
strong chronodependency, with myoclonic jerks and GTCS in the morning after 
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awakening or during relaxation periods in the evening (37). Although generalized 
myoclonic epilepsy in RRs also shows a strong association with the sleep–wake 
cycle, myoclonic twitches and EEG discharges appeared predominantly in the 
relaxed state, at rest, or during the first stages of sleep, mirroring subtypes of JME 
(38). The observed differences may reflect species-specific differences in bio- 
rhythmicity and sleep regulation or may indicate parallels to other genetic sleep-
associated epilepsies, such as myoclonic epilepsy in infancy, which sometimes 
progresses to JME (39), or autosomal dominant nocturnal frontal lobe epilepsy 
(NFLE) (40). 
DIRAS1 is a novel epilepsy gene with a robust expression pattern in the CNS 
tissues. It is part of the Ras family of small GTPases, which have been linked to 
many cellular signaling pathways in cell growth and differentiation, synaptic 
plasticity, learning, and memory (41–43). DIRAS1 and DIRAS2 form a 
biochemically and functionally distinct branch of Ras GTPases, which are 
characterized by a fast guanidine–nucleotide exchange rate (16). The biological 
function of DIRAS1 in mammals is poorly characterized. DIRAS1 has been 
suggested to function as a tumor suppressor in glioblastoma and other tumor cell 
lines through the inhibition of Ras-mediated transformation, altered NF-κB 
transcription activity, diminished ERK1/2 and MAPK signaling, and 
antagonization of pro-oncogenic small Ras GTPases (44). Studies in C. elegans 
have demonstrated that the DIRAS1 and exchange protein directly activated by 
cAMP (EPAC) orthologs colocalize at the presynaptic membranes and are needed 
for the maintenance of normal presynaptic acetylcholine release at neuromuscular 
junctions (17). DIRAS1 was also suggested to play a role in cell migration, neurite 
outgrowth, and dendrite architecture in the developing nervous system of a 
zebrafish model (18). 
Understanding the role and mechanisms of DIRAS1 in cholinergic 
neurotransmission and epilepsy remains an important task. Nicotinergic cholinergic 
activity influences brain excitability and cognition, regulates the 
excitatory/inhibitory switch of GABA during neuronal development (45), 
stimulates glutamate release from thalamocortical terminals, controls GABA 
release onto pyramidal neurons, and maintains nonrapid eye movement sleep by 
low levels of acetylcholine, whereby cholinergic stimulation is associated with 
microarousals in this sleep stage (46). Mutations in nicotinergic acetylcholine 
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receptor (nAChR) subunits CHRNA4, CHRNA2, and CHRNB2 are associated with 
autosomal dominant NFLE and sporadic NFLE (47). CHRNA7 coding for the α7 
subunit of the nAChR is also a potential candidate gene for JME in humans (48). 
Abnormal DIRAS1 function could alter cholinergic neurotransmission or formation 
of neuronal circuits and network assembly in the developing brain resulting in 
myoclonic epilepsy and photosensitivity. This canine model establishes a prime 
resource to address these questions and mechanisms in future experiments, 
including mutation-specific–induced neuronal cultures. 
In summary, careful clinical and genetic studies identified a candidate gene for one 
of the most common forms of human epilepsy with a postulated function in 
cholinergic neurotransmission. While inspecting the gene in human myoclonic and 
epilepsy cohorts for risk variants, future functional studies should identify the 
DIRAS1-mediated mechanisms in neurotransmission and provide drug targets for 
common epilepsies. 
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Materials and Methods 
Study Cohorts. Twenty-four RR cases were identified (Table S2). Inclusion 
criteria were clinical observation of myoclonic jerks on video recordings or 
observation at one of the study sites and completion of an online questionnaire or 
an interview. Altogether, 538 EDTA-blood and tissue samples were collected from 
privately owned RRs in Germany, Finland, and 11 other countries (Table S6). A 
cohort of 965 epileptic dogs from 12 other breeds from Finland was included (Table 
S6). Sample collection was ethically approved by the Animal Ethics Committee of 
State Provincial Office of Southern Finland, Hämeenlinna, Finland 
(ESAVI/6054/04.10.03/ 2012), “Cantonal Committee for Animal Experiments” 
(Canton of Bern; permit 23/10), and the German Animal Welfare Act. Further 
details are provided in SI Materials and Methods. 
Neurodiagnostic Investigation. All RR cases underwent a clinical, neurological, 
and laboratory examination. Structural epilepsy was excluded by imaging through 
MRI in 12 RR cases and postmortem examination of 1 dog. Additional 
investigations comprising CSF analysis, neurometabolic screening, imaging 
through CT, skin biopsy, and AED serum concentration measurements were 
performed for a number of studied dogs. Further details are provided in SI Materials 
and Methods. 
EEG. Awake ambulatory wireless video-EEG was conducted in 17 RR cases and 
11 RR control dogs. Recordings were performed in a quiet environment, with dogs 
encouraged to lie down. EEG was recorded routinely using 15 (7 in one dog) 
subdermal needle electrodes. In six cases and four controls an additional video-EEG 
with photic stimulation was conducted at the end of the EEG study. Further details 
are provided in SI Materials and Methods. 
Postmortem Examination. Postmortem examination was conducted on one 
affected RR. The animal underwent routine autopsy in which the brain was removed 
in toto and trimmed according to standardized algorithms (49). Relevant brain areas 
(prosencephalon, cerebellum, brainstem) were sampled and histologically 
evaluated using neurohistological standard stains on paraffin sections. 
GWAS. Genotyping of 10 affected RRs from the initial study cohort and 18 
unaffected RRs was performed. The genotype data were filtered and frequency and 
genotyping pruned. A case-control association test was performed by PLINK (50) 
III. Publications      46 
and by Mendel software’s Ped-GWAS (51). Further details are provided in SI 
Materials and Methods. 
Resequencing. Dog exome libraries for two German RR cases were generated. The 
sequencing data were analyzed and filtered under a recessive model against 169 
additional exomes (Table S3). The pathogenicity of the coding variants was 
predicted in the CanFam 3.1 annotation. One RR case was whole-genome 
sequenced and filtered against 99 additional whole genomes (Table S3) and the 
presence of the candidate mutation was inspected visually. Further details are 
provided in SI Materials and Methods. 
Sanger Sequencing and TaqMan Genotyping. The identified candidate variant 
was validated by a standard PCR followed by Sanger sequencing in 33 German RR 
samples, including 12 cases from the initial study cohort. For a larger mutation 
screening in additional samples (Table S6), a TaqMan assay was run. Further details 
are provided in SI Materials and Methods. 
Gene Expression. Fresh postmortem samples were collected (for the full list, see 
Fig. 3 and Fig. S4) from one case and six control dogs. RNA was extracted and 
reverse-transcribed into cDNA. The canine DIRAS1 transcript was amplified and 
sequenced. Semiquantitative and quantitative PCRs were performed. Further details 
are provided in SI Materials and Methods. 
Immunohistochemistry. Tissue studies were conducted on the brains 
(prosencephalon, cerebellum, brainstem) of one RR case and three control RRs 
(LMU Munich neuropathology brain archive). Primary antibodies (pAB) were 
directed at DIRAS1 and the vesicular acetylcholine transporter. The slides were 
antigen-demasked, incubated with pAB, and stained using polymer technology and 
a diaminobenzidine tetrahydrochloride. Further details are provided in SI Materials 
and Methods. 
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Supporting Information 
SI Materials and Methods 
Study Cohorts. Twenty-four RR cases were identified. Four study sites (Veterinary 
Hospital Trier, Trier, Germany; Veterinary Practice Bathen-Noethen, Cologne, 
Germany; Department of Small Animal Medicine and Surgery, University of 
Veterinary Medicine, Hannover, Germany; Clinic of Small Animal Medicine, LMU 
Munich, Germany) participated in recruitment of the initial cohort. Additional cases 
were recruited via call for study participants on the homepage of LMU Munich and 
referral by diplomates of the European College of Veterinary Neurology. Inclusion 
criteria were clinical observation of myoclonic jerks on video recordings or 
observation at one of the study sites and completion of an extensive online 
questionnaire (semse.vetmed.uni-
muenchen.de/umfragen/index.php?sid=%2018469&lang=de) or personal 
interview. Dogs with other types of muscle contractions (e.g., tremor, 
fasciculations) or GTCS or focal seizures as the only manifestation of epilepsy were 
excluded. Dogs without video documentation of myoclonic jerks with insufficiently 
completed questionnaires were denied study participation. 
Altogether, 538 EDTA-blood and tissue samples were collected from privately 
owned RRs in Germany, Finland, and 11 other countries (Table S6). The German 
RR study cohort included blood samples of 19 affected RRs displaying the 
generalized myoclonic epilepsy phenotype, 11 unaffected relatives (dam and sire 
of two litters, four littermates, one additional dam and her sister, one cousin) and 
18 controls (13 healthy RRs, 4 RRs with idiopathic GTCS, 2 RRs with other types 
of muscle twitches). Genotyping analysis included also a cohort of 965 epileptic 
dogs from 12 other breeds from Finland (Table S6). The samples were stored at −20 
°C until genomic DNA was extracted using a semiautomated Chemagen extraction 
robot (PerkinElmer Chemagen Technologie) or the Nucleon Bacc2 kit (GE 
Healthcare). DNA concentration was determined either with the NanoDrop ND-
1000 UV/Vis Spectrophotometer or Qubit 3.0 Fluorometer (Thermo Fisher 
Scientific). Sample collection was ethically approved by the Animal Ethics 
Committee of State Provincial Office of Southern Finland, Hämeenlinna, Finland 
(ESAVI/6054/04.10.03/ 2012), “Cantonal Committee For Animal Experiments” 
(Canton of Bern; permit 23/10), and the “Institutional Review Board” of the Clinic 
of Small Animal Medicine (LMU Munich, Germany 28.05.13). 
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Neurodiagnostic Investigation. All dogs underwent a clinical and neurological 
examination by a veterinary neurologist. Laboratory investigations comprised 
complete blood cell count and serum biochemistry profile (alanine 
aminotransferase, alkaline phosphatase, total bilirubin, urea, creatinine, total 
protein, albumin, glucose, sodium, potassium, chloride, calcium, phosphate), fasted 
venous ammonia (14 cases), fasted and postprandial bile acids (7 cases), creatine 
kinase activity (8 cases), ionized calcium (4 cases), coagulation profile (PT, PTT, 
TT; 1 case), and thyroid panel (total T4, free T4, thyroid stimulating hormone; 7 
cases). AED serum concentration measurements (IDEXX Laboratories) were 
accomplished in six dogs treated with phenobarbital and four dogs treated with 
potassium bromide. Neurometabolic screening comprised urinary organic acids, 
oligosaccharides, mucopolysaccharides, and urinary and serum amino acids in 10 
cases and 1 related control RR in specialized laboratories (Children’s Hospital 
Frankfurt, Germany; Biocontrol, Labor Ingelheim, Ingelheim, Germany; 
Comparative Biochemical Genetics Laboratory Veterinary Unit, University of 
California, San Diego, CA; Metabolic Genetics Screening Laboratory, School of 
Veterinary Medicine, University of Philadelphia, PA). Skin biopsy from one 
affected dog was immersed in 2.5% glutaraldehyde and was screened for 
ultrastructural evidence of metabolic disorders by electronmicroscopy (ZM906, 
Zeiss). Advanced imaging through MRI (LMU Munich: 1.5 T Magnetom 
Symphony Syngo MR Siemens; University of Leipzig: Philips MR Ingenia 3T with 
Omega HP Gradient; Philips Medical Systems; various other high- and low-field 
MR machines) or CT was undertaken in 12 and 7 dogs, respectively. CSF for 
analysis was obtained following sterile preparation by atlantooccipital puncture 
with the dogs under general anesthesia in 17 cases. 
EEG. Awake ambulatory wireless video-EEG was conducted in 17 RR cases and 
11 RR control dogs (10 healthy RRs and 1 RR with idiopathic epilepsy with GTCS) 
using a Trackit MK3 EEG/Polygraphy Recorder with video (Lifelines 
Neurodiagnostic Systems) and Persyst 12 software (Persyst Development 
Corporation and Micromed Morpheus Home LTM ambulatory EEG recorder 
(Micromed Neurodiagnostic)). Because the episodes in question emerged primarily 
when the dogs were relaxed, recordings were performed in a quiet environment 
where the dogs had the possibility to lie down in a comfortable position. EEG was 
recorded routinely using 15 subdermal stainless steel needle electrodes (F3, Fz, F4, 
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F7, F8, C3, Cz, C4, O1, Pz, O2, T1, T2, Ref, Neut; NatusEurope, product number 
019-475800). Electrode placement was as described by Pellegrino and Sica (52) for 
mesencephalic dogs, but modified for our demands: we placed subdermal needles 
at the anterior canthus of the base of the ear for the temporal loci (T3, T4) and the 
reference more caudally between the medial canthi of the eyes both as proposed by 
James et al. (53). We did not use the frontopolar leads, but added two additional 
electrodes 1- to 1.5-cm dorsolateral of the lateral canthi of the eyes (F7, F8). After 
positioning, all electrodes were fixed in place with medical tape (Leukoplast). 
Subsequently, the recorder - as well as the remaining wires - were attached to a 
harness on the dog’s back via cohesive bandages (Co-Flex). In one dog, seven 
subdermal electrodes were used, including two frontal (F3, F4), one central (V), 
and two occipital electrodes (O1, O2), as well as a reference at the dorsum of the 
nose (Ref) and a ground in the neck (Neut). Three cases and one control required 
sedation for electrode placement (0.015 mg/kg dexmedetomidine, reversal with 
0.15 mg/kg atipamezole). In one case and one control, video-EEG recording was 
undertaken upon awakening from general anesthesia. Impedance was kept under 10 
kΩ in most cases (up to 20 kΩ in rare cases). In six cases and four controls, an 
additional video-EEG with photic stimulation was conducted at the end of the EEG 
study (Micromed Morpheus Home LTM ambulatory EEG recorder, Micromed 
Neurodiagnostic). A lamp with circular reflector and a viewing distance of 30 cm 
was used. Stimulation was conducted for 10 s followed by a rest of 5 s per each 
flash frequency. The following flash frequencies (in Hz) were used in this order: 1–
6–11– 18–7–12–16–4–25–10–17–9–14–3. 
GWAS. Genotyping of 10 affected and 18 unaffected RRs from the German study 
cohort (Fig. S2) was performed using Illumina’s Canine HD array (173 k). The 
genotype data were filtered with a SNP call rate of >95%, array call rate of >95%, 
minor allele frequency of >5% and by using a Hardy–Weinberg equilibrium of P ≤ 
0.00005. After frequency and genotyping pruning (with a window size of 50, a step 
of five SNPs, and an r² threshold of 0.5) no individual dogs were removed and 
110,492 SNPs remained for analysis. A case-control association test (GWAS) was 
performed by PLINK (50) and by Ped-GWAS, using Mendel software (51). Two 
cases and four controls were excluded in PLINK analysis because of relatedness. 
After Ped-GWAS quality control analysis, 107,852 SNPs were included in the 
analysis. 
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Resequencing. Dog exome libraries for two German RR cases were generated from 
standard indexed Illumina libraries using a custom Roche/Nimblegen solution-
based capture library (120705_CF3_Uppsala_Broad_EZ_HX1) according to the 
protocol described previously by Elvers et al. (54). The sequencing data were 
analyzed using our in-house scripts as previously described (55). The average 
sequencing coverage varied between 25–35× per sample and revealed on average 
∼108,909 variants per sample. The two affected dogs shared 30,506 homozygous 
variants; however, filtering under a recessive model against 169 additional exomes 
from other nonaffected breeds available (Table S3) resulted in a total of 10 case-
specific homozygous variants (Table S4), of which 6 variants were in the predicted 
coding regions (1 indel, 5 synonymous). SnpEff (56) was used to predict the 
pathogenicity of the coding variants in the CanFam 3.1 annotation. One RR case 
was whole genome-sequenced in the Science for Life Laboratory in Stockholm, 
Sweden, as described previously (57). The RR whole genome (∼25×) was filtered 
against 99 additional whole genomes from other nonaffected breeds available 
(Table S3). Variants in the 890-kb critical region at chromosome 20 were 
investigated, revealing the previously identified mutation in the case, although none 
of the other dogs carried it. The presence of the candidate mutation was inspected 
visually in the BAM file using the Integrative Genomics Viewer. Structural 
variation analysis in the associated region was performed using DELLY v0.6.7 to 
detect possible case-specific deletions or duplications in the WGS data of an 
epileptic RR against 99 nonepileptic control genomes including two RRs (Table 
S3). The detected sites were merged and regenotyped across all samples using 
DELLY v0.7.5. Genotyped copy number variants were required to have both split-
read (SR) and paired-end (PE) support (SR > 1 and PE > 5 or SR > 5 and PE > 1) 
to retain a high-confidence call set. 
Sanger Sequencing and TaqMan Genotyping. The identified candidate variant 
(chr20:g.56’474’668_56’474’671delAGAC) was first validated by a standard PCR 
followed by Sanger sequencing in 33 German samples, including 12 cases from the 
initial study cohort. Forward (ACAATGTCAAGGAGCTCTTCC) and reverse 
(GCTCACATGAGGACGCATT) primers were designed to amplify the mutation 
region using AmpliTaq Gold 360 Mastermix (Applied Biosystems, Life 
Technologies) or Biotools’ DNA Polymerase. The sequencing reactions were then 
performed on an ABI 3730 capillary sequencer (Applied Biosystems, Life 
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Technologies), after treatment with exonuclease I and shrimp alkaline phosphatase. 
The Sanger sequence data were analyzed using Sequencher 5.1 (GeneCodes). For 
a larger mutation screening in additional samples (Table S6), a TaqMan assay 
(Applied Biosystems) was developed (probes: 
GGAACATGAGCCTCAACATCGAT and GGACGCATTTGCCCTTGAC) and 
reactions were run by the Bio-Rad’s CFX96 Touch Real-Time PCR Detection 
System instrumentation according to the manufacturer’s instructions. 
Sequence Alignment. The CanFam 3.1 assembly was used for all analyses. All 
numbering within the canine DIRAS1 gene correspond to the accessions 
XM_005633100.2 and XP_005633157.1. For the annotation of the gene and the 
identified risk variant, we have used Broad Institute CanFam3 Improved 
Annotation Data v1. The sequence alignments of the normal and mutated DIRAS1 
proteins were constructed by using the Clustal Omega tool 
(www.ebi.ac.uk/Tools/msa/clustalo/). The aligned protein sequences were derived 
from the Entrez Protein database (https://www.ncbi.nlm.nih.gov/protein). The 
domain structures were investigated by SMART (smart.embl-heidelberg.de/). 
Gene Expression. Fresh postmortem samples were collected from seven dogs. 
Twenty-eight different tissues were collected from one Finnish epilepsy-free 
Belgian Shepherd dog (for the full list, see Fig. S4) killed at the age of 4 y and 10 
mo. The frontal cortex was collected from five other epilepsy-free control dogs (one 
2-mo-old Wire Fox Terrier, one 5-mo-old Labrador Retriever, two Great Danes 
aged 23 mo and 5 y and 3 mo, one 9-y-old Saluki) and one case RR. The 24-mo-
old female RR case was killed because of severe seizures nonresponsive to 
treatment with phenobarbital and the control dogs because of nonepilepsy- related 
disorders or behavior by owners’ consent. Samples were harvested immediately 
after killing and snap-frozen in liquid nitrogen before storage in −80 °C. Total RNA 
was extracted from the canine tissues by using the RNeasy Mini Kit (Qiagen), and 
sample concentrations were measured by using a Qubit 3.0 Fluorometer (Thermo 
Fisher Scientific). The High Capacity RNA-to-cDNA Kit (Applied Biosystems, 
Life Technologies) was then used to reverse-transcribe equal amounts of total RNA 
into cDNA. In both semiquantitative and quantitative PCR, the canine DIRAS1 
transcript was amplified and sequenced by using a primer pair 
(TGAAGATGGACGTCATACTGCTT and GAACACCACCACTCGGTAGTC) 
that was designed to span over exon–intron boundaries to control for genomic DNA 
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contamination. Semiquantitative PCR was performed in three different cycles (27, 
32, and 37 cycles) before visualization of the amplicons on a 2.5% (wt/vol) agarose 
gel (100 V, 2 h). GAPDH was used as a loading control. Quantitative PCR was 
performed for triplicates of each sample using Bio-Rad’s CFX96 Touch Real- Time 
PCR Detection System instrumentation according to the manufacturer’s 
instructions. YWHAZ and GAPDH were used as loading controls. The relative 
normalized expression pattern was calculated with Bio-Rad’s CFX Manager 
Software. The SE between triplicates was below 0.13 in each studied sample. 
Immunohistochemistry. Tissue studies were conducted on the brain of one 
affected RR (case 2) donated by the owner for postmortem examination. The animal 
underwent routine autopsy on which the brain was removed in toto and trimmed 
according to standardized algorithms (49). Relevant brain areas (prosencephalon, 
cerebellum, brainstem) were sampled and histologically evaluated using 
neurohistological standard stains on paraffin sections. Identical sections were 
obtained and examined from three unaffected (two dogs without seizures and one 
with seizures secondary to acute hemorrhagic stroke) RRs admitted for diagnostic 
reasons unrelated to the purpose of this study. pAB were directed at DIRAS1 
protein (rabbit polyclonal, PA5-26409, Fisher Scientific) and Vesicular 
Acetylcholine Transporter (VAChT, rabbit polyclonal, Ab68984, Abcam). Anti-
DIRAS1 polyclonal antibody was developed against synthetic peptide between 109 
and 136 amino acids from the central region of human DIRAS1. This epitope has 
100% amino acid identity with the corresponding canine epitope. Therefore, 
sequence homology scale renders specific cross-reaction of the antibody very 
likely. Before staining, the slides underwent microwave-based antigen demasking 
in citrate buffer. Slides were incubated with pAB (DIRAS1 1:500; VAChT 1:100) 
for 18 h at 4 °C. Subsequent staining used polymer technology (IMPRESS Linaris) 
and a diaminobenzidine tetrahydrochloride staining kit. 
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Fig. 1. Ictal EEG. LFF: 1 s; HFF: 70 Hz. (A and B) Minor head and eyelid twitches 
were accompanied by 4-Hz spike-and-wave complexes with a central maximum (A: 
Cz referential montage; B: bipolar montage). 
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Fig. 2. GWAS. (A) Manhattan plot indicates best P values at chromosome 20. (B) 
An 890-kb haplotype is shared by cases. (C) The associated region contains 33 
genes including DIRAS1. (D) Chromatograms of an affected, carrier, and wild-type 
dog indicate the c.564_567delAGAC variant. 
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Fig. 3. DIRAS1 expression. (A) The increase in the expression of the DIRAS1 
transcript by age was observed when comparing six different age points in the 
frontal cortex (the ages of 2 mo, 5 mo, 23 mo, 4 y and 10 mo, 5 y and 3 mo, and 9 
y, n = 1 in each). (B) The stability of the DIRAS1 transcript was studied in the frontal 
cortices of age-matched (24- and 23-mo-old) case (RR, n = 1) and control (Great 
Dane, n = 1) dogs by a quantitative PCR. The result suggests a modest decrease in 
the stability of the mutant transcript. The error bars refer to variance in experimental 
triplicates (SD < 0.13 in each). YWHAZ and GADPH were used as loading controls 
in quantitative PCR. 
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Fig. 4. Immunohistochemical DIRAS1 expression. Wild-type RRs show 
predominantly nuclear staining (black arrowhead) as seen in the parietal cortex (A; 
blue frame) and cholinergic forebrain nuclei (C; black frame). With DIRAS1 
mutation (B and D) protein expression is abundant and there is a more diffuse 
staining of nerve cell perikarya (white arrowhead) in all brain regions, including the 
brainstem. Figure shows expression in parietal cortex (B; blue frame), and forebrain 
nuclei (D; black frame). Cholinergic target areas were confirmed by staining for the 
vesicular acetylcholine transporter (AChT), as demonstrated in the Inset. (Scalebar: 
A–D,35 μm; inlet AChT, 150 μm). 
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Fig. S1. Video-EEG with interictal SWC and ictal spikes. LFF: 1 s; HFF: 70 Hz. 
(A and B) These 4-Hz spike-and-wave complexes were not accompanied by any 
visible movements (A: Cz referential montage; B: bipolar montage). (C and D) 
Ictal spikes (C: Cz referential montage; D: bipolar montage). 
 
 
 
 
Fig. S2. Pedigree. An example of a RR pedigree with generalized myoclonic 
epilepsy, suggesting a recessive mode of inheritance. 
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Fig. S3. Sequence comparison. (A) Sequence alignment of the normal and mutated 
DIRAS1 protein was constructed to assess the effect of the c.564_567delAGAC 
frameshift. The variant changes the last 10 amino acids of the normally 198 amino 
acids-long protein and produces a stop loss leading to a protein 104 amino acids 
longer than the wild-type. The Ras domain remains intact. (B) Schematic overview. 
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Fig. S4. DIRAS1 expression pattern. Expression profiling of the DIRAS1 transcript 
across 28 tissues indicates abundant pattern in the different regions of the brain but 
more limited pattern is found in nonneural tissues. The stability of 
the DIRAS1 transcript is not markedly altered in the frontal lobes of a case (RR) 
and a control (Belgian Shepherd) dog by a semiquantitative PCR using GADPH as 
a loading control. A, arteria; L, lobus. 
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Table S1. Clinical protocols 
 
RR dog 
on site 
observation 
of 
myoclonic 
seizures 
video 
documen-
tation 
completed 
questionnaire 
pedigree 
available 
neuro-
imaging CSF 
neuro-
metabolic 
screening1 
EEG 
EEG 
with 
ILS 
case 1 yes yes no no MRI yes yes yes no 
case 2 yes yes no yes MRI yes yes yes2 no 
case 3 yes yes no no CT yes yes no no 
case 4 yes yes yes no CT yes yes yes no 
case 5 yes no yes no CT, MRI yes no no no 
case 6 yes yes yes yes - yes yes yes no 
case 7 yes no no no MRI yes no no no 
case 8 yes no no yes MRI yes yes no no 
case 9 yes yes yes yes - no no yes no 
case 10 yes yes yes yes - no no yes no 
case 11 yes yes yes yes - no yes yes no 
case 12 yes yes yes yes - no yes yes no 
case 13 yes yes yes yes MRI yes yes yes3 yes 
case 14 no4 no4 yes yes CT yes no no no 
case 15 yes yes yes no MRI yes no yes3 no 
case 16 yes yes yes yes CT yes no no no 
case 17 yes yes yes no MRI yes no yes3 no 
case 18 yes yes yes no MRI yes yes no no 
case 19 yes yes yes yes MRI yes no yes no 
case 20 yes yes yes yes - no no yes yes 
case 21 yes yes no yes - no no yes yes 
case 22 no yes no yes - no no yes yes 
case 23 yes yes yes yes CT, MRI yes no yes yes 
case 24 yes yes yes yes CT, MRI yes no yes yes 
control 1 - - - no - - no yes no 
control 2 - - - no - - yes yes3 no 
control 3 - - - no - - no yes no 
control 4 - - - no - - no yes no 
control 5 - - - no - - no yes no 
control 6 - - - no - - no yes no 
control 7 - - - no - - no yes yes 
control 8 - - - yes - - no yes yes 
control 9 - - - yes - - no yes yes 
control 10 - - - yes - - no yes yes 
control 11 - no yes yes MRI yes no yes2 no 
 
Summary of the used diagnostic investigation protocols. 
ILS = intermittent light stimulation. 1neurometabolic screening: urinary amino 
acids and urinary organic acids; case 2, 6 and 13 also serum amino acids. 2recording 
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upon awakening from general anesthesia (isoflurane, propofol). 3sedation for 
electrode placement with 0.015 mg/kg dexmedetomidine, reversal with 0.15 mg/kg 
atipamezole. 4this dog was included despite lack of onsite observation or video 
documentation of myoclonic twitches, as one sibling (dog 13) was affected as well 
and those two dogs were possessed by the same owner. 
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T
able
 S2
.
 Clinical
 and
 EEG
 d
ata
 
 
outcome 
(observation 
time) 
alive 
dead 
(euthanised 
due to poor 
seizure 
control; 
nercropsy 
wnl) 
dead 
alive 
EEG 
with 
ILS 
- 
- 
- 
- 
interictal 
EEG 
findings 
wnl 
generalized 
4-5 Hz 
SWC 
- 
generalized 
4 Hz SWC 
with 
anterior 
maximum 
ictal EEG 
findings 
no myoclonic 
jerks during 
recordingi 
generalized 
4-5 Hz SWC, 
at times 
epileptogenic 
discharges 
precede the 
myoclonic 
jerks 
-
g
 
generalized 4 
Hz SWC 
with anterior 
maximum, at 
times 
preceded by 
5 Hz slowing, 
at times 
polyspikes 
neuro-
metabolic 
screen 
wnl 
serum 
alanine 
elevated 
results not 
available, 
reported 
wnl 
wnl 
CSF 
wnl 
wnla 
wnl 
wnl 
brain imaging 
T1 and T2 
hypointensity in 
the transition 
area of the 
frontal lobe and 
the olfactory 
bulb (MRI) 
wnl (MRI) 
wnl (CT) 
asymmetric 
lateral 
ventriclese (CT) 
neurologic 
examination 
spinal pain 
PL proprio-
ceptive 
deficits, mild 
lumbosacral 
pain 
wnl 
abraded 
claws of all 
limbs 
clinical 
photo-
sensi-
tivity 
no 
no 
- 
no 
onset 
GTCS 
- 
1 y 11 m 
- 
- 
onset 
myoclonic 
seizures 
18 m 
17 m 
7 m 
10 w 
geno-
type 
dd 
dd 
- 
dd 
sex 
f 
f 
m 
m 
RR 
case 1 
case 2 
case 3 
case 4 
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T
able
 S2
.
 C
o
nt
.
 
 
outcome 
(observation 
time) 
dead (ana-
plasmosis, 
AIHA, 
ARF) 
dead 
(ruptured 
splenic 
tumour) 
dead 
(foreign 
body, renal 
tumor) 
dead 
(euthanised 
due to poor 
seizure 
control) 
alive 
EEG 
with 
ILS 
- 
- 
- 
- 
- 
interictal 
EEG 
findings 
- 
wnl 
- 
- 
right side 
dominant 
spikes and 
4-5 Hz 
SWC (C4, 
T4, F8, Cz, 
C3), at 
times 
spikes in 
C4/T4 and 
C3 do not 
generalize 
ictal EEG findings 
-
g
 
myoclonic jerks without 
clear EEG correlatec 
-
g
 
-
g
 
right side dominant (C4, 
T4, F8, Cz, C3) 5-6 Hz 
biphasic spikes that 
approach a 4-5 Hz SWC 
morphology at points; 
events generalize, 
occasionally with a time 
lag, and often with 
independent spikes 
occurring at different 
channels 
neuro-
metabolic 
screen 
- 
wnl 
- 
wnl 
- 
CSF 
wnl 
wnl 
wnl 
wnl 
- 
brain imaging 
asymmetric 
lateral 
ventriclese 
(CT, MRI) 
- 
wnl (MRI) 
wnl (MRI) 
- 
neurologic 
exam-
ination 
inconsisten
t menace 
OS 
wnl 
wnl 
wnl 
wnl 
clinical 
photo-
sensi-
tivity 
no 
no 
no 
yes 
yes 
onset 
GTCS 
1 y 5 m 
8 m 
1 y 5 m 
- 
- 
onset 
myoclonic 
seizures 
3 m 
5 m 
11 m 
10 w 
10 w 
geno-
type 
- 
dd 
- 
- 
dd 
sex 
m 
m 
f 
f 
f 
RR 
case 5 
case 6 
case 7 
case 8 
case 9 
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able
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.
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o
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.
 
 
outcome 
(observation 
time) 
alive 
alive 
alive 
alive 
EEG with ILS 
- 
- 
- 
photoconvulsive 
responses with 4 
Hz generalized 
SWC (stimulation 
frequencies 8-14 
Hz) 
interictal 
EEG 
findings 
single 
spikes with 
anterior 
maximum 
generalized 
4 Hz SWC 
with 
anterior 
maximum 
wnl 
generalized 
4 Hz SWC 
with 
anterior 
maximum 
ictal EEG 
findings 
single spikes or 
polyspikes 
4-5 Hz 
(occasionally 3 
Hz) generalized 
SWC with 
anterior 
maximum, at 
times preceded by 
4 Hz slowing, 
bursts of 7-8 Hz 
polyspikes 
singlet or douplet 
SW 
generalized 4-5 
Hz SWC with 
anterior 
maximum, at 
times SW or 
slowing precede 
the myoclonic 
jerks 
neuro-
metabolic 
screen 
- 
wnl 
smear in 
urinary 
organic acids 
(qualitative 
analysis) 
wnl 
CSF 
- 
- 
- 
wnl 
brain imaging 
- 
- 
- 
lateral 
ventricle 
asymmetrye 
and mild 
meningeal 
contrast 
enhancement 
(MRI) 
neurologic 
exam-
ination 
wnl 
wnl 
wnl 
wnl 
clinical 
photo-
sensi-
tivity 
yes 
yes 
no 
yes 
onset 
GTCS 
- 
- 
2 y 7 m 
4.5 m 
onset 
myoclonic 
seizures 
10 w 
14 m 
9 w 
3 m 
geno-
type 
dd 
dd 
dd 
dd 
sex 
m 
f 
m 
m 
RR 
case 10 
case 11 
case 12 
case 13 
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.
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outcome 
(observation 
time) 
dead 
(euthanised 
due to poor 
seizure 
control) 
alive 
alive 
alive 
alive 
alive 
EEG 
with 
ILS 
- 
- 
- 
- 
- 
- 
interictal EEG findings 
- 
generalized 4 Hz SWC or 
single spikes, central 
maximum, at times 
switching side 
- 
single spikes 
- 
irregular generalized 4 
Hz SWC with anterior 
maximum switching 
between different leads, 
generalized 4 Hz 
slowing, at times 
emerging into SWC 
ictal EEG findings 
-
g
 
generalized 4 Hz SWC or 
single spikes, central 
maximum, at times switching 
side, at times jerks are 
preceded by a crescendo of 
epileptogenic discharges, 
occasionally myoclonic jerks 
without clear EEG correlated 
-
g
 
single spikes, occasionally 
myoclonic jerks without clear 
EEG correlated 
-
h
 
irregular generalized 4 Hz 
SWC, generalized 4 Hz 
slowing with anterior 
maximum switching between 
different leads, at times 
emerging into SWC, 
occasionally myoclonic jerks 
without clear EEG correlated 
neuro-
metabolic 
screen 
- 
- 
- 
- 
wnlb 
- 
CSF 
wnl 
wnl 
wnl 
wnl 
wnl 
wnl 
brain 
imaging 
wnl (CT) 
wnl 
(MRI) 
wnl (CT) 
wnl 
(MRI) 
slight 
reduction 
of brain 
volume 
(MRI)f 
wnl 
(MRI) 
neurologic 
exam-
ination 
wnl 
wnl 
wnl 
wnl 
wnl 
wnl 
clinical 
photo-
sensi-
tivity 
no 
no 
no 
no 
no 
no 
onset 
GTCS 
- 
- 
- 
- 
8 m 
7 m 
onset 
myoclonic 
seizures 
6 m 
8 m 
11 m 
6 m 
6 m 
6 w 
geno-
type 
- 
dd 
dd 
dd 
dd 
dd 
sex 
m 
m 
m 
m 
f 
m 
RR 
case 14 
case 15 
case 16 
case 17 
case 18 
case 19 
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outcome 
(observation 
time) 
alive 
alive 
alive 
alive 
alive 
EEG with ILS 
photoconvulsive 
responses with 4 Hz 
generalized SWC with 
occipital maximum 
(stimulation frequencies 
6-17 Hz) 
no PPR 
no PPR 
photoconvulsive 
responses with 4 Hz 
generalized SWC with 
occipital maximum 
(stimulation frequencies 
3-4 Hz) 
photoconvulsive 
responses with 4 Hz 
generalized SWC with 
occipital maximum 
(stimulation frequencies 
6-10 Hz) 
interictal EEG 
findings 
single spikes and 
SW 
wnl 
wnl 
wnl 
no epileptogenic 
discharges during 
recording without 
activation 
procedures 
ictal EEG 
findings 
single spikes 
and SW 
single spikes 
no myoclonic 
jerks during 
recordingi 
polyspikes 
and SW 
no myoclonic 
jerks during 
recording 
without 
activation 
proceduresi 
neuro-
metabolic 
screen 
- 
- 
- 
- 
- 
CSF 
- 
- 
- 
wnl 
wnl 
brain 
imaging 
- 
- 
- 
wnl (CT, 
MRI) 
wnl (CT, 
MRI) 
neurologic 
exam-
ination 
wnl 
wnl 
wnl 
wnl 
wnl 
clinical 
photo-
sensi-
tivity 
yes 
no 
no 
yes 
yes 
onset 
GTCS 
8 m 
- 
- 
- 
- 
onset 
myoclonic 
seizures 
8 w 
4 m 
10 w 
10 w 
8 w 
geno-
type 
dd 
dd 
dd 
dd 
dd 
sex 
m 
f 
f 
m 
m 
RR 
case 20 
case 21 
case 22 
case 23 
case 24 
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T
able
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.
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.
 
 
outcome 
(observation 
time) 
alive 
alive 
alive 
alive 
alive 
alive 
alive 
alive 
alive 
alive 
alive 
EEG 
with ILS 
- 
- 
- 
- 
- 
- 
no PPR 
no PPR 
no PPR 
no PPR 
- 
interictal 
EEG 
findings 
wnl 
wnl 
wnl 
wnl 
wnl 
wnl 
wnl 
wnl 
wnl 
wnl 
wnl 
ictal EEG 
findings 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
neuro-
metabolic 
screen 
- 
wnl 
- 
- 
- 
- 
- 
- 
- 
- 
- 
CSF 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
wnl 
brain 
imaging 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
wnl 
(MRI) 
neurologic 
exam-
ination 
wnl 
wnl 
wnl 
wnl 
wnl 
wnl 
wnl 
wnl 
wnl 
wnl 
wnl 
clinical 
photo-
sensitivity 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
no 
onset GTCS 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
1 y 10 m 
onset 
myoclonic 
seizures 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
genotype 
DD 
Dd 
DD 
DD 
DD 
- 
- 
Dd 
Dd 
Dd 
DD 
sex 
f 
m 
m 
m 
f 
f 
m 
f 
f 
f 
m 
RR 
control 1 
control 2 
control 3 
control 4 
control 5 
control 6 
control 7 
control 8 
control 9 
control 10 
control 11 
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Table S2. Cont. 
Summary of all clinical and EEG data of generalized myoclonic epilepsy in 24 RR 
dogs (cohort used for clinical characterization). 
AIHA: autoimmune hemolytic anemia; ARF: acute renal failure; CT computed 
tomographic imaging; DD: wildtype genotype; Dd: heterozygous DIRAS1 
mutation (carrier); dd: homozygous DIRAS1 mutation; GTCS: generalized tonic-
clonic seizures; ILS: intermittent light stimulation; MRI: magnetic resonance 
imaging; OS: left eye; PPR: photoparoxysmal response; SW: spike-and-wave; 
SWC: spike-and-wave complexes; wnl: within normal limits. amild increase in 
monocytes and banded neutrophils in cytospin preparations, normal total nucleated 
cell count, normal protein; bmild elevation in amino acids cystathionine and 
homocysteine; organic acids wnl; cEEG correlate was obscured by muscle artifact; 
dEEG correlate was occasionally obscured by muscle artifact; emay be clinically 
irrelevant as ventricle asymmetry is seen in 38% of healthy dogs and 44% of dogs 
with idiopathic epilepsy (15); funremarkable on repeat 3T MRI; gunavailable for 
EEG; hnon-diagnostic EEG (panting); itreated with AED. 
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Table S3. Breeds with NGS data 
Breed Whole exome Whole genome 
Akita 1  -  
Alaskan Malamute 5 1 
American Hairless Terrier 4  -  
American Staffordshire Terrier  -  1 
Australian Cattle dog  -  2 
Australian Kelpie 11  -  
Australian Terrier 13  -  
Beagle  -  1 
Bearded Collie  -  7 
Belgian Shepherd 16  -  
Berger Blanc Suisse  -  1 
Bichon Frisé 4  -  
Border Collie 8 25 
Boston Terrier 1  -  
Boxer 4  -  
Central Asian Shepherd dog  -  1 
Chihuahua 2  -  
Coton de Tulear 2  -  
Dachshund  -  1 
Dalmatian dog  -  1 
Dandie Dinmont Terrier  -  1 
Doberman Pinscher 9 3 
Elo  -  1 
English Bulldog 1  -  
Entlebucher Sennenhund  -  8 
Eurasier  -  2 
Finnish Hound 3  -  
Finnish Lapphund 6 1 
Finnish Spitz 6  -  
Fox Terrier 4  -  
French Bulldog 1 1 
German Pointer 3  -  
German Shepherd 1 1 
German Wirehaired  -  1 
Great Dane 16  -  
Irish Soft-Coated Wheaten Terrier 4 1 
Irish Terrier  -  1 
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Table S3. Cont.   
Breed Whole exome Whole genome 
Italian Greyhound 2 1 
Karelian Beardog 6 1 
King Charles Spaniel 2  -  
Kromfohrländer  -  1 
Kuvasz 3  -  
Labrador Retriever  -  3 
Lagotto Romagnolo 1 4 
Lancashire heeler 1  -  
Landseer  -  2 
Leonberger  -  1 
Malinois  -  2 
Miniature Schnauzer 2  -  
Mixed breed  -  1 
Newfoundland Dog 4  -  
Norwegian Lundehund 1  -  
Parson Russel Terrier 1  -  
Perro de Agua Español  -  1 
Pinscher 1  -  
Pomeranian  -  1 
Pyrenean Shepherd 1  -  
Rhodesian Ridgeback (cases) 2 1 
Rhodesian Ridgeback  -  2 
Rottweiler 2 2 
Saluki 2 1 
Samoyed 1  -  
Schnauzer 5  -  
Shetland Sheepdog 3  -  
Siberian Husky (not purebred)  -  3 
Sloughi  -  3 
Swedish Vallhund 2 2 
Welsh Springer Spaniel  -  2 
West Highland White Terrier  -  1 
Whippet 4 1 
White Shepherd  -  1 
Yorkshire Terrier  -  1 
Total 171 100 
 
A summary of the breeds with whole exome and genome data. 
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Table S4. Candidate mutations 
Chr Position 
(bp) 
Reference Alternative Gene 
name 
Function 
(Ensembl) 
 Exonic 
function 
(Ensembl) 
Effect 
(snpEff) 
Impact 
(snpEff) 
16 1855004 G A Y_RNA down-
stream 
. inter-
genic 
modifier 
X 41819512 G A WDR13 splicing . down-
stream 
modifier 
16 2006387 G A CUL1 splicing . intron modifier 
3 85098858 C CTTTAAA
TGTAACA
TTTTGTT
TTTTTGT
TTTTTTTT
TTT 
SEPSECS intronic . intron modifier 
20 56474664 GGACAG
AC 
GGAC DIRAS1 exonic frame-shift 
deletion 
frame-
shift 
high 
2 77117099 C T WNT4 exonic synony-
mous SNV 
synony-
mous 
coding 
low 
X 57124177 C T CDX4 exonic synony-
mous SNV 
synony-
mous 
coding 
low 
X 60408672 G T TAF9B exonic synony-
mous SNV 
synony-
mous 
coding 
low 
16 2023357 G A CUL1 exonic synony-
mous SNV 
synony-
mous 
coding 
low 
X 55708156 C T ENSCAF
G000000
17103_11 
exonic synony-
mous SNV 
synony-
mous 
coding 
low 
 
A summary of 10 case-specific variants identified in the whole exome sequencing 
analysis after filtering against 169 control exomes. 
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Table S5. GWAS hits 
 
Chr Predictor name Position (bp) P value SNP 
model or 
adjusted 
P value 
Ped-GWAS Marginal 
P value 
SNP 
model 
20 BICF2G630446654 53461931 0.97687E-05 Add 
20 BICF2P1269879 52411334 0.97687E-05 Add 
20 TIGRP2P277323_RS 53534730 0.10225E-04 Add 
5 BICF2S23234898 44292103 0.21872E-04 Add 
5 BICF2P419745 44230649 0.21872E-04 Add 
5 BICF2G630187408 44061256 0.21872E-04 Add 
20 TIGRP2P278055_RS 55666391 0.37939E-04 Add 
20 TIGRP2P278052_RS 55661675 0.37939E-04 Add 
20 BICF2S23636929 55653830 0.37939E-04 Add 
20 BICF2P1342156 55615324 0.45206E-04 Add 
 
      
PLINK Unadjusted 
P value 
Adjusted 
P value 
20 BICF2S23636929 55653830 1.557e-05 1.557e-05 
20 TIGRP2P278052_RS8588937 55661675 1.557e-05 1.557e-05 
20 TIGRP2P278055_RS8819835 55666391 1.557e-05 1.557e-05 
20 BICF2G630445927 54625801 2.834e-05 2.834e-05 
20 BICF2G630447057 52856293 2.834e-05 2.834e-05 
20 BICF2G630445375 55637322 3.219e-05 3.219e-05 
20 BICF2G630445416 55621611 3.219e-05 3.219e-05 
20 BICF2P1342156 55615324 3.219e-05 3.219e-05 
20 BICF2G630446654 53461931 4.32e-05 4.32e-05 
20 BICF2P1269879 52411334 4.32e-05 4.32e-05 
 
Top 10 SNPs identified by Ped-GWAS and PLINK in the GWAS.  
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Table S6. Genotyped dogs: Epidemiological investigation  
 
Breed Country Wild-
type 
Carrier Mutation 
homozygote 
Total 
Rhodesian Ridgeback Czech Republic 31 3  -  34 
Rhodesian Ridgeback Denmark 5  -   -  5 
Rhodesian Ridgeback Finland 189 32  -  221 
Rhodesian Ridgeback Germany 46 15 18 79 
Rhodesian Ridgeback Hungary 2 1  -  3 
Rhodesian Ridgeback Latvia 6 2  -  8 
Rhodesian Ridgeback Poland 4  -   -  4 
Rhodesian Ridgeback Russia 24 11  -  35 
Rhodesian Ridgeback Slovakia 11  -   -  11 
Rhodesian Ridgeback South-Africa 3  -   -  3 
Rhodesian Ridgeback Spain  -   -  1 1 
Rhodesian Ridgeback Sweden 2  -  1 3 
Rhodesian Ridgeback Switzerland 111 19  -  130 
Rhodesian Ridgeback Unknown 1  -   -  1 
 Total 
 
435 83 20 538 
 Percent   80,9 15,4 3,7 100 
 Percent 
 (Germany 
 excluded) 
  84,7 14,8 0,4 100 
Australian Shepherd   45  -   -  45 
Belgian Shepherd   175  -   -  175 
Border Collie   88  -   -  88 
Border Terrier   92  -   -  92 
Finnish Spitz   158  -   -  158 
Kromfohrländer   44  -   -  44 
Lagotto Romagnolo   46  -   -  46 
Miniature Pinscher   45  -   -  45 
Pyrenean Shepherd   22  -   -  22 
Saluki   78  -   -  78 
Schipperke   120  -   -  120 
Whippet   52  -   -  52 
 Total   965     965 
 
A summary of the breeds and dogs genotyped for the DIRAS1 mutation.  
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2. Absence seizures as a feature of juvenile myoclonic epilepsy 
in Rhodesian Ridgeback dogs 
The following manuscript entitled “Absence seizures as a feature of juvenile 
myoclonic epilepsy in Rhodesian Ridgeback dogs” has been accepted for 
publication in the “Journal of Veterinary Internal Medicine” (JVIM) on October 31, 
2017 (received for review August 17, 2017). 
Copyright © 2017 The Authors. Journal of Veterinary Internal Medicine published 
by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal 
Medicine. 
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Absence seizures as a feature of juvenile myoclonic epilepsy in 
Rhodesian Ridgeback dogs  
F. Wielaender1, F.M.K. James2, M.A. Cortez3,4, G. Kluger5,6, J.N. Neßler7, A. 
Tipold7, H. Lohi8 and A. Fischer1,*. 
 
1Centre for Clinical Veterinary Medicine, LMU Munich, Munich, Germany 
2Department of Clinical Studies, Ontario Veterinary College, University of Guelph, 
Guelph, ON, Canada 
3Department of Pediatrics, University of Toronto, Toronto, ON, Canada 
4Neurosciences & Mental Health Program, Peter Gilgan Centre for Research and 
Learning, SickKids Research Institute, Toronto, ON, Canada 
5Department of Neuropediatrics, Epilepsy Center, Schoen Klinik, Vogtareuth, 
Germany 
6Paracelsus Medical University, Salzburg, Austria 
7Department of Small Animal Medicine and Surgery, University of Veterinary 
Medicine, Hannover, Germany 
8Department of Veterinary Biosciences and Research Programs Unit, Molecular 
Neurology, University of Helsinki and Folkhalsan Research Centre, Helsinki, 
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Short title: Absence Seizures in a Rhodesian Ridgeback 
Keywords: Canine; DIRAS1; Electroencephalography (EEG); Wireless video-EEG  
*Corresponding author: A. Fischer, Centre for Clinical Veterinary Medicine, 
LMU Munich, Veterinärstr. 13, 80539 Munich, Germany; e-mail: 
andreafischer@lmu.de. 
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Data were collected at the Centre for Clinical Veterinary Medicine, LMU Munich, 
Munich, Germany, and the Department of Small Animal Medicine and Surgery, 
University of Veterinary Medicine, Hannover, Germany. 
Part of this study was presented as an oral presentation, “Absence Seizures in a 
Rhodesian Ridgeback with Juvenile Myoclonic Epilepsy,” at the 30th Annual 
Symposium of ESVN-ECVN in Helsinki, Finland. 
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Abstract 
Myoclonic epilepsy in Rhodesian Ridgeback (RR) dogs is characterized by 
myoclonic seizures occurring mainly during relaxation periods, a juvenile age of 
onset and generalized tonic-clonic seizures in one-third of patients. An 8-month-
old female intact RR was presented for myoclonic seizures and staring episodes that 
both started at 10 weeks of age. Testing for the DIRAS1 variant indicated a 
homozygous mutant genotype. Unsedated wireless video-electroencephalography 
(EEG) identified frequent, bilaterally synchronous, generalized 4 Hz spike-and-
wave complexes (SWC) during the staring episodes in addition to the characteristic 
myoclonic seizures with generalized 4–5 Hz SWC or 4–5 Hz slowing. Photic 
stimulation did not evoke a photoparoxysmal response. Repeat video-EEG 2 
months after initiation of levetiracetam treatment disclosed a >95% decrease in 
frequency of myoclonic seizures, and absence seizures were no longer evident. 
Absence seizures represent another seizure type in juvenile myoclonic epilepsy 
(JME) in RR dogs, which reinforces its parallels to JME in humans. 
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A novel genetic myoclonic epilepsy in juvenile Rhodesian Ridgeback (RR) dogs, 
characterized by vigorous myoclonic seizures that occur mainly during relaxation 
periods, recently has been described.1 More than one-third of affected dogs develop 
generalized tonic-clonic seizures in the course of the disease, and 35% are reported 
to be photosensitive.1 The mean age of onset is 6 months (range, 6 weeks–1.5 
years).1 Wireless video-electroencephalography (EEG) in unsedated dogs was used 
as a tool to investigate the spontaneous and recurrent epileptic nature and to 
characterize the EEG features of the electroclinical syndrome.1 Ambulatory video-
EEG confirmed the epileptic origin of the myoclonic twitches.1 Typically, affected 
dogs show generalized 4–5 Hz spike-and-wave complexes (SWC) and polyspike-
wave complexes (PSWC) with a fronto-central maximum.1 Genetic analyses 
identified a fully penetrant autosomal recessive 4-bp truncating deletion mutation 
in the DIRAS1 gene, which is suggested to play a role in ACh release.1,2 
Myoclonic epilepsy in RRs has important parallels to juvenile myoclonic epilepsy 
(JME) in humans, including juvenile onset, myoclonic seizures as the predominant 
seizure type with propagation to generalized tonic-clonic seizures, similar EEG 
characteristics and photosensitivity.3-6 In humans with JME however, apart from 
myoclonic seizures and generalized tonic-clonic seizures (80–95% of patients), a 
third seizure type, namely absence seizures (approximately 30% of patients), is 
reported.7,8 In the following case report, we describe the occurrence of absence 
seizures in a RR dog diagnosed with JME, completing the triad of seizure types 
observed in humans with JME. 
An 8-month-old female intact RR was presented for multiple episodes of 
unresponsiveness, staring into space without any visible purposeful movement. 
Additionally, the dog experienced myoclonic jerks that occurred mainly at rest. Age 
of onset of both entities was 10 weeks with myoclonic seizures being observed a 
few days earlier than the staring episodes. At the beginning, myoclonic jerks 
manifested as nodding movements of the head, but became more vigorous in the 
course of the disease. At time of presentation, myoclonic seizures were said to 
resemble an electric shock such that the dog would jump into the air. 
Photosensitivity was not reported. Prior treatment with imepitoin (12.6 mg/kg PO 
q12h) decreased the intensity but not the frequency of the myoclonic seizures and 
did not influence the frequent staring episodes. According to the owner, the dog's 
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behavior was normal between episodes, and the dog did not show learning 
difficulties or any developmental delay. 
Results of physical and neurologic examinations, as well as CBC, serum 
biochemistry profile, plasma ammonia concentrations, and abdominal ultrasound 
examination were unremarkable. Testing for the DIRAS1 variant identified the 
homozygous mutant genotype (c.564_567delAGAC). Unsedated wireless video-
EEG with synchronized video recording was performed using an ambulatory EEG 
recordera in a quiet environment in which the dog was encouraged to lie down, 
because the episodes in question were reportedly more likely to occur at rest. Fifteen 
subdermal stainless-steel needle electrodes were used (F3, Fz, F4, F7, F8, C3, Cz, 
C4, O1, Pz, O2, T3, T4, Ref, Neut). Electrodes were placed as described previously 
and could be placed without any sedation.1 Impedance was kept <10 kOhm. Time 
of recording was approximately 2 hours. At the end of the EEG study, photic 
stimulation was performed, utilizing a lamp with circular reflector and a viewing 
distance of 30 cm. The following flash frequencies (in Hz) were used in this order: 
1 – 6 – 11 – 18 – 7 – 12 – 16 – 4 – 25 – 10 – 17 – 9 – 14 – 3, employing a period of 
10 seconds of stimulation followed by a rest of 5 seconds per flash frequency. 
Frequent episodes occurred, where the dog stared into the space and did not respond 
to any stimulus presented by us. Video-EEG confirmed the occurrence of 
generalized 4 Hz SWC associated with the staring events (Fig 1). During these 
episodes, the dog occasionally would lower the neck and appear as if the dog were 
about to buckle (Video S1; 14:12:30 hours). The dog's behavior was normal before 
(Video S2; 13:54:58 hours) and after the staring events (Video S3; 14:13:11 hours). 
The dog also showed several vigorous myoclonic seizures (213 jerks in the first 
hour of recording) that were characterized by twitches of the face, cervical, and 
proximal limb musculature or the trunk, accompanied by generalized 4–5 Hz SWC 
with a central maximum (Fig 2, Video S4; 14:13:52 hours) or 4–5 Hz slowing, and 
sporadic single spikes. During photic stimulation, some myoclonic seizures 
occurred, but seizure frequency did not change and the myoclonic seizures were not 
associated in time with the photic stimuli. Therefore, the dog was not classified as 
photosensitive. A diagnosis of JME in RRs with occurrence of myoclonic seizures 
and absence seizures was made. 
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A 20-minute wireless video-EEG with subsequent photic stimulation was 
performed on 5 healthy relatives with known genotype (mother [heterozygous], 2 
sisters [both wild type], 2 brothers [1 wild type, 1 heterozygous]), and 1 affected 
littermate (male, homozygous for the DIRAS1 variant, 1 hour of recording). 
Healthy controls had normal EEG and no photosensitivity. The affected brother had 
myoclonic twitches that started at 9 weeks of age. Generalized tonic-clonic seizures 
or absence seizures were not observed by the owner. The EEG demonstrated 
myoclonic seizures associated with polyspikes or PSWC, no absence seizures, and 
no photoparoxysmal response upon photic stimulation. 
Treatment with levetiracetam (24 mg/kg PO q8h) was initiated, and imepitoin was 
tapered. Owners were asked to keep a seizure diary. To ensure punctual drug 
administration, the owners used an automated dispensing machine that was filled 
with the pills embedded in treats. Owners reported a substantial decrease in seizure 
frequency and intensity, from multiple violent myoclonic jerks per day to 1 mild 
myoclonic twitch per week and a complete cessation of absence seizures. 
Two months after treatment onset with levetiracetam, a follow-up EEG was 
performed. One-hour unsedated video-EEG disclosed only 6 mild and hardly 
visible myoclonic seizures (97.2% decrease in seizure frequency compared to the 
initial recording), and absence seizures were no longer recorded. 
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Discussion 
In human medicine, JME is a common type of idiopathic generalized epilepsy, 
accounting for 4.1% of all epilepsies and 26.7% of idiopathic generalized 
epilepsies.4 Juvenile myoclonic epilepsy usually begins between 12 and 18 years of 
age, with a mean age of onset of approximately 14 years.9 Myoclonic jerks usually 
occur after awakening, are bilateral, arrhythmic, and predominate on the upper 
limbs, making the patients drop or throw objects.3 Most patients with JME continue 
to develop rare generalized tonic-clonic seizures, which often are preceded by a 
cluster of myoclonic jerks, and approximately 30% experience absence seizures.7,8 
Photosensitivity is seen in another 30% of patients.10 Electroencephalography 
identifies generalized and irregular SWC and PSWC with a fronto-central 
accentuation.4,11 Complete seizure control is achieved in the majority of patients, 
but relapse rate after antiepileptic drug (AED) withdrawal may be up to 91%.12,13 
Despite a strong genetic background with positive family history in at least 40% of 
patients and several genetic loci associated with this syndrome, no unique 
pathogenic mechanism has yet been identified.9,14 
Juvenile myoclonic epilepsy in humans and dogs shares a wide range of similar 
characteristics such as myoclonic seizures, generalized tonic-clonic seizures, ictal 
and interictal EEG features, and photosensitivity. The disease occurs in juvenile 
patients in both species, but onset may be much earlier in a substantial portion of 
dogs, with some being as young as 6 weeks of age.1 In the current case report, we 
describe the manifestation of absence seizures in a RR dog suffering from JME, 
highlighting another important parallel to JME in humans. 
The International League Against Epilepsy (ILAE) defines absence seizures as 
“sudden cessation of activity with a brief pause and staring, sometimes with eye 
fluttering and head nodding or other automatic behaviors” with an obligatory EEG 
pattern of generalized spike waves.15 This definition holds true for the behavior and 
EEG pattern observed in the dog described here. 
Several theories have been advanced to explain the pathophysiology of absence 
seizures.16 The initial hypothesis suggests that generalized SWC are created by a 
pacemaker in the brainstem and diencephalon (centrencephalic theory), whereas the 
“thalamic clock theory” assumes a pacemaker in the reticular thalamic nucleus.16,17 
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The “corticoreticular theory”, proposing a thalamocortical network for the 
generation of generalized seizures and SWC, has attracted much attention.16,17 
Although this concept postulates that the SWC seen in absence seizures are a 
consequence of the transformation of sleep spindles in the hyperexcitable cortex, 
another study concluded that, although both spike-wave discharges and sleep 
spindles arise from the cortico-thalamo-cortical network, the initiation site of the 
activity is different with sleep spindles emerging from the thalamus and spike-wave 
discharges from the cortex (cortical focus theory).16,18,19 
To our knowledge, only 1 other case report describes absence seizures with 
myoclonic features in a dog.20 An 8-month-old Chihuahua was presented for staring 
episodes associated with head and nose twitching.20 Diagnostic evaluation 
(neurologic examination and blood evaluation, magnetic resonance imaging [MRI]) 
was unremarkable.20 Long-term video-EEG identified generalized bilaterally 
synchronous 4 Hz SWC time-locked to the clinical events.20 However, the 
prevalence of absence seizures in dogs may be highly underestimated. In 1 study, 
owners perceived a generalized tonic-clonic seizure to be more harmful than a focal 
seizure and were less likely to report a focal seizure to their veterinarian.21 
Similarly, owners and veterinarians might underestimate the impact of absence 
seizures or not even identify those episodes as being epileptic. Some patients with 
absence seizures may go on to develop generalized tonic-clonic seizures. Therefore, 
the clinician should specifically ask about the occurrence of absence seizures and 
educate the owner about the semiology of this seizure type. Moreover, a definitive 
diagnosis of absence seizures requires confirmation by EEG. In the majority of 
studies in which EEG was used as a diagnostic tool, dogs were sedated or even 
anesthetized.22-27 This technique makes the diagnosis of absence seizures 
challenging, because level of alertness or consciousness, a key factor for the 
diagnosis of absence seizures, cannot be assessed. Consequently, EEG should be 
performed in unsedated dogs to enable the diagnosis of absence seizures.28 
The dog in our study exhibited typical absence seizures characterized by impaired 
consciousness in association with generalized SWC with a frequency of 4 Hz. In 
human medicine, absence seizures are considered as transient impairment of 
consciousness time-locked to generalized 3 Hz spike-wave discharges.29 In the 
current understanding, however, typical absence seizures that occur in association 
with idiopathic generalized epilepsies are characterized by generalized spike- or 
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polyspike-wave discharges with a frequency of >2.5 Hz (mainly 3-4.5 Hz) similar 
to those observed in the dog of our study.19,30 In contrast, atypical absence seizures 
are observed in human patients in the context of cognitive-related conditions and 
symptomatic epilepsies (eg, Lennox-Gastaut syndrome) and are characterized by 
lower frequencies.19,30 Furthermore, the frequency of spike-wave discharges in 
absence seizures varies with different types of epilepsy syndromes in humans.29 In 
JME, absence seizures with 3–4 Hz spike-wave discharges are described similar to 
the 4 Hz SWC in the dog described here and the Chihuahua with absence seizures 
with myoclonic features.20,29 
Short elimination half-life time (90-120 minutes) prevents the use of valproic acid 
in dogs, which is the first choice AED in humans with JME, reaching effectiveness 
of 85-90%.9 Therefore, other AEDs with an appropriate pharmacokinetic profile 
are used in dogs. Levetiracetam is another effective drug to treat JME in humans 
and is superior to phenobarbital for the treatment of myoclonic seizures in cats with 
feline audiogenic reflex seizures.31,32 For the RR in this report, treatment with 
imepitoin resulted only in mild reduction in intensity of myoclonic seizures, but 
frequency of myoclonic and absence seizures did not change. In contrast, much 
improvement of intensity and frequency of myoclonic seizures and complete 
cessation of absence seizures were achieved by levetiracetam treatment. Therefore, 
levetiracetam may be considered for the treatment of myoclonic seizures as well as 
absence seizures in veterinary medicine. However, more studies are warranted to 
confirm our observations. 
Our study had several limitations. Because there is currently only 1 case with 
proven absence seizures in a RR with JME, occurrence of this seizure type could 
just be a coincidental finding. However, humans with idiopathic generalized 
epilepsies can present with various generalized seizure types such as generalized 
tonic-clonic, tonic, clonic, atonic, myoclonic, or absence seizures.33 Therefore, 
absence seizures indeed can be a feature of JME in RRs. Moreover, several owners 
of RRs with JME that were presented to our clinics reported that their dogs were 
experiencing staring episodes. Although confirmation by video-EEG was not 
attempted in those dogs, these observations suggest that absence seizures might be 
a more common seizure type in RRs with JME than expected. In the present case, 
absence seizures were confirmed by EEG at the age of 8 months, whereas for the 
controls (1 affected and 4 healthy littermates), EEG was performed at the age of 10 
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months. Therefore, absence seizures could have been an age-related phenomenon 
that vanished over time. However, in contrast to the current case, owners of controls 
never observed staring episodes in their dogs. Brain imaging was not performed in 
the RR of this case report. However, the neurologic examination was normal and 
the dog tested positive for the DIRAS1 variant. In the previous study, RRs with 
JME had normal MRI findings.1 Furthermore, the RR of this report had an EEG 
pattern of generalized epileptic discharges and no focal discharges. Taking these 
points together, we considered structural brain disease very unlikely. 
The current case report describes the occurrence of absence seizures in a RR 
diagnosed with JME. Our findings expand the spectrum of JME to include a third 
seizure type and highlight the potential to use this dog breed as a large animal 
translational model for the investigation of pathophysiologic, therapeutic, and 
genetic aspects of JME in humans. Furthermore, the usefulness of unsedated 
wireless video-EEG for the diagnosis of seizure types and electroclinical syndromes 
with staring episodes is emphasized. 
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Fig 1. Absence seizure with generalized 4 Hz spike-and-wave complexes. 
Referential montage (G2=Ref). Low pass filter: 70 Hz; high pass filter: 0.53 Hz; 
gain: 150µV/cm. 
 
 
Fig 2. Myoclonic seizure with generalized 4–5 Hz spike-and-wave complexes. 
Referential montage (G2=Ref). Low pass filter: 70 Hz; high pass filter: 0.53 Hz; 
gain: 150µV/cm.
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IV. DISCUSSION 
The present study provides a detailed clinical and electroencephalographic 
description of a novel genetic epilepsy in dogs. The epilepsy was classified as a 
generalized idiopathic epilepsy, and a novel epilepsy gene DIRAS1 was discovered 
based on the clinical investigations described here. Wireless video-EEG in 
unsedated dogs was established as a novel diagnostic tool to prove the epileptic 
origin of involuntary movements and behavioural paroxysms. This method also 
allowed characterization of canine epilepsies at a level that enabled comparison to 
human epilepsy syndromes. The main goals achieved in this study were (1) the 
diagnosis and description of new seizure types previously underreported in dogs, 
namely myoclonic seizures and absence seizures, which were identified in 
association with JME in RRs, and (2) the comparison of canine and human IGEs at 
a syndromic level, which requires a complete description of the electroclinical 
syndrome including EEG manifestations. The introduction of wireless video-EEG 
into veterinary diagnostics and the recognition of currently underrecognized types 
of generalized seizures will likely influence the future approach to the diagnosis of 
seizures and epilepsy in dogs and to the comparison of canine and human epilepsies 
to enhance translational research. 
1. Classification of Juvenile Myoclonic Epilepsy in Rhodesian 
Ridgebacks 
1.1. Veterinary epilepsy classification system 
The present work provides a detailed description of a novel electroclinical 
syndrome in RRs. A structural cause was ruled out by comprehensive diagnostic 
investigations, EEG confirmed the generalized nature of the epileptic seizures, and 
genetic analyses identified the underlying variant in the DIRAS1 gene. 
In 2015, the International Veterinary Epilepsy Task Force (IVETF) proposed a 
classification system for epilepsy in dogs (BERENDT et al., 2015). An aetiological 
classification system distinguishes between idiopathic and structural epilepsy as 
well as epilepsy of unknown cause (BERENDT et al., 2015). Idiopathic epilepsy is 
further divided into (a) genetic epilepsy, (b) suspected genetic epilepsy, and (c) 
epilepsy of unknown cause (BERENDT et al., 2015). Moreover, the semiological 
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classification differentiates focal and generalized epileptic seizures, and focal 
epileptic seizures with propagation to generalized epileptic seizures (BERENDT et 
al., 2015). 
By applying these veterinary guidelines, JME in RRs can therefore be classified as 
an idiopathic genetic epilepsy with generalized epileptic seizures. 
1.2. Human epilepsy classification system 
Based on the human classification scheme of the International League Against 
Epilepsy (ILAE), RRs with JME have a generalized seizure onset, a generalized 
epilepsy, and the epilepsy syndrome of JME in RRs with a genetic aetiology. 
In human medicine, epilepsy classification represents a dynamic process. Since the 
introduction of a classification system in the early 1960s, the ILAE has made a 
number of additional proposals, mirroring the increase in knowledge about epilepsy 
and its underlying mechanisms (SCHEFFER et al., 2017). The current 2017 ILAE 
Seizure Classification comprises three levels (SCHEFFER et al., 2017). In the first 
level, a diagnosis of seizure type (focal, generalized, or unknown seizure onset) is 
made (SCHEFFER et al., 2017). In the next level, the type of epilepsy is 
determined, including focal, generalized, combined generalized and focal epilepsy, 
and an unknown epilepsy group (SCHEFFER et al., 2017). The last level involves 
the identification of the epilepsy syndrome (SCHEFFER et al., 2017). An epilepsy 
syndrome is defined as a combination of several characteristics such as seizure type, 
electroencephalographic characteristics, and brain imaging findings (SCHEFFER 
et al., 2017). Additionally, similarities in age of onset, triggering factors, 
chronodependency, response to treatment, and prognosis are often encountered 
(SCHEFFER et al., 2017). An aetiological diagnosis should be attempted at each of 
the three levels and includes the following groups: structural, genetic, infectious, 
metabolic, immune, and unknown (Figure 2) (SCHEFFER et al., 2017). 
Currently, very few epilepsy syndromes have been described in dogs, probably 
because of the lack of solid EEG data. Juvenile myoclonic epilepsy in RRs is 
therefore one of the first electroclinical syndromes described in dogs. 
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Figure 2: 2017 ILAE Seizure Classification (SCHEFFER et al., 2017) 
 
2. Clinical aspects 
2.1. New seizures types 
The present work introduces two new seizure types that have been underrecognized 
in veterinary medicine. The main feature of JME in RRs is myoclonic seizures, and 
a subset of dogs also has absence seizures. In contrast, the current veterinary 
literature focuses on focal and generalized tonic-clonic seizures (BERENDT et al., 
2015). Other seizure types such as absence seizures have been neglected or in the 
case of myoclonic seizures only been regarded in the context of Lafora disease and 
NCLs, but hardly ever in association with idiopathic epilepsies (AWANO et al., 
2006a; BERENDT et al., 2015; KOLICHESKI et al., 2016; LOHI et al., 2005a; 
LOWRIE & GAROSI, 2017; LOWRIE et al., 2016; POMA et al., 2010). The 
present study shows that the spectrum of seizure types in dogs is much broader than 
expected. Loss of consciousness may not be a mandatory feature of generalized 
seizures, as seen with generalized myoclonic seizures (BERENDT et al., 2015). On 
the other hand, generalized seizures can present solely as an impaired level of 
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consciousness without a motor component, as in the case of absence seizures 
(POMA et al., 2010). The new technique of wireless video-EEG in unsedated dogs 
facilitated the diagnosis of these seizure types in RRs with JME. Moreover, a focal 
origin could be ruled out because EEG constitutes a valuable tool to differentiate 
focal and generalized seizures and to determine the epileptogenic focus. This novel 
diagnostic method will presumably aid in the identification of further seizures types 
that have not yet been recognized in dogs. 
2.1.1. Myoclonic seizures 
One of the main goals of this study was to clarify whether or not the myoclonic 
jerks had an epileptic origin. This was achieved with the help of wireless video-
EEG in unsedated dogs - a new diagnostic approach. The epileptic nature of the 
myoclonic seizures was confirmed in 82% of the dogs examined. Myoclonic 
seizures were typically characterized by generalized 4-5 Hz SWC or PSWC with a 
frontocentral maximum. Therefore, wireless video-EEG confirmed the diagnosis of 
a generalized epilepsy syndrome and revealed an EEG pattern similar to that 
observed in human JME, highlighting the parallels between these two 
electroclinical syndromes. The diagnosis of a myoclonic epilepsy syndrome also 
had important implications for the affected dogs. It enabled early treatment of the 
epilepsy, selection of AEDs that were effective for this seizure type, and 
classification of the epilepsy onset. 
To date, there has been a paucity of descriptions of epileptic myoclonus in the 
veterinary literature and most have been limited to Lafora disease in dogs. It is 
therefore likely that the results of this study will change the approach to myoclonus. 
The current veterinary literature suggests subdividing myoclonus into epileptic 
(cortical) and non-epileptic myoclonus similar to classification schemes used in 
human medicine (LOWRIE & GAROSI, 2017). Non-epileptic myoclonus can have 
a subcortical (brainstem), spinal, or peripheral origin (LOWRIE & GAROSI, 2017). 
In a recent review, Lowrie et al. suggested using the occurrence of concomitant 
GTCS to distinguish epileptic myoclonus from non-epileptic myoclonus (LOWRIE 
& GAROSI, 2017). However, the results of the present EEG study challenge this 
approach because only a third of the 24 affected RRs developed GTCS in the course 
of the disease. Thus, when this classification scheme is applied to the RR cohort of 
the present study, 16 dogs (and all dogs at the time of initial presentation) would 
have been erroneously diagnosed with a non-epileptic myoclonus. Therefore, the 
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use of wireless video-EEG in unsedated dogs is strongly encouraged to distinguish 
epileptic from non-epileptic myoclonus. 
In veterinary medicine, myoclonic seizures are a fairly underrecognized seizure 
type. In the literature, they are mainly described in the context of structural 
epilepsies such as Lafora disease and NCLs, but reports of idiopathic myoclonic 
epilepsy are scarce (AWANO et al., 2006a; BERENDT et al., 2015; KOLICHESKI 
et al., 2016; LOHI et al., 2005b; LOWRIE & GAROSI, 2017; LOWRIE et al., 
2016). A current review of myoclonus in dogs only mentions myoclonic seizures in 
Lafora disease and NCLs, and myoclonic epilepsy of unknown origin in older dogs 
(LOWRIE & GAROSI, 2017). The latter is characterized by myoclonic seizures 
with a geriatric age of onset and unremarkable initial neurological examination and 
brain imaging, but a precise description, EEG details, and histological data are not 
provided (LOWRIE & GAROSI, 2017). However, as the dogs develop cognitive 
decline and other neurological signs in the course of the disease, the authors propose 
that this epilepsy syndrome is again part of a neurodegenerative brain disease 
(LOWRIE & GAROSI, 2017). Myoclonic seizures as a feature of idiopathic 
epilepsy are not mentioned in this review (LOWRIE & GAROSI, 2017). Similarly, 
the IVETF lists myoclonic seizures as a type of generalized epileptic seizures, but 
states that generalized epileptic seizures in dogs and cats present predominantly as 
GTCS and only rarely as myoclonic or atonic seizures (BERENDT et al., 2015). In 
contrast, the present study demonstrated myoclonic seizures as the main seizure 
type in an idiopathic genetic epilepsy syndrome. 
In the present study, the owners of two affected RRs that tested homozygous for the 
DIRAS1 variant stated that their dogs had never experienced clinical signs. 
However, during EEG recording, the dogs showed several subtle myoclonic jerks, 
and EEG proved their epileptic nature (unpublished observation). It is therefore 
very likely that myoclonic seizures are often dismissed by owners and veterinarians, 
especially when they are subtle, and myoclonic epilepsy is probably a widely 
underestimated seizure entity. Some dogs with myoclonic or absence seizures may 
go on to develop GTCS, which then prompt the owner to seek veterinary advice. 
Similarly, many humans with JME only consult a physician after their first GTCS 
because myoclonic jerks are often overlooked or underrated by patients and their 
families (GENTON et al., 2013; WOLF et al., 2015; YACUBIAN, 2017). In these 
cases, it is up to the clinician to specifically ask about the previous occurrence of 
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other seizure types. Otherwise determination of age of onset will be biased. These 
findings concerning neglected seizure types should be taken into consideration 
when reviewing the current literature, and age of onset should be evaluated with 
caution due to the possible bias that occurs when age of onset is determined by the 
first GTCS and other preceding subtle seizure types are disregarded. 
2.1.2. Absence seizures 
The results of the present study provided further proof of the existence of absence 
seizures in dogs. Furthermore, the findings suggested that this seizure type may be 
underrecognized in dogs because EEG is not routinely used as a diagnostic tool in 
cases with epilepsy. Specifically, the practice of performing EEG only in sedated 
or anesthetized dogs has virtually excluded the detection of absence seizures in dogs 
to date because their recognition requires an ictal EEG in awake dogs during the 
episodes in question. 
The initial description of JME in RRs did not include the occurrence of absence 
seizures. However, as the number of affected dogs referred to our clinics increased, 
we became increasingly aware of this peculiar seizure type and finally managed to 
confirm it by EEG in one RR. This dog had frequent staring episodes that were 
associated with 4 Hz SWC, and EEG was essential for recognition of this seizure 
type. Although there is currently only one proven case of absence seizures in a RR 
with JME, owner descriptions suggest a higher prevalence of this seizure type. 
The above-mentioned dog had absence seizures characterized by multiple episodes 
of unresponsiveness and freezing or staring in association with generalized SWC 
that had a frequency of 4 Hz. In human medicine, absence seizures were 
traditionally considered as transient impairment of consciousness associated with 
generalized SWC with a frequency of 3 Hz (CORTEZ et al., 2016; 
PANAYIOTOPOULOS et al., 1989). However, the current understanding is that 
typical absence seizures are characterized by generalized SWC or PSWC with a 
frequency of >2.5 Hz (mainly 3-4.5 Hz) (CORTEZ et al., 2016; 
PANAYIOTOPOULOS, 2008). Moreover, in typical absence seizures in humans, 
frequency often varies during one event, with a fast 3.5-4.5 Hz opening phase, 
followed by a gradual slowing to 2.5-3.5 Hz (DRURY & HENRY, 1993; 
PANAYIOTOPOULOS, 2008; PANAYIOTOPOULOS et al., 1989). Furthermore, 
frequency of spike-wave discharges in human absence seizures varies with the 
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different types of epilepsy syndrome (PANAYIOTOPOULOS et al., 1989). In 
CAE, for example, SWC have a frequency of 2.5-3.5 Hz, whereas in juvenile 
absence epilepsy, the frequency is often faster than 3 Hz, and in JME, absence 
seizures with 3-4 Hz spike-wave discharges are described (PANAYIOTOPOULOS 
et al., 1989). Finally, in a case report of a Chihuahua with absence seizures with 
myoclonic features, SWC with a frequency of 4 Hz were described (POMA et al., 
2010). 
To date in veterinary medicine, absence seizures have attracted little attention. In 
the IVETF consensus report on the definition, classification, and terminology of 
epilepsy, this seizure type is not even mentioned (BERENDT et al., 2015). Based 
on the results of the present study it is possible that absence seizures are widely 
underdiagnosed and underrecognized. There is currently only one other case report 
describing absence seizures with myoclonic features; continuous video EEG 
monitoring was used to document absence seizures in a Chihuahua dog similar to 
the methodology used in the present study (POMA et al., 2010). Packer et al. 
showed that owners perceive a GTCS to be more harmful than a focal seizure and 
are less likely to report a focal seizure to their veterinarian (PACKER et al., 2017). 
Similarly, it is possible that owners and veterinarians underestimate the impact of 
absence seizures or are unable to identify these episodes as being epileptic. Thus, 
for the phenotyping of canine epilepsies, the clinician should specifically include 
questions about the occurrence of absence seizures in history taking and educate 
owners about the semiology of this seizure type. Moreover, EEG should be 
performed in unsedated dogs suspected of having absence seizures to confirm their 
diagnosis. 
2.2. Electroencephalography 
In the present study, wireless video-EEG was established as a novel tool to 
investigate the epileptic nature of the paroxysmal events and to further characterize 
the electroclinical syndrome. Electroencephalography enabled the characterization 
of two new previously underreported seizure types in dogs, namely myoclonic 
seizures and absence seizures. Furthermore, EEG proved the generalized onset of 
the seizures and excluded focal seizures. Critical for this assessment was the use of 
an extended electrode montage with 15 electrodes in most dogs, which increased 
spatial resolution and therefore allowed exclusion of a focal origin. Lastly, by 
performing EEG with simultaneous video recordings in unsedated dogs, ictal and 
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interictal EEG changes could be differentiated and specifically characterized and it 
could be determined whether the onset of myoclonic activity was consistent with 
the onset of ictal EEG discharges or whether motor manifestations were preceded 
by a crescendo of EEG paroxysms. 
In order to verify these findings, EEG was also carried out in other related and 
unrelated control dogs, and recordings were compared to those from affected RRs. 
In addition, EEG recordings were reviewed by a neuropediatrician (G. Kluger), a 
neurophysiologist (M. Cortez), and a veterinary expert (F. James). 
The IVETF states that “the use of EEG in veterinary medicine is currently of 
questionable routine clinical value” (BERENDT et al., 2015). However, the present 
study demonstrates that EEG can be a valuable tool to investigate the epileptic 
nature of paroxysmal events of unknown aetiology and to further characterize the 
EEG pattern of specific electroclinical syndromes. Juvenile myoclonic epilepsy in 
RRs proved particularly useful for recording ictal events due to the frequent 
occurrence of the myoclonus. Previous studies of canine EEG usually employed an 
interictal short-term EEG in sedated or even anesthetized dogs (BERENDT et al., 
1999; BRAUER et al., 2012a; JAGGY & BERNARDINI, 1998; JESEREVICS et 
al., 2007; JOKINEN et al., 2007; WRZOSEK et al., 2017). In contrast, the aim of 
the present study was not only to demonstrate interictal epileptiform discharges but 
also to capture the paroxysms occurring during an ictal event on EEG. Since most 
of the RRs with JME experience multiple myoclonic seizures per day, this goal was 
achieved in the majority of cases. Electroencephalography revealed epileptiform 
discharges in 82% of the dogs examined. It appears logical that ictal EEG 
recordings are more easily achieved when events occur on a daily base or on 
multiple occasions during the day, which is the case in many RRs with JME. It may 
be much more difficult to achieve ictal EEG recordings in epilepsies with rare 
seizure events. It may also be more difficult to achieve readable EEG recordings if 
vigorous convulsions occur due to muscle activity obscuring the EEG signal. In 
these situations, EEG diagnosis may rely solely on interictal recordings 
demonstrating epileptiform discharges. This approach has been most commonly 
used in veterinary medicine with short-term interictal EEG in sedated dogs. 
Alternatively, more long-term EEG monitoring would be needed to capture the ictal 
events. In the current study, a definitive diagnosis could not be made via EEG in 
only three dogs; two dogs were on AED medication and seizure-free at the time of 
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recording, and muscle artefact was superimposed on the EEG correlate and 
therefore inconclusive in the other dog. Other veterinary EEG studies report success 
rates of 20 to 86%, and in humans, a diagnosis can be made in 58% of cases 
(JAMES et al., 2017; MCGONIGAL et al., 2004). The comparatively high 
diagnostic yield of the present study is likely due to the high frequency of myoclonic 
seizures. Electroencephalographic records from the present study were also part of 
another study that investigated the likelihood of EEG leading to a diagnosis 
(JAMES et al., 2017). Video-EEG was considered diagnostic when ictal or 
interictal epileptiform discharges were detected or EEG records during an event 
were unremarkable (JAMES et al., 2017). That study demonstrated that the 
likelihood of achieving a diagnosis via EEG improved as the frequency of the 
episodes increased (JAMES et al., 2017). 
A major concern in dogs is muscle artifact that obscures the EEG. Therefore, in the 
majority of veterinary studies in which EEG was used as a diagnostic tool, dogs 
were sedated or even anesthetized (BERENDT et al., 1999; BRAUER et al., 2012a; 
JAGGY & BERNARDINI, 1998; JESEREVICS et al., 2007; JOKINEN et al., 
2007; WRZOSEK et al., 2017). Electroencephalography in unsedated dogs was 
regarded unfeasible because the patients were considered to be uncooperative and 
the EEG inconclusive due to movement and muscle artefacts, especially those of 
the large temporal muscle that covers the skull in dogs (JESEREVICS et al., 2007). 
However, in the present study, it was shown that the dogs were cooperative, and 
despite muscle and movement artefacts, a certain proportion of the recordings were 
free of artefacts. In addition, unsedated video-EEG is not only less invasive than 
the traditional method, but it may also have a higher diagnostic success rate. The 
last resort in treating a dog with status epilepticus is inducing general anaesthesia 
to suppress epileptic brain activity. Hence, it can be assumed that general 
anaesthesia will also reduce interictal epileptiform discharges during EEG 
recording. Therefore, it could be speculated that EEG in unsedated dogs will 
increase the diagnostic success rate even if no ictal recordings are obtained. Finally, 
sedation or general anaesthesia prohibits the assessment of consciousness; 
responsiveness and level of consciousness are important aspects for the 
characterization of distinct types of epilepsy and a key factor in the diagnosis of 
absence seizures. 
In the author’s experience, dogs required approximately 20 minutes to become 
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accustomed to the procedure of EEG recording, but then started to relax and most 
fell asleep. Therefore, after the initial 20 minutes, muscle and movement artefacts 
largely vanished and recordings were much more conclusive. The fact that the 
majority of previous studies used short-time EEGs with a duration of only 20 
minutes may explain their low diagnostic yield (BRAUER et al., 2012a; 
JESEREVICS et al., 2007; JOKINEN et al., 2007). Moreover, several studies used 
different drugs, for example lidocaine or rocuronium, to reduce muscle artefact 
(BRAUER et al., 2012b; WARD et al., 2016). However, it is possible that 
prolongation of time of recording makes such treatments unnecessary. 
Consequently, the results of the present study strongly recommend expanding the 
time of recording to at least one hour. 
A major concern was the use of a standardized montage in canine EEG. In human 
epileptology, there is an internationally recognized protocol for standardized 
electrode positioning called the 10-20 system. Veterinary medicine lacks such a 
standardized protocol, which complicates comparison of the results of different 
studies. In addition, many studies use a montage that contains a small number of 
electrodes, which cover only a small percentage of the cerebral cortex because the 
electrical activity captured by one electrode has a surface diameter of only 1-2 cm 
(BRAUER et al., 2012b, 2012a, 2011; HOLLIDAY & WILLIAMS, 1999). 
Therefore, an electrode positioning protocol with a larger number of electrodes is 
necessary to differentiate focal from generalized epileptic seizures, to exclude a 
focal onset of generalized epileptiform discharges, and to determine the 
epileptogenic zone. An extended electrode placement protocol that used 15 
electrodes and was easy to apply in unsedated dogs was employed in the present 
study. This protocol was initially introduced by Pellegrino et al. and thereafter 
modified by James et al. for use in ambulatory EEG and long-term recordings 
(JAMES et al., 2011; PELLEGRINO, 2004). The present study demonstrates the 
feasibility of this method in a large cohort of dogs for the electroencephalographic 
description of a novel canine epilepsy syndrome. Nevertheless, this electrode 
placement protocol requires further validation, and the exact anatomic correlations 
of the electrode positions need to be determined, a process that was beyond the 
scope of this study. 
The present study illustrates that long-term wireless video-EEG in unsedated dogs 
is a novel and feasible technique for the investigation of frequent paroxysmal events 
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of unknown etiology and the classification and investigation of epilepsy syndromes 
in dogs for comparison to human epilepsy syndromes. Furthermore, the study 
revealed that in some circumstances this method is crucial, especially for the 
diagnosis of absence and myoclonic seizures. Further research is needed to 
determine the diagnostic success of EEG with rare events. Thus, with the help of 
EEG, researchers can obtain an expanded view of seizure activity occurring in the 
canine brain. The use of EEG can also identify more episodes of epileptic activity 
compared with observation and registration of GTCS alone. Further research on 
expansion and standardization of this technique in dogs with spontaneous naturally 
occurring epilepsy is warranted. 
2.3. Photosensitivity 
The present study demonstrated that reflex epileptic traits occur in dogs with IGE. 
In veterinary medicine, photosensitivity is a rather neglected and understudied 
phenomenon. Only in the context of structural epilepsies such as Lafora disease are 
seizures triggered by visual stimuli occasionally reported; even then, this reflex 
epileptic trait is only described and not called by its name – photosensitivity 
(HAJEK et al., 2016; LOHI et al., 2005a; SCHOEMAN et al., 2002; WEBB et al., 
2009). Moreover, although current neurological evaluation rarely uses EEG as a 
diagnostic tool, photic stimulation, as an activation method, is used even less. The 
present study shows that photosensitivity can constitute an important feature of an 
idiopathic epilepsy syndrome and demonstrates the diagnostic value of photic 
stimulation. Furthermore, a detailed description of an appropriate ILS protocol is 
provided. 
In human medicine, photic stimulation is a long-established activation technique to 
enhance the diagnostic yield of EEG. Interestingly, photosensitivity has currently 
become a main focus of interest in human epilepsy research. Not only does it have 
therapeutic consequences, but it is considered a biomarker for IGE, an 
endophenotype with prognostic impact and is used as a model to study the efficacy 
of new AEDs (KASTELEIJN-NOLST TRENITÉ et al., 1996; WALTZ et al., 1992; 
YACUBIAN, 2017). 
In the initial study cohort, clinical photosensitivity was observed in 35% of affected 
RRs. Subsequently, EEG with ILS was performed in six affected dogs; four dogs 
(66%) had a grade four PPR with photoconvulsions. Photic stimulation did not 
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evoke a PPR in one unrelated (wildtype) and three related (all heterozygous) 
healthy control dogs. Although the prevalence of clinical and 
electroencephalographic photosensitivity seems to be divergent, the small number 
of dogs examined by EEG with ILS should be taken into consideration. In a 
subsequent study setting that focussed on the confirmation of absence seizures, two 
more affected RRs and members of their family were examined by EEG with photic 
stimulation. Neither of the affected RRs nor their healthy relatives showed clinical 
or electroencephalographic photosensitivity. In human JME, there is some 
discrepancy between the number of patients that show clinical photosensitivity in 
daily life (15%) and the number of affected individuals that exhibit a PPR on EEG 
upon photic stimulation (30-90%) (ALFRADIQUE & VASCONCELOS, 2007; 
ANDERSON & HAMANDI, 2011; APPLETON et al., 2000; BAYKAN & WOLF, 
2017; GENTON et al., 2013; KASTELEIJN-NOLST TRENITÉ et al., 2013a; 
NICOLSON & MARSON, 2010; SERAFINI et al., 2013; WELTY, 2006; WOLF 
et al., 2015). Current data suggest a similar distribution pattern for JME in RRs. 
However, the prevalence rates may change when a larger number of dogs are 
evaluated. In contrast to JME in humans, clinical photosensitivity was predictive of 
the results of EEG with photic stimulation in RRs. Therefore, all affected RRs that 
were clinically photosensitive also showed a PPR upon photic stimulation, and 
individuals that did not show myoclonic seizures following visual stimuli did not 
have a PPR on EEG. 
According to Waltz et al., four grades of PPR can be distinguished (WALTZ et al., 
1992). Interestingly, photosensitivity in RRs with JME follows an all-or-none law: 
either the dogs do not show PPR or they exhibit a grade four PPR with 
photoconvulsions. Therefore, photosensitivity could constitute an endophenotype 
of JME in RRs and it appears to be closely linked to the DIRAS1 mutation. Further 
studies should investigate, whether this reflex epileptic trait has an influence on 
outcome and prognosis of affected individuals. 
Photic stimulation is an activation technique that is rarely used in veterinary 
medicine. Brauer et al. used two activation techniques, namely photic stimulation 
and hyperventilation, to investigate their ability to increase the diagnostic yield of 
short-time EEG (BRAUER et al., 2012b, 2011, 2012a). Dogs and cats, suffering 
from idiopathic or symptomatic (structural) epilepsy as well as healthy controls 
were examined under propofol anaesthesia (BRAUER et al., 2012b, 2011, 2012a). 
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Photic stimulation did not evoke a PPR in any of the examined individuals 
(BRAUER et al., 2012b, 2011, 2012a). Therefore, the use of the two activation 
techniques was discouraged as both methods had no influence on the diagnostic 
value of short-time EEG under propofol anesthesia (BRAUER et al., 2012b, 2011, 
2012a). In a recent study, dogs with a variety of epileptic encephalopathies were 
examined by EEG with photic stimulation under medetomidine sedation 
(WRZOSEK et al., 2017). Although ILS raised the number of spikes and sharp 
waves in dogs with meningoencephalitis of unknown origin and in dogs with 
portosystemic shunt, and dogs with idiopathic epilepsy had more spike waves 
following photic stimulation, total frequency of epileptiform discharges was not 
significantly affected by ILS (WRZOSEK et al., 2017). In contrast, the present 
study showed that a PPR was observed in 66% of the examined cases and one dog 
that exhibited an initially normal EEG had a grade four PPR with photoconvulsions 
only upon photic stimulation. 
The results of the present study demonstrate that it is essential to identify 
photosensitivity because it has important therapeutic consequences. Owners can be 
advised to avoid having visual stimuli, such as camera flashes, sudden light 
changes, and television, in the presence of affected dogs. Routine inclusion of 
photic stimulation in EEG recording protocols appears to be warranted. 
Furthermore, the gene discovery indicates an important pathway for future 
investigations of the mechanisms of photosensitivity. 
2.4. Age of onset 
Age of onset is an important clinical aspect for the classification of epilepsy 
syndromes (SCHEFFER et al., 2017). However, determination of seizure onset 
largely relies on owner observation. In the current study, many dogs had a history 
of mild myoclonic twitches that then progressed to more violent myoclonic 
seizures. Therefore, there may have been some delay between true seizure onset 
and the age of onset reported by the owners if initial subtle twitches were not 
noticed. In fact, two owners did not know that their dogs were suffering from mild 
myoclonic seizures until proven otherwise by video-EEG. Consequently, age of 
onset may be biased, and JME in RRs may have a younger age of onset than 
expected. Early EEG examinations should be done in dogs that test homozygous 
for the DIRAS1 variant to clarify the actual onset of seizures. 
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Juvenile myoclonic epilepsy in RRs has a mean age of onset of six months and a 
median age of onset of 3.5 months. Because the literature on human epilepsy 
syndromes refers to the mean age of onset, the mean value was also used in RRs 
with JME for comparison with other human epilepsies. However, median age of 
onset may better reflect the true age of onset. Studies investigating the 
developmental stages in dogs, especially the differences between the various breeds 
and comparison to child development, are scarce. In general, the development of 
locomotor skills precedes that of social skills in dogs, whereas primary socialization 
precedes locomotor development in humans (SCOTT & FULLER, 1965). In 
puppies, the neonatal period is followed by the socialization period (until the age of 
twelve weeks), the juvenile period (twelve weeks - six months or longer), and 
adolescence (~ six months - one to two years depending on the breed) (SCOTT & 
FULLER, 1965; SERPELL & DUFFY, 2016). Therefore, 14 dogs in the present 
study had a juvenile or adolescent age of onset. However, ten dogs were between 
six and ten weeks of age when they first had a myoclonic seizure. This observation 
may challenge the classification of a juvenile epilepsy syndrome. Nevertheless, 
some variance in age of onset is also encountered in human epilepsy syndromes. 
The introduction of two groups of diagnostic criteria in human JME mirrors this 
clinical heterogeneity (KASTELEIJN-NOLST TRENITÉ et al., 2013b; WOLF et 
al., 2015). Class I criteria are quite narrow and require an age of onset of ten to 25 
years, whereas class II criteria are more flexible and allow an age of onset of six to 
25 years (KASTELEIJN-NOLST TRENITÉ et al., 2013b; WOLF et al., 2015; 
YACUBIAN, 2017). Therefore, an age of onset during childhood does not exclude 
the diagnosis of JME in humans. 
Further studies using early video-EEG examinations should investigate the real age 
of onset of JME in RRs, which is possibly younger than current data suggest. 
However, JME in RRs could still constitute a valuable translational model for JME 
in humans. In many well-recognized animal models of human disease some 
inconsistencies exist. For example, Lafora disease in humans and dogs is 
characterized by myoclonus, progressive neurological decline, and the same genetic 
background (DE SIQUEIRA, 2010; LOHI et al., 2005a; SHAHWAN et al., 2005). 
However, age of onset differs greatly: children are as young as twelve to 17 years 
of age, whereas Lafora disease occurs in older dogs between six and nine years of 
age (LOHI et al., 2005a; SHAHWAN et al., 2005). Moreover, in dogs, the disease 
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seems to be less progressive compared with humans (LOHI et al., 2005a; 
SHAHWAN et al., 2005). Nevertheless, Lafora disease and other PMEs such as 
NCLs are frequently and successfully used as large animal translational models 
(ASHWINI et al., 2016; KATZ et al., 2017, 2015; KOLICHESKI et al., 2017; 
SANDERS et al., 2011; TRACY et al., 2016; WHITING et al., 2016). 
2.5. Diagnostic investigations 
In the present study, diagnostic investigations were consistent with idiopathic 
epilepsy and failed to identify a structural cause for the epilepsy. Physical and 
neurological examinations as well as blood and CSF analyses were unremarkable 
in the dogs. 
Neurometabolic screening revealed mild abnormalities in three affected dogs 
(elevated serum alanine; smear in urinary organic acids in the qualitative analysis; 
mild elevation in amino acids cystathionine and homocysteine). However, these 
findings were inconsistent and neurometabolic screening was normal for the 
remaining dogs. Therefore, a neurometabolic disorder was considered unlikely as a 
cause for JME in RRs. 
Brain imaging was performed in the majority of dogs (16 dogs). Diagnostic imaging 
failed to identify gross or consistent abnormalities, and all findings were indicative 
of idiopathic epilepsy. However, imaging of epilepsy still has important draw-
backs. Firstly, computed tomography was carried out in few dogs of this study 
cohort and is considered an inadequate method for the investigation of epileptic 
seizures due to lack of detail. Secondly, recent recommendations by the IVETF 
suggest using imaging protocols that focus on the detection of changes in the 
hippocampus (RUSBRIDGE et al., 2015). Lastly, a wide variation in imaging 
quality and protocols were used in this study, ranging from CT and low-field 0.5T 
MRI to 1.5T and 3T MRI with IVETF-suggested protocols (RUSBRIDGE et al., 
2015). Brain imaging revealed minor abnormalities of questionable significance in 
five dogs. Findings included ventricle asymmetry (three dogs), mild meningeal 
contrast enhancement, suspected mild brain atrophy, and T1 and T2 hypointensity 
in the transition area of the frontal lobe and the olfactory bulb in one dog each. 
Ventricle asymmetry has been described as an incidental finding in dogs because it 
can also be frequently found in dogs without epileptic seizures (PIVETTA et al., 
2013). Likewise, a small amount of meningeal contrast enhancement is often 
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present in healthy dogs (JOSLYN et al., 2011). In one dog, slight brain atrophy was 
suspected on initial imaging, but follow-up examination using 3T PET-MRI ruled 
this out. The focal findings observed in one RR may very well have been an 
epileptogenic focus. Although an effect of this structural abnormality on seizure 
phenotype, such as lowering seizure threshold, cannot be excluded, the EEG was 
clearly indicative of a generalized and not a focal epilepsy syndrome. 
One limitation of the present study was that necropsy and detailed post-mortem 
examination of the brain were done in only one dog. In this dog, post-mortem 
examination revealed postictal changes only and structural epilepsy was excluded. 
Most importantly, there was no evidence of Lafora bodies, thus excluding Lafora 
disease in these dogs. The results of brain MRI were unremarkable in the remaining 
dogs, and long-time follow-up revealed no signs of neurological or cognitive 
deterioration. These observations suggest that JME in RRs is truly a generalized 
idiopathic epilepsy syndrome. Nevertheless, histologic examination of further 
affected dogs would be desirable. 
2.6. Seizure frequency 
The results of the present study show that data on seizure frequency should be 
interpreted carefully. The frequency of GTCS, myoclonic, and absence seizures is 
based on owner observations. However, for several reasons, seizure frequency may 
be highly underestimated. On the one hand, few owners can directly observe their 
dogs 24 hours a day and therefore, it is possible that owners do not notice every 
epileptic seizure. On the other hand, the manifestation of myoclonic seizures may 
be very variable, ranging from very subtle twitches of the face (for example jerks 
of the eyelids, ears, or cheeks) to pronounced jerks that affect the whole body. Mild 
myoclonic twitches in particular can be easily overlooked or disregarded by the 
owner. It is particularly difficult to recognize absence seizures because they are by 
definition a short period of loss of consciousness without motor activity. Therefore, 
the frequency of absence seizures may be easily underestimated, or this type of 
seizure may be overlooked completely. For accurate quantification of seizure 
frequency, telemetry and/or long-term video-EEG or invasive EEG monitoring is 
needed. Current research focusses on development of seizure recognition and 
seizure alert technology in humans, and invasive long-term EEG monitoring has 
been successfully applied to dogs in a research setting (DAVIS et al., 2016; 
HOWBERT et al., 2014). 
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2.7. Influence of heat and neutering status 
Dog owners always question the effect of oestrus (heat) and sex hormones on the 
manifestations of epilepsy. The recurrent oestrus-associated deterioration observed 
in three bitches in the present study may be similar to the effect that sex steroid 
hormones have on seizures in women. A twofold increase in average daily seizure 
frequency in relation to the menstrual cycle is defined as catamenial epilepsy in 
women (HERZOG, 1997). This phenomenon is attributed to the neuroactive 
properties of steroid hormones (HERZOG, 1997). Although the potential of 
oestrogens to facilitate or inhibit seizures is controversial, it is well-recognized that 
progesterone has an anticonvulsant effect in humans and there is a positive 
correlation between oestrogen/progesterone ratio and seizure frequency 
(BACKSTROM, 1976; HERZOG, 1997; REDDY, 2009; VELÍŠKOVÁ, 2006). 
Further studies are needed to determine whether this finding is specific for the 
syndrome in RRs with JME, reflects the general effect of sex hormones on epilepsy 
in dogs, or is just an incidental finding (VAN MEERVENNE et al., 2014). 
The effect of castration on the course of an epilepsy has not been clarified. It is 
interesting that in some RRs, a reduction of seizure frequency after neutering was 
reported by the owners. While some studies could not demonstrate a correlation 
between castration and epilepsy of unknown cause or the incidence of cluster 
seizures, others showed an increased risk for cluster seizures in castrated dogs and 
an increased incidence of epilepsy of unknown cause in male neutered dogs 
(KEARSLEY-FLEET et al., 2013; MONTEIRO et al., 2012; PACKER et al., 2016; 
SHORT et al., 2011). 
Similar to oestrus, the interaction of sexually intact dogs with their conspecifics 
results in stress for many dogs. In the present study, most owners stated that stress 
was a potent triggering factor for their dog’s epilepsy. It is therefore possible that 
the increased stress level alone led to an increased seizure frequency and 
amelioration after castration is attributable to the elimination of those stress peaks, 
which was proposed by Berendt et al. (BERENDT et al., 2008). 
2.8. Treatment and outcome 
Comparison of response to treatment was challenging because a multitude of 
different treatment regimens were used by the referring veterinarians. This applied 
in particular to the initial phase of the study, when reasonable differentials for the 
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sleep-associated twitches included sleep disorders and paroxysmal dyskinesias in 
addition to epileptic seizures. To date, the best results were achieved with LEV and 
KBr. However, carefully planned and executed studies with a larger number of dogs 
are necessary to confirm this observation. Valproic acid is the drug of choice in 
humans with JME and provides a seizure control rate of up to 90% (CRESPEL et 
al., 2013; WELTY, 2006). However, valproic acid has a very short elimination half-
life in dogs, and other AEDs with a better pharmacokinetic profile must be used in 
this species. Levetiracetam is another effective drug to treat JME in humans and is 
the first-line treatment for women of childbearing age (CRESPEL et al., 2013; 
NOACHTAR et al., 2008). Furthermore, in a prospective randomized open-label 
study, Lowrie et al. showed that LEV is superior to PB for the treatment of 
myoclonic seizures in cats with feline audiogenic reflex seizures (LOWRIE et al., 
2017). These findings support the preliminary observations on the beneficial effects 
of LEV in RRs with JME. 
One limitation of the present study was that evaluation of AED efficacy was based 
mainly on the results of owner-based seizure monitoring and therefore relied on 
owner compliance. In one dog however, owner observations were confirmed by a 
follow-up EEG with synchronized video recording. In this case, seizure frequency 
could be objectively compared to the initial recording and revealed a reduction of 
myoclonic seizures of 97.2%. 
Furthermore, owners stated that their dogs had no learning difficulties or 
developmental delays and retained normal cognition throughout life. Although the 
follow-up time of some dogs was more than eight years, which is almost the life 
expectancy of an RR, validated questionnaires and objective learning tasks would 
be desirable for assessing cognitive impairment or behavioural abnormalities. In 
addition, because of the small size of the cohort in the present study, behavioural 
changes or cognitive impairment in a subset of RRs with JME could not definitely 
be excluded. 
In the present study, preliminary observations suggest that when treatment with 
LEV or KBr was initiated in the early phase of the disease, dogs were more likely 
to become seizure free or at least experience a marked reduction in seizure 
frequency than when treatment was delayed. Dogs that had a major delay in the 
start of treatment with LEV or KBr or were treated with AEDs other than LEV or 
KBr appeared to have a higher risk for treatment resistance. The potential benefit 
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of starting treatment promptly requires further study. The identification of the gene 
variant causing JME in RRs and the widespread availability of genetic testing for 
the DIRAS1 variant raises another question: would a dog with a homozygous mutant 
genotype benefit from prophylactic treatment, i.e. a treatment that starts before 
clinical manifestation of epileptic seizures? In other words, would prophylactic 
treatment have a positive effect on the course of the disease or even prevent the dog 
from experiencing seizures? In recent years, a multitude of studies investigated the 
potential antiepileptogenic properties of LEV and a variety of other AEDs, with 
controversial results (BRANDT et al., 2007; HEUERMANN & CHETKOVICH, 
2016; KLEE et al., 2015; OHNO et al., 2010; SUGAYA et al., 2010; 
VINOGRADOVA & VAN RIJN, 2008). Whether LEV has an antiepileptogenic 
effect remains to be seen, and further studies are warranted to determine whether 
starting treatment early in the course of JME in RRs is beneficial. 
3. DIRAS1 
Based on the genetic investigations of the epilepsy cohort identified in the present 
study, a causal variant in a new epilepsy gene was identified. DIRAS1 is widely 
expressed in the mammalian brain and has not been associated with epilepsy thus 
far. The encoded protein belongs to the family of guanosine triphosphatases 
(GTPase), whereby its GTPase activity is low and it predominantly remains in its 
guanosine triphosphate (GTP)-bound state (COLICELLI, 2004; KONTANI et al., 
2002). The biological function of DIRAS1 in mammals is poorly understood. 
A recent study investigated the role of diras1a and diras1b in a zebrafish model. 
The authors could show, that the two genes are predominantly expressed in the brain 
and retina ganglion cells (YEH & HSU, 2016). Transfection of mouse Neuro-2a 
cell lines with green fluorescent protein (GFP)-diras1a or GFP-diras1b revealed 
that zebrafish diras1a and diras1b may promote neurite outgrowth of these cells 
(YEH & HSU, 2016). Furthermore, in a model of developing zebrafish, in which 
knockdown of diras1a and/or diras1b was attempted by morpholino antisense 
oligonucleotides, reduced axon guidance and a decreased number of trigeminal 
ganglia were observed (YEH & HSU, 2016). 
Tada et al. used Caenorhabditis elegans to further elucidate the function of 
DIRAS1, and showed that drn1 (homologue to DIRAS1) mutants obtained some 
resistance to aldicarb treatment (TADA et al., 2012). Aldicarb is an 
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acetylcholinesterase inhibitor that causes hypercontraction of muscles and paralysis 
due to insufficient breakdown of ACh (TADA et al., 2012). Furthermore, the 
aldicarb-hypersensitive phenotype caused by gain of function of gsa-1 was partially 
reversed in drn1 mutants (TADA et al., 2012). In addition, the investigators showed 
that the DIRAS1 and exchange protein directly activated by cyclic adenosine 
monophosphate (cAMP) (EPAC) orthologues colocalize at the presynaptic 
membranes and are involved in the regulation of presynaptic ACh release at 
neuromuscular junctions. 
The understanding of the role of DIRAS1 in cholinergic neurotransmission and 
epilepsy remains an important area of study. Nicotinergic cholinergic activity 
influences brain excitability and cognition, regulates the excitatory/inhibitory 
switch of GABA during neuronal development, stimulates glutamate release from 
thalamocortical terminals, controls GABA release onto pyramidal neurons, and 
maintains non-REM sleep by low levels of ACh whereby cholinergic stimulation is 
associated with microarousals in this sleep stage (BECCHETTI et al., 2015; LIU et 
al., 2006). Mutations in the nAChR subunits cholinergic receptor nicotinic alpha4 
subunit (CHRNA4), cholinergic receptor nicotinic alpha2 subunit (CHRNA2), and 
cholinergic receptor nicotinic beta2 subunit (CHRNB2) are associated with 
autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) and sporadic 
nocturnal frontal lobe epilepsy (NFLE) (CONTI et al., 2015). Several models for 
the pathogenic mechanism have been postulated (COMBI et al., 2004; 
RAGGENBASS & BERTRAND, 2002). As a common trait, either an increased 
ACh sensitivity or a shift in the proportion of low-sensitivity and high-sensitivity 
receptors has been proposed (FERINI-STRAMBI et al., 2012). Other mechanisms 
are an imbalance between excitation and inhibition enhancing and synchronizing 
spontaneous oscillations in thalamocortical circuits, and abnormal formation of 
neuronal circuits and alteration of network assembly in the developing brain leading 
to epilepsy (MANFREDI et al., 2009; RAGGENBASS & BERTRAND, 2002). A 
mutation in PRIMA1 encoding for a transmembrane protein that anchors 
acetylcholinesterase is associated with autosomal recessive NFLE, probably due to 
overstimulation of nAChRs (HILDEBRAND et al., 2015). CHRNA7 coding for the 
α7 subunit of the nAChR is also a potential candidate gene for JME in humans 
(HELBIG et al., 2009). Therefore, abnormal DIRAS1 function could alter 
cholinergic neurotransmission or facilitate neurodevelopmental defects resulting in 
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myoclonic epilepsy. 
Interestingly, DIRAS2 has recently been associated with ADHD and co-morbid 
impulsive disorders in humans (REIF et al., 2011). Attention deficit hyperactivity 
disorder has been associated with BFJE in Lagotto Romagnolo dogs and is a 
frequently observed comorbidity in human epilepsy syndromes (JOKINEN et al., 
2015). It would therefore be interesting to determine whether a similar condition 
occurs in RRs with JME. 
Other studies investigating the function of DIRAS1 proposed that it plays an 
important role in oncogenesis. It has been shown that DIRAS1 is down-regulated in 
cultured glioma cells and primary glioblastoma samples (LIGON et al., 1997). 
Thus, it was postulated that an altered expression and distribution pattern of 
DIRAS1 may promote malignant progression of human glioblastomas (LIGON et 
al., 1997). Down-regulation of DIRAS1 was also observed in 50% of human patients 
with oesophageal squamous cell carcinoma, where it was significantly associated 
with advanced stage of disease, metastasis, and a lower overall three-year survival 
rate (ZHU et al., 2013). DIRAS1 and DIRAS2 are also down-regulated in ovarian 
cancer and are correlated with a reduced disease-free interval and overall survival 
time (SUTTON et al., 2018). Finally, the promotor region of DIRAS1 was 
methylated in 47% of human specimens of primary colorectal cancer, whereas no 
methylation was found in healthy control tissue (ZHENG et al., 2017). This 
methylation led to a diminished expression of DIRAS1 and was significantly 
associated with an advanced tumour stage and a reduced survival time (ZHENG et 
al., 2017). Bergom et al. showed that DIRAS1 binds to small GTP-binding protein 
guanosine diphosphate (GDP) dissociation stimulator (SmgGDS), a protein that 
promotes the activation of several oncogenic GTPases (BERGOM et al., 2016). Via 
this binding, DIRAS1 prevents SmgGDS from binding to oncogenic small 
GTPases, such as Κ-Ras4B, RhoA, and Ras-related protein 1A (Rap1A) 
(BERGOM et al., 2016). Furthermore, DIRAS1 suppresses basal nuclear factor κB 
(NF-κB) activation in glioblastoma and other tumour cell lines (BERGOM et al., 
2016). Therefore, it was suggested that DIRAS1 plays a role as a tumour suppressor 
gene (BERGOM et al., 2016; ELLIS et al., 2002; ZHENG et al., 2017). 
At the time of publication, seven of the 24 dogs from the initial study cohort had 
died. Of the seven dogs, two were euthanized because of neoplasia; one was 
diagnosed with a renal tumour at the age of four years, and the other died from a 
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ruptured splenic tumour at six years of age. Another dog from this population died 
due to a splenic tumour at ten years of age, and one other was euthanized at two 
years of age because of lymphoma, which was diagnosed histologically 
(unpublished data). Future studies should therefore focus on the prevalence of 
tumours in RRs that carry the DIRAS1 variant to determine whether this 
subpopulation is at increased risk of developing neoplastic disease. 
4. Comparison with human epilepsy syndromes 
The present study proposes that generalized myoclonic epilepsy in RRs shares 
many common features with JME in humans, which is the most common human 
IGE. Initial reports on the symptoms of RRs with JME consisted of sleep-associated 
jerks with an early age of onset. Therefore, initial differentials for this breed-
specific syndrome not only included myoclonic seizures but also paroxysmal 
dyskinesias, non-epileptic myoclonus, and parasomnias. Consequently, a wide 
range of human and canine disorders were considered and evaluated for common 
features, outlined in the following part of the discussion. 
4.1. Juvenile Myoclonic Epilepsy 
Juvenile myoclonic epilepsy in humans is a primary generalized epilepsy syndrome 
with multiple associated gene mutations and a mean age of onset of 14 years 
(WELTY, 2006). Typically, people present with myoclonic seizures without loss 
of consciousness (GENTON et al., 2013). Myoclonic jerks usually occur after 
awakening, are bilateral and arrhythmic, and predominate in the upper limbs, 
making the patients drop or throw objects (GENTON et al., 2013). Seizures are 
often precipitated by sleep deprivation, stress, and alcohol consumption (GENTON 
et al., 2013; KASTELEIJN-NOLST TRENITÉ et al., 2013a). The majority of 
patients (80-95%) develop rare GTCS after a mean delay of 1.3 to 3.3 years 
(GENTON et al., 2013; WOLF et al., 2015). Often GTCS are preceded by a cluster 
of myoclonic jerks (GENTON et al., 2013). A smaller number also present with 
absence seizures (NICOLSON & MARSON, 2010; WOLF et al., 2015; 
YACUBIAN, 2017). Neurological examination and brain imaging are normal, and 
there are no intellectual deficits (WELTY, 2006). Electroencephalography typically 
reveals generalized and irregular SWC and PSWC, often with a frontocentral 
accentuation (BAYKAN & WOLF, 2017; KOEPP et al., 2014; SERAFINI et al., 
2013). Electroencephalographic paroxysmal responses upon photic stimulation are 
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common (30%), although the prevalence of clinical response to visual stimuli in 
daily life is lower (BAYKAN & WOLF, 2017; GENTON et al., 2013). Therefore, 
of all epilepsies, JME has one of the strongest associations with photosensitivity 
(GUERRINI & GENTON, 2004). 
There are striking similarities between JME in humans and RRs: the prevailing 
seizure type is myoclonic seizures with propagation to GTCS in a subgroup of 
patients (humans: 80-95%; RRs: 38%) (GENTON et al., 2013; WOLF et al., 2015). 
These GTCS are often preceded by a series of myoclonic seizures in both species. 
Whereas absence seizures are encountered in 30% of human patients, to date there 
is only one proven case of this seizure type in RRs (NICOLSON & MARSON, 
2010; WOLF et al., 2015; YACUBIAN, 2017). Nevertheless, owner observations 
suggest a higher prevalence of absence seizures in canine JME. Mean age of onset 
occurs around puberty in humans and dogs (humans: 14 years; RRs: six months), 
although some dogs were as young as six weeks of age when they experienced their 
first myoclonic seizures (WELTY, 2006). Seizures follow a circadian rhythm in 
humans and dogs. In human patients, myoclonic seizures and GTCS occur 
predominantly within the first two hours after awakening, although another peek 
during relaxation periods in the evening is encountered in some patients 
(KASTELEIJN-NOLST TRENITÉ et al., 2013b). In RRs, myoclonic seizures 
mainly occur when the animals are in a recumbent position and relaxed, drowsy, or 
in the first stages of sleep. Neurological examination and routine brain imaging are 
normal in both species (ANDERSON & HAMANDI, 2011). Moreover, JME in 
humans and dogs share similar EEG characteristics. Both epilepsy syndromes are 
characterized by SWC or PSWC with a frontocentral accentuation (BAYKAN & 
WOLF, 2017; KOEPP et al., 2014; SERAFINI et al., 2013). Photosensitivity is a 
striking feature of JME in humans and dogs. A PPR upon photic stimulation is 
observed in 30-50% of human patients (up to 90% with prolonged stimulation), 
although clinical photosensitivity is only encountered in 15% (ALFRADIQUE & 
VASCONCELOS, 2007; ANDERSON & HAMANDI, 2011; APPLETON et al., 
2000; BAYKAN & WOLF, 2017; GENTON et al., 2013; NICOLSON & 
MARSON, 2010; SERAFINI et al., 2013; WELTY, 2006; WOLF et al., 2015). In 
contrast, all dogs that showed a PPR upon photic stimulation, also had 
photosensitivity in daily life (35%). Short elimination half-life (90-120 min) and 
hepatotoxicity prevent the use of valproic acid in dogs, which is the first choice 
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AED in humans with JME, having an efficacy of up to 85-90% (ALFRADIQUE & 
VASCONCELOS, 2007; BAYKAN & WOLF, 2017; BAYKAN et al., 2013; 
WELTY, 2006; YACUBIAN, 2017). Therefore, other AEDs with an appropriate 
pharmacokinetic profile have been used in dogs. The best results were achieved 
with LEV, which is also an effective drug for JME in humans, and KBr was also 
effective (NOACHTAR et al., 2008). Although JME in humans is a genetically 
heterogenous disorder, one associated microdeletion at 15q13.3 encompasses 
CHRNA7 as the prime candidate gene (HELBIG et al., 2009). This gene codes for 
the α7 subunit of the nAChR (HELBIG et al., 2009). Juvenile myoclonic epilepsy 
in RRs is caused by a deletion mutation in DIRAS1, which has been proposed to 
play a role in presynaptic ACh release. Therefore, the pathomechanism of both 
diseases may implicate abnormal cholinergic neurotransmission. 
4.2. Myoclonic Epilepsy of Infancy 
Myoclonic epilepsy of infancy (MEI) is an idiopathic generalized epilepsy 
syndrome that occurs in children with normal development in the first three years 
of life (CARABALLO et al., 2013). Infants have brief, spontaneous and/or reflex, 
generalized myoclonic seizures during wakefulness and drowsiness, most notably 
in the upper limbs and head (CARABALLO et al., 2013; DARRA et al., 2006). 
Electroencephalography reveals ictal and interictal generalized SWC, polyspikes, 
and PSWC, and some patients are photosensitive (CARABALLO et al., 2013; 
ZUBERI & O’REGAN, 2006). Other seizure types do not occur (CARABALLO et 
al., 2013). Prognosis is good in terms of seizure control, but about one third of 
patients develop neuropsychological problems, and in rare cases other epilepsy 
syndromes may develop after remission of myoclonic seizures (CARABALLO et 
al., 2013). 
A syndrome comparable to MEI in humans has not been observed in dogs to date. 
Juvenile myoclonic epilepsy in RRs shares many features with MEI, including EEG 
findings, photosensitivity, and otherwise normal development. Although the mean 
age of onset occurs in juvenile RRs, a substantial number of dogs have a much 
earlier onset, mirroring the infantile age of onset observed in MEI. However, a large 
proportion of RRs develop other seizure types such as GTCS or absence seizures in 
addition to myoclonic seizures. Furthermore, remission has not been observed in 
any of the affected RRs, and thus it remains a lifelong epilepsy. 
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4.3. Nocturnal Frontal Lobe Epilepsy 
Nocturnal frontal lobe epilepsy is an idiopathic focal epilepsy syndrome originating 
in the frontal lobe (FERINI-STRAMBI et al., 2012; NOBILI et al., 2014). Seizures 
occur predominantly during non-rapid eye movement (non-REM) sleep, especially 
during light (stage two) sleep (PROVINI et al., 1999). They tend to coincide with 
K-complexes and often recur in a quasi-periodic rhythm at a rate similar to that of 
K-complexes (PROVINI et al., 1999). A third of patients occasionally experience 
seizures during daytime wakefulness, and another third have rare secondarily 
generalized seizures (PROVINI et al., 2000a). The syndrome is characterized by a 
wide spectrum of clinical features of variable duration and complexity (NOBILI et 
al., 2014). Three subtypes, which are considered different aspects of one 
heterogeneous syndrome, are distinguished: (a) paroxysmal arousals: brief events 
with a duration of less than 20 s manifesting as abrupt arousals accompanied by 
stereotyped and often dystonic movements; (b) nocturnal paroxysmal dystonia: 
episodes, lasting up to two minutes, with wide, dyskinetic, dystonic, or even 
ballistic movements; and (c) episodic nocturnal wanderings: events of up to three 
minutes duration characterized by paroxysmal, agitated, and stereotyped 
ambulation and vocalization (HALÁSZ et al., 2012; PROVINI et al., 1999, 2000a, 
2000b). Consciousness is often preserved throughout the attacks (SCHEFFER, 
2000). Nocturnal frontal lobe epilepsy has a mean age of onset of 14 years and 
occurs predominantly in males (PROVINI et al., 1999). Most patients benefit from 
carbamazepine, although about one third are drug resistant (NOBILI et al., 2014; 
PROVINI et al., 1999). There is a positive family history in 25% of patients 
(FERINI-STRAMBI et al., 2012). Autosomal dominant nocturnal frontal lobe 
epilepsy is a familial variant of NFLE. It has an autosomal dominant mode of 
inheritance and does not differ from the sporadic form of NFLE with respect to 
clinical and electroencephalographic findings (PROVINI et al., 1999). To date, 
several mutations in a total of six genes have been identified in the context of 
ADNFLE; three of the genes are associated with the neuronal nAChR (NOBILI et 
al., 2014). The diagnosis of NFLE is often challenging because the clinical 
symptoms can be mistaken for non-REM sleep parasomnias (PROVINI et al., 
1999). This is further complicated by the fact that interictal wake and sleep EEG as 
well as ictal EEG are normal in about half of the patients, and only 8% show clear-
cut epileptic activity (spikes or SWC) on ictal EEG (PROVINI et al., 1999). 
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To date, there are no reports of a disorder comparable to NFLE in dogs. The results 
of the present study revealed an epileptic disorder that was predominantly sleep-
associated and in which some dogs experienced rare episodes during daytime 
wakefulness similar to the diurnal pattern observed in NFLE. Some RRs developed 
GTCS, and in addition, disease onset occurred in juvenile dogs. The genetic 
background was identified with a proposed involvement of presynaptic ACh 
release. However, the disease has an autosomal recessive mode of inheritance. 
Moreover, the type of movement encountered in the dogs in the present study was 
myoclonic rather than dystonic, and there was no gender predisposition. Another 
issue is that an electroencephalographic correlate comprising ictal and interictal 
generalized SWC was found in a great majority of the dogs examined. 
4.4. REM sleep behaviour disorder 
Rapid eye movement (REM) sleep behaviour disorder (RBD) is not an epilepsy 
syndrome but instead a sleep disorder. Nevertheless, it is given consideration in this 
discussion because of its association with sleep and myoclonus-like properties. 
Rapid eye movement sleep behaviour disorder is a parasomnia characterized by a 
dream enactment behaviour during REM sleep comprising abnormal motor 
behaviour, abnormal vocalization, and an altered dream mentation (BOEVE, 2010). 
Motor activity is often very violent and manifests in humans as punching, kicking, 
beating, biting, flailing, running, or jumping out of bed (BOEVE, 2010; IRANZO 
et al., 2009). In healthy individuals, there is minimal skeletal muscle activity during 
REM sleep due to activation of inhibitory neurons in the pons and medulla 
oblongata, which inhibit lower motor neuron ventral horn cells in the brainstem and 
spinal cord (BOEVE et al., 2007; SCHUBERT et al., 2011). In RBD, skeletal 
muscle atonia during REM sleep is lost leading to the above-mentioned vigorous 
limb movements (BOEVE et al., 2007). Because dream enactment behaviour 
resembles other diseases, such as obstructive sleep apnoea, somnambulism, and 
nocturnal epilepsy, most experts agree that a polysomnography is required for the 
clinical diagnosis of RBD and to prove the presence of REM sleep without atonia 
and the absence of epileptiform activity on EEG (BOEVE et al., 2007). In human 
medicine, men between the age of 50 and 80 years are overrepresented, and RBD 
is often associated with neurodegenerative diseases including Parkinson’s disease, 
dementia with Lewy bodies, and multiple system atrophy (BOEVE, 2010, 2013). 
The majority of patients respond well to clonazepam and/or melatonin (BOEVE, 
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2010). 
Rapid eye movement sleep behaviour disorder has been reported in dogs as well 
(BUSH et al., 2004; SCHUBERT et al., 2011). Violent limb movements, chewing, 
teeth grinding, biting, growling, howling, and barking were the presenting features 
(SCHUBERT et al., 2011). A gender predisposition has not been detected to date 
(BUSH et al., 2004; SCHUBERT et al., 2011). Schubert et al. proposed that two 
different forms of RBD occur in dogs: a form that has a juvenile onset (two years 
of age or less) and a form that has an adult onset (three years of age and older), with 
71% having a juvenile onset in that study (SCHUBERT et al., 2011). In contrast to 
humans, dogs do not appear to benefit from clonazepam or melatonin, but KBr and 
tricyclic antidepressants have been shown to be effective (BUSH et al., 2004; 
SCHUBERT et al., 2011). 
The RRs in the present study also experienced vigorous limb movements, which 
were associated predominantly with sleep. Unfortunately, a polysomnography, 
which would require inclusion of EMG recordings, was not used. Therefore, a clear 
distinction between the different sleep stages and an exclusion of the presence of 
REM sleep without atonia was not possible. However, those episodes were 
observed in all dogs during drowsiness as well as in awake dogs that were in lateral 
or sternal recumbency or even in a standing position, making a sole parasomnia 
unlikely. Moreover, the epileptic nature of the events was confirmed by EEG. Some 
RRs responded very well to KBr similar to the dogs in the study of Schubert et al., 
but as KBr is an AED, the effect seen in the RRs of the present study can be 
explained by the anticonvulsant properties of KBr (SCHUBERT et al., 2011). 
4.5. Progressive myoclonic epilepsies 
In human beings, the PMEs are an uncommon and heterogeneous group of inherited 
neurodegenerative disorders that are resistant to treatment, leading to a debilitating 
course and poor outcome (DE SIQUEIRA, 2010; SHAHWAN et al., 2005). 
Common features are myoclonic seizures, other types of seizures, particularly 
GTCS, and progressive neurological dysfunction, especially dementia and ataxia 
(DE SIQUEIRA, 2010; SHAHWAN et al., 2005; SHIELDS, 2004). Most patients 
with PMEs present in late childhood or adolescence, and with the exception of 
myoclonic epilepsy with ragged red fibres (MERRF), dentatorubral-pallidoluysian 
atrophy (DRPLA), and some forms of NCLs (see below) have an autosomal 
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recessive mode of inheritance (SHIELDS, 2004). Electroencephalography may be 
normal at the beginning of the disease, but as the disease progresses, background 
slowing and epileptiform discharges become apparent in most cases (SHAHWAN 
et al., 2005). In addition to other rare forms of this syndrome, there are six main 
causes of PME (DE SIQUEIRA, 2010). 
The most common one is Unverricht-Lundborg disease, an autosomal recessive 
disorder associated with mutations in CSTB encoding cystatin B (DE SIQUEIRA, 
2010; SHAHWAN et al., 2005). Myoclonus is stimulus-sensitive (visual, auditory, 
and proprioceptive) and prevails upon awakening (DE SIQUEIRA, 2010; 
SHAHWAN et al., 2005). Electroencephalography shows a high sensitivity to 
photic stimulation (SHAHWAN et al., 2005). The disease is progressive but seems 
to stabilize after age 40, and life expectancy is not overly shortened (DE 
SIQUEIRA, 2010; SHAHWAN et al., 2005; SHIELDS, 2004). 
Lafora disease has an autosomal recessive mode of inheritance and is caused by 
mutations in the genes EPM2A or NHLRC1 (formerly EPM2B) (DE SIQUEIRA, 
2010; SHAHWAN et al., 2005). Apart from myoclonus and other seizure types, 
patients typically show occipital seizures with transient blindness and visual 
hallucinations, and photosensitivity is a common feature (DE SIQUEIRA, 2010; 
SHAHWAN et al., 2005). As there is rapid and severe progression of the disease, 
most patients die within ten years after onset (DE SIQUEIRA, 2010; SHAHWAN 
et al., 2005). Diagnosis can be established by demonstration of the pathognomonic 
Lafora bodies, which are PAS-positive polyglucosan inclusions found in neurons 
and other tissues, especially the excretory ducts of eccrine sweat glands (CONRY, 
2002; DE SIQUEIRA, 2010; SHAHWAN et al., 2005). 
Myoclonic epilepsy with ragged red fibres is transmitted by mitochondrial 
inheritance (SHAHWAN et al., 2005). In addition to the typical signs of PME, 
myopathy, neuropathy, hearing loss, and optic atrophy are often present (DE 
SIQUEIRA, 2010; SHAHWAN et al., 2005). The course of the disease may be 
slowly or rapidly progressive (CONRY, 2002; LEPPIK, 2003). Muscle biopsy 
reveals ragged red fibres in over 90% of patients (SHAHWAN et al., 2005). 
The NCLs are a group of neurodegenerative disorders (LEPPIK, 2003). A 
characteristic finding is the accumulation of autofluorescent ceroid lipofuscin 
(lipopigments) in different tissues (DE SIQUEIRA, 2010). To date, 14 genes have 
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been associated with NCL, and 13 genes have already been identified (CLN1-CLN8 
and CL10-CLN14) (MOLE & COTMAN, 2015; NITA et al., 2016). The great 
majority of NCLs have an autosomal recessive mode of inheritance (MOLE & 
COTMAN, 2015). Loss of vision occurs in most cases (DE SIQUEIRA, 2010; 
SHAHWAN et al., 2005). The clinical course is characterized by rapid deterioration 
and premature death (DE SIQUEIRA, 2010; SHAHWAN et al., 2005). Detection 
of intracellular inclusions by electron microscopy in eccrine secretory cells and 
conjunctival, muscle, or rectal mucosa biopsy specimens is used to confirm the 
diagnosis (DE SIQUEIRA, 2010; SHAHWAN et al., 2005). 
Sialidosis type I and type II are autosomal recessive disorders that belong to the 
group of lysosomal storage disorders and are related to mutations in the NEU1 gene 
causing a deficiency of alpha-N-acetyl neuraminidase-1 (CACIOTTI et al., 2009; 
SHAHWAN et al., 2005). Patients show pure action and intention myoclonus, 
evolution of visual failure, and a slow clinical progression without mental 
deterioration (DE SIQUEIRA, 2010; SHAHWAN et al., 2005). Fundoscopy reveals 
characteristic cherry-red spots in the macula (DE SIQUEIRA, 2010). Evaluation of 
urine for sialyloligosaccharides and demonstrating a deficiency of neuraminidase 
activity in leucocytes or cultured fibroblasts are used to diagnose this disorder 
(LEPPIK, 2003; SHAHWAN et al., 2005). 
The autosomal dominant disorder DRPLA is caused by an unstable expansion of 
CAG repeats of a gene at 12p13.31 and can be divided into three clinical forms: a 
choreoathetoid, a pseudo-Huntington, and a PME form (DE SIQUEIRA, 2010; 
SHAHWAN et al., 2005). Patients under the age of 20 usually present with the PME 
form (DE SIQUEIRA, 2010; SHAHWAN et al., 2005). Magnetic resonance 
imaging reveals atrophy of the cerebellum and brainstem, and pathological 
examination shows degeneration of the rubral and dentato-pallidoluysian systems 
(SHAHWAN et al., 2005). 
The main difference between JME in RRs and the PMEs is the lack of a progressive 
course of disease; dogs in the present study did not develop neurological 
dysfunction such as ataxia or have cognitive decline. In addition, Lafora disease 
and NCL were ruled out based on the absence of PAS-positive inclusion bodies or 
NCL specific autofluorescent inclusion bodies on post-mortem or skin biopsy 
evaluation. Similarly, MERRF was ruled out because of the lack of ragged red 
fibres in muscle biopsy samples as well as the absence of any neuro- or myopathy 
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and visual or auditory deficits. Furthermore, unremarkable ophthalmic examination 
and metabolic screening for oligosaccharides did not support a diagnosis of 
sialidosis in the RRs of the present study. A diagnosis of DRLPA was also 
considered unlikely because there was no ataxia, dementia, or progressive course 
of disease, and the results of MRI and pathological examination were unremarkable. 
In summary, all of the above-mentioned syndromes share some features with JME 
in RRs. However, RBD, a parasomnia, could be ruled out because affected dogs 
also have myoclonic twitches during wakefulness in a standing position and EEG 
clearly demonstrated the epileptic nature of the episodes in question. Similarly, 
NFLE was considered unlikely because EEG was indicative of a generalized and 
not a focal epilepsy syndrome. Myoclonic epilepsy of infancy shares many 
similarities with JME in RRs. However, MEI was considered less likely because 
the majority of dogs had a juvenile age of onset, developed other seizure types 
besides myoclonic seizures, and lacked a remitting course of disease. The PMEs 
were excluded because of the lack of a progressive course of disease and structural 
alterations in brain imaging and necropsy. In contrast, JME in humans reveals 
striking similarities to JME in RRs. They both have a juvenile age of onset, 
myoclonic seizures as the prevailing seizure type with progression to generalized 
tonic-clonic or absence seizures, similar EEG features, photosensitivity in a 
substantial portion of patients, and good response to LEV treatment. Therefore, 
JME in RRs is considered a valuable translational model for the investigation of 
clinical, genetic, and therapeutic aspects of human JME, as well as photosensitivity. 
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V. PERSPECTIVE 
The present study shows that long-term wireless video-EEG in unsedated dogs is a 
feasible and valuable technique to investigate the epileptic background of 
paroxysmal events and to further characterize the EEG patterns of specific epilepsy 
syndromes. This novel method was used to confirm the diagnosis of myoclonic 
seizures and absence seizures in RRs with JME, two seizure types that were 
previously underrecognized in dogs with idiopathic epilepsy. The current veterinary 
literature focuses on focal and generalized tonic-clonic seizures. Other seizure types 
have been neglected. The present study determined that the spectrum of seizure 
types in dogs is much broader than expected. In the future, the use of wireless video-
EEG in unsedated dogs will enable the diagnosis of myoclonic and absence epilepsy 
and facilitate the identification of new seizures types that have not yet been 
recognized in dogs. 
There are laboratories that now offer genetic testing for the DIRAS1 variant, which 
facilitates the development of breeding programs aimed at preventing this disease. 
It is thus conceivable that the disease will vanish with time and the percentage of 
heterozygous carriers will decrease. Therefore, the findings of the present study 
may help to improve the health of the RR population. 
In human medicine, the treatment regimen for epilepsy is determined by the specific 
seizure type and epilepsy syndrome. Treatment based on this type of differentiation 
does not exist in veterinary neurology, where a small number of veterinary licensed 
products are used for all types of epilepsy syndromes. Therefore, future treatment 
studies should focus on the specific epilepsy syndrome to evaluate the efficacy of a 
particular AED. Moreover, veterinarians should attempt to make a definitive 
diagnosis of the precise type of epilepsy and choose an appropriate AED. 
Genetic analyses of the cohort in the present study were done in a joint approach 
with researchers at the University of Helsinki and identified a fully penetrant 4-bp 
deletion mutation in the DIRAS1 gene with a proposed role in presynaptic ACh 
release (TADA et al., 2012). It was shown that important parallels exist between 
JME in RRs and human JME, which is one of the most common types of IGEs in 
people (SERAFINI et al., 2013). Common features include young age of onset, 
myoclonic seizures as the predominant seizure type with propagation to generalized 
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tonic-clonic or absence seizures, and similarities in EEG characteristics, 
photosensitivity, and response to LEV treatment. The findings of the present study 
provide evidence for a role of DIRAS1 in epilepsy and a base to further elucidate 
the function of this gene and the contribution of cholinergic neurotransmission in 
myoclonic epilepsies. Moreover, RRs may represent a valuable large animal 
translational model for clinical, therapeutic. and genetic aspects of human 
epilepsies and photosensitivity. 
The present study gave rise to a number of subsequent investigations. The study by 
Waltz. et al. served as a model to further investigate the impact and genetics of 
photosensitivity in RRs with JME (WALTZ et al., 1992). With that purpose in 
mind, affected dogs and their families and relatives will be examined by video-EEG 
with photic stimulation. Furthermore, two different approaches will be used to 
generate translational animal models. In addition to a transgenic mouse line, 
morpholinos will be used to produce a knockout of the diras1a and/or diras1b gene 
in zebrafish larvae. These two models will then be used to further investigate the 
function of DIRAS1 and to validate the efficacy of a variety of well-established as 
well as novel AEDs. Moreover, these models will be used to study the role of 
DIRAS1 as a tumour-suppressor gene. The results of these studies will hopefully 
contribute to better understanding and treatment of JME in humans and dogs. 
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VI. SUMMARY 
Dogs represent a promising large animal translational model for human disease. 
The aim of the present study was to provide a detailed clinical and 
electroencephalographic description of a novel myoclonic epilepsy syndrome in 
Rhodesian Ridgeback (RR) dogs and to investigate the underlying genetic cause. 
The following were required for inclusion of dogs in the study: on-site observation 
of myoclonic jerks or video recordings of seizure activity that were available for 
review, the results of neurological examination, and data collected from owner 
interview or completion of an online questionnaire. Extensive diagnostic work-up 
(blood examination, magnetic resonance imaging and/or computed tomography, 
cerebrospinal fluid examination, urine neurometabolic screening) was offered. 
Wireless video-electroencephalography (EEG) in unsedated dogs was established 
as a tool to investigate the epileptic nature of the myoclonic jerks and to characterize 
the EEG features of the electroclinical syndrome. Recordings were a minimum of 
one hour in length. Electroencephalography with photic stimulation was used in a 
subset of dogs. Pedigree analyses were conducted, and blood samples were 
collected for subsequent genetic analyses in collaboration with the University of 
Helsinki to identify the underlying genetic cause. 
Ninety-five RRs were evaluated, and 24 met the inclusion criteria. These dogs 
shared a common phenotype. The hallmark of the epilepsy was vigorous myoclonic 
seizures that occurred mainly during periods of relaxation. Age of onset varied from 
six weeks to 1.5 years (mean six months). In more than one third of the dogs, the 
disease progressed to include generalized tonic-clonic seizures (GTCS), and a third 
of the dogs were clinically photosensitive. Another feature of juvenile myoclonic 
epilepsy (JME) in RRs was absence seizures. The results of magnetic resonance 
imaging of the brain and post-mortem examination were unremarkable and served 
to rule out a structural epilepsy. Ambulatory video-EEG confirmed the epileptic 
origin of the myoclonic twitches. Typically, affected dogs showed myoclonic 
seizures accompanied by generalized 4-5 Hz spike-wave complexes (SWC) and 
polyspike-wave complexes with a frontocentral maximum. Absence seizures were 
associated with generalized 4 Hz SWC. Two thirds of the dogs examined showed 
photoconvulsions upon photic stimulation. The best treatment results were achieved 
with levetiracetam or potassium bromide. Pedigree analyses were consistent with 
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an autosomal recessive mode of inheritance. Genetic analyses identified a fully 
penetrant recessive 4-bp truncating deletion mutation in the DIRAS1 gene, which is 
involved in presynaptic acetylcholine release (TADA et al., 2012). 
Wireless video-EEG in unsedated dogs is a novel, feasible, and valuable technique 
for the investigation of paroxysmal events of unknown aetiology in veterinary 
clinics. This diagnostic method will presumably influence the approach to diagnosis 
of canine epilepsy and facilitate the identification of further seizure types that have 
not yet been recognized in dogs. Furthermore, JME in RRs has important parallels 
to JME in humans, including young age of onset, myoclonic seizures as the 
predominant seizure type with propagation to GTCS or absence seizures, and 
similar EEG characteristics, photosensitivity, and response to treatment with 
levetiracetam. Comparison of spontaneous canine and human epilepsies offers a 
unique opportunity to study the clinical, genetic, and therapeutic aspects of 
epilepsies and photosensitivity in a translational setting. 
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VII. ZUSAMMENFASSUNG 
Hunde stellen ein vielversprechendes translationales Tiermodell für Erkrankungen 
des Menschen dar. Ziel der vorliegenden Arbeit war es, ein neues myoklonisches 
Epilepsiesyndrom bei Rhodesian Ridgeback (RR) Hunden klinisch und 
elektroenzephalographisch zu charakterisieren und die zugrundeliegende 
genetische Ursache zu identifizieren. Einschlusskriterien waren direkte 
Beobachtung der myoklonischen Zuckungen oder zur Auswertung verfügbare 
Videoaufzeichnungen, eine neurologische Untersuchung und ein persönliches 
Interview oder die Beantwortung eines Online-Fragebogens. Eine umfangreiche 
Diagnostik (Blutuntersuchung, Magnetresonanztomographie, neurometabolisches 
Screening des Urins) wurde angeboten. Die kabellose Video-
Elektroenzephalographie (EEG) wurde als Untersuchungsmethode bei unsedierten 
Hunden etabliert, um den epileptischen Ursprung der Myoklonien zu untersuchen 
und das EEG der erkrankten Hunde im Detail zu beschreiben. Die Dauer einer EEG-
Untersuchung betrug mindestens eine Stunde. Im Anschluss wurde bei einem Teil 
der RRs eine Photostimulation durchgeführt. Die Stammbäume der betroffenen 
RRs wurden analysiert und Blutproben für nachfolgende genetische Analysen in 
Zusammenarbeit mit der Universität Helsinki gesammelt. 
Die Krankengeschichten, Online-Fragebögen und Videoaufzeichnungen von 95 
RRs wurden ausgewertet, von denen 24 RRs die Einschlusskriterien erfüllten und 
einen gemeinsamen Phänotyp aufwiesen. Hauptcharakteristikum der Erkrankung 
waren heftige Myoklonien, die überwiegend in Ruhephasen auftraten. Der 
Krankheitsbeginn lag zwischen sechs Wochen und 1,5 Jahren (sechs Monate im 
Durchschnitt). Mehr als ein Drittel der Hunde entwickelte im Verlauf auch 
generalisierte tonisch-klonische Anfälle. Photosensibilität wurde bei einem Drittel 
der Hunde beschrieben. Ein weiteres Merkmal der juvenilen myoklonischen 
Epilepsie (JME) des RRs waren Absence Anfälle. Die unauffälligen Befunde der 
Kernspintomographie und pathologischen Untersuchung des Gehirns schlossen 
eine strukturelle Epilepsie aus. Das ambulatorische Video-EEG bestätigte den 
epileptischen Ursprung der Myoklonien. Betroffene Hunde zeigten im EEG 
generalisierte 4-5 Hz Spike-Wave Komplexe und Polyspike-Wave Komplexe mit 
einem frontozentralen Maximum während der myoklonischen Anfälle. Absencen 
waren mit generalisierten 4 Hz Spike-Wave Komplexen assoziiert. Bei der 
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Photostimulation zeigten zwei Drittel der untersuchten Hunde Photokonvulsionen. 
Die besten Behandlungserfolge wurden mit Levetiracetam oder Kaliumbromid 
erzielt. Die Stammbaumanalysen wiesen auf eine autosomal-rezessive Erkrankung 
hin. Die genetischen Analysen identifizierten eine vollständig penetrante, rezessive, 
vier basenpaargroße trunkierende Deletionsmutation im DIRAS1 Gen, welches eine 
Rolle bei der präsynaptischen Freisetzung von Acetylcholin spielen soll (TADA et 
al., 2012). 
Das kabellose Video-EEG bei unsedierten Hunden erwies sich als eine praktikable 
und wertvolle Technik zur Klärung des epileptischen Ursprungs von paroxysmalen 
Episoden unbekannter Ursache. Diese Methode kann die Vorgehensweise bei der 
Diagnostik von Epilepsien des Hundes beeinflussen und die Identifizierung von 
epileptischen Anfällen ermöglichen. Die JME des RRs weist wichtige Parallelen 
zur JME des Menschen auf, darunter der frühe Krankheitsbeginn, das Auftreten von 
myoklonischen Anfällen als vorwiegendem Anfallstyp mit einem Fortschreiten zu 
generalisierten tonisch-klonischen Anfällen oder Absence Anfällen, ähnliche EEG-
Muster, Photosensibilität und gutes Ansprechen auf eine Therapie mit 
Levetiracetam. Der Vergleich zwischen Epilepsien des Hundes und des Menschen 
ermöglicht es in einer translationalen Herangehensweise, klinische, genetische und 
therapeutische Aspekte von Epilepsien und Photosensibilität zu untersuchen. 
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